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Abstract 
Reports concerning the quantitative analysis of pharmaceuticals in marine 
ecosystems are somewhat limited. It is necessary to determine pharmaceutical fate 
and assess any potential risk of exposure to aquatic species and ultimately, seafood 
consumers. However, in Ireland very little research has been carried out to 
determine the presence of pharmaceutical residues in the aquatic environment. 
The research carried out investigates the occurrence of pharmaceuticals in 
the Irish aquatic environment and their potential to bioaccumulate in aquatic 
organisms and pose a risk to human health via dietary intake. Pharmaceutical 
residues were determined in liquid matrices, such as wastewater effluent, marine 
surface water (MSW) and artificial seawater (ASW), using solid phase extraction 
(SPE) in combination with liquid chromatography-tandem mass spectrometry (LC-
MS/MS). Pharmaceutical extraction from marine mussels and fish tissues required 
an additional pressurised liquid extraction (PLE) step prior to SPE and LC-MS/MS.  
The results of an in situ study, in which caged Mytilus spp. were deployed at 
three sites on the Irish coastline over a 1-year period are presented. All of the 
selected pharmaceuticals were quantified in wastewater effluent and marine surface 
waters and three out of the five monitored pharmaceuticals were detected in 
environmentally exposed mussel tissue. 
The potential for pharmaceutical bioaccumulation in fish via trophic level 
transfer was investigated. A 28-day in vivo experiment was carried out in a flow-
through system in which rainbow trout were fed wild marine mussels sampled from 
one of the most contaminated sites in Ireland. Although low-level residues of 
trimethoprim were detected in the mussel tissues, no bioaccumulation was reported 
for this drug or any of the other selected compounds in the liver of the exposed fish. 
The effect of steaming on the concentrations of five pharmaceutical residues 
in exposed mussel tissue was investigated in an attempt to assess the potential risk 
of exposure to humans via ingestion of contaminated seafood. An in vivo 
experiment was carried out exposing marine mussels to pharmaceutical 
concentrations via direct injection and water uptake. A selection of water-exposed 
mussels were cooked (via steaming) resulting in a significant increase of parent 
pharmaceutical concentrations in the bivalves.  
viii 
Acknowledgements 
This research was carried out as part of the Science, Technology, Research and 
Innovation for the Environment (STRIVE) Programme which is funded by the Irish 
Government under the National Development Plan 2007-2013 and administered on 
behalf of the Department of the Environment, Heritage and Local Government by 
the Environmental Protection Agency. This research was also partly funded by the 
Science Foundation of Ireland (Grant Number 08/SRC/B1412). 
I would like to thank Dr. Brian Quinn and Prof. Brett Paull for providing me with 
the opportunity to be a part of such great research groups such as the ICET and the 
ISSC and for the opportunity to travel to many domestic and international 
conferences throughout my studies. I would also like to thank Dr. Brian Kelleher 
and Dr. Leon Barron for their input and their much appreciated support and advice. 
Dr. Wiebke Schmidt is also acknowledged for her help and advice throughout this 
work.  
Kind thanks to Lynn Vanhaecke and Julie Kiebooms for their hospitality expressed 
when visiting Ghent University in Belgium. Thanks to Iarfhlaidh Connellan, 
Edward Grant, Thomas Cleary, Robert Hernan, Liam Morrison, Kathleen 
O’Rourke, Martina Mulligan and Rachel McArdle for their help with experimental 
set-up and sample collection. 
A big thank you to all the ISSC, School of Chemical Sciences and NCSR staff 
members and technicians, especially Stephen Fuller and Maurice Burke. 
Thanks to everyone who has come and gone through the ISSC - Patrick, Orla, Amy, 
Ruth, Sara, Sinead, Ali, Disha, Mercedes, Damian, Katya, Dave, Lily, Ugis, Aymen 
and finally Nicola, who was a great support and friend throughout. I would also like 
to thank all those in the School of Chemical Sciences and Biotechnology.  
Finally, a special thank you to all my great friends and my entire family especially 
my Mum, Johnny, Dad, Katie and Al for their constant love, support and 
encouragement. 
 
  
ix 
List of Publications and Conference Presentations 
Publications 
 
 Schmidt, W., Rainville, L.C., McEneff, G., Sheehan, D., Quinn, B. (2013) A 
proteomic evaluation of the effects of the pharmaceuticals diclofenac and 
gemfibrozil on marine mussels (Mytilus spp.): evidence for chronic sublethal 
effects on stress-response proteins. Drug Testing and Analysis. DOI: 
10.1002/dta.1463. 
 
 McEneff, G., Barron, L., Kelleher, B., Paull, B., Quinn, B. (2013) The 
determination of pharmaceutical residues in cooked and uncooked marine 
bivalves using pressurised liquid extraction, solid phase extraction and liquid 
chromatography–tandem mass spectrometry’, Analytical and Bioanalytical 
Chemistry. 405, 9509-9521. 
 
 McEneff, G., Barron, L., Kelleher, B., Paull, B., Quinn, B. A year-long study 
of the spatial occurrence and relative distribution of pharmaceutical residues in 
sewage effluent, receiving marine waters and marine bivalves, Science of the 
Total Environment. Accepted December 2013. 
 
Oral presentations 
 
 McEneff, G., Barron, L., Kelleher, B., Paull, B., Quinn, B. LC-MS/MS 
analysis of pharmaceuticals in the aquatic environment. The 22
nd
 Irish 
Environmental Researchers Colloquim, University College Dublin, Ireland, 
7
th
-9
th
 March 2012. 
 
 McEneff, G., Barron, L., Kelleher, B., Paull, B., Quinn, B. LC-MS/MS 
analysis of pharmaceuticals in the aquatic environment. RSC/ChromSoc 
Advances in Clinical Analysis, Guy’s Hospital Tower, London, UK, 30th 
October 2012. 
(Invited Speaker) 
 
x 
 McEneff, G., Barron, L., Kelleher, B., Paull, B., Quinn, B. LC-MS/MS 
analysis of pharmaceuticals in the aquatic environment. Irish Mass 
Spectrometry Society (IMSS) Conference, Red Cow Hotel Dublin, Ireland, 1
st
 
May 2013. 
 
Poster Presentations 
 
 McEneff, G., Schmidt, W., Quinn, B. A comparative in situ study on 
ecotoxicological effects of pharmaceuticals in Ireland. 8
th
 Annual EPA 
Postgraduate Seminar, The Conference Centre Dublin, Ireland, 11
th
 November 
2010. 
 
 McEneff, G., Schmidt, W., Barron, L., Paull, B., Quinn, B. Solid phase 
extraction and LC-MS/MS analysis of pharmaceutical and personal care 
products in the Irish aquatic environment and their potential to bioconcentrate. 
Conference on Analytical Sciences, Ireland (CASi), Dublin City University, 
Ireland, 21
st
-22
nd
 February 2011. 
 
 McEneff, G., Schmidt, W., Barron, L., Paull, B., Kelleher, B., Quinn, B. Solid 
phase extraction and LC-MS/MS analysis of pharmaceutical and personal care 
products in the Irish aquatic environment. Instrumental Methods of Analysis – 
Modern Trends and Applications (IMA), MAICh Conference Centre, Chania, 
Crete, Greece, 18
th
-22
nd
 September 2011. 
 
 McEneff, G., Kellleher, B., Barron, L., Paull, B., Quinn, B., Solid phase 
extraction and LC-MS/MS analysis of pharmaceuticals in the Irish aquatic 
environment. 9
th
 Annual EPA Postgraduate Seminar, The Conference Centre 
Dublin, Ireland, 17
th
 November 2011. 
 
 McEneff, G., Schmidt, W., Barron, L., Paull, B., Kelleher, B., Quinn, B. Solid 
phase extraction and LC-MS/MS analysis of pharmaceuticals in the Irish 
aquatic environment. 6
th
 Society of Environmental Toxicology and Chemistry 
(SETAC) World Congress, Estrel Hotel Berlin, Germany, 20
th
-24
th
 May 2012. 
 
xi 
 McEneff, G., Barron, L., Kelleher, B., Paull, B., Quinn, B. LC-MS/MS 
analysis of pharmaceuticals in the Irish aquatic environment. 39
th
 International 
Symposium of High Performance Liquid Chromatography and Related 
Techniques (HPLC), RAI Conference Centre Amsterdam, Netherlands, 16
th
-
20
th
 June 2013. 
 
xii 
List of Figures 
Figure 1.1: Sources of pharmaceuticals in the environment 
Figure 1.2: The primary metabolic pathway of gemfibrozil 
Figure 1.3:  Schematic diagram of the basic overview of an activated sludge 
wastewater treatment plant 
Figure 1.4: Sample preparation and analysis of pharmaceuticals in aqueous and 
biotic matrices 
Figure 1.5: Overview of the objectives and ultimate aim of the research project 
including both chemical and biological analysis 
Figure 2.1(a): Image of the constructed mesh cages filled with Mytilus spp. 
mussels before deployment 
Figure 2.1(b): Image of the constructed mesh cages filled with Mytilus spp. 
mussels before deployment 
Figure 2.2: Map of Ireland showing the sampling locations CON, EXP1 and 
EXP2 
Figure 2.3(a): Satellite view of EXP1 with locations of effluent outfall and mussel 
cage marked  
Figure 2.3(b): Mussel cage tied to bridge and WWTP1 and effluent outfall 
observed in background 
Figure 2.4(a): Satellite view of EXP2 and the effluent outfall pipe onto which the 
mussel cage is attached 
Figure 2.4(b): Buoy from which mussel cage hangs and under which lies the 
effluent outfall pipe. WWTP2 observed in background 
Figure 2.5: EICs of the most concentrated occurrence of selected 
pharmaceuticals in samples of wastewater effluent, marine surface 
water and marine mussels collected from exposure sites over one 
year 
Figure 2.6:  Cumulative pharmaceutical concentrations (µg.L
-1
) detected in 
effluent from WWTP1 and marine surface water from EXP1 and 
WWTP flow rates (May 2011-April 2012) 
Figure 2.7: Cumulative pharmaceutical concentrations (µg.L
-1
) detected in 
effluent from WWTP2 and marine surface water from EXP2 and 
WWTP flow rates (May 2011-August 2011) 
xiii 
Figure 3.1(a): Flow-through system connected to 9 x 70 L tanks. Fish and air 
stones visible in each labelled tank. 
Figure 3.1(b): Flow-through system connected to 9 x 70 L tanks. Fish and air 
stones visible in each labelled tank. 
Figure 3.2: Set-up of labelled fish tanks for in vivo exposure  
Figure 3.3: EICs of selected pharmaceuticals (250 ng.g
-1
 DW) spiked in fish 
liver 
Figure 3.4: EIC of trimethoprim in wild marine mussel tissue sampled from a 
wastewater effluent exposure site 
Figure 4.1(a): Image of the in vivo experimental set-up exposing pharmaceuticals 
to Mytilus spp. via direct injection and water uptake 
Figure 4.1(b): Image of the in vivo experimental set-up exposing pharmaceuticals 
to Mytilus spp. via direct injection and water uptake 
Figure 4.2: The steaming of water-exposed mussels collected at t96 
Figure 4.3: Pharmaceutical concentrations in ASW (n=1) from water exposure 
tank spiked at approximately 1 mg.L
-1
 and measured over 19 h 
Figure 4.4: EICs of the most concentrated occurrence of selected 
pharmaceuticals in the water-exposed marine mussel samples 
Figure 4.5: Pharmaceutical concentrations (µg.g
-1 
DW) detected in mussel tissue 
extracts before (n=2) and after cooking (n=2). Water-exposed 
mussels sampled at t96h were steamed and compared to uncooked 
mussels also sampled at t96h. 
Figure 5.1: Schematic overview of the main outputs of this thesis 
 
  
xiv 
List of Tables 
Table 1.1: OSPAR list of pharmaceuticals of possible concern to the marine 
environment 
Table 1.2: Removal efficiencies of selected pharmaceuticals in the 
conventional activated sludge process 
Table 1.3: Effects of pharmaceuticals at environmentally relevant 
concentrations on non-target species following chronic exposure 
studies  
Table 2.1: Chemical structure, class and physicochemical properties of selected 
pharmaceutical compounds 
Table 2.2: Electrospray ionisation tandem mass spectrometric conditions 
Table 2.3: Precursor, quantification and confirmation ions (m/z) for each 
pharmaceutical and their corresponding fragmentation amplitudes 
Table 2.4: Method performance data for pharmaceuticals in ultra-pure water 
(500 mL), wastewater effluent (500 mL), marine surface water (500 
mL) and marine mussel tissue (1 g) 
Table 2.5: Comparison of method performance results for pharmaceuticals in 
solid matrices from selected literature using LC-MS analysis 
Table 3.1: Weights (g) of juvenile rainbow trout in each tank measured pre-
exposure 
Table 3.2: Method performance data for pharmaceuticals in ultra-pure water 
(500 mL), marine mussel tissue (1 g) and fish liver (0.4 g) 
Table 3.3: Days on which water measurements, such as temperature (°C), pH, 
DO (%), TOC (mg.L
-1
) and hardness (CaCO3 mg.L
-1
), were 
collected 
Table 3.4: Average measurements of temperature (°C), pH, DO (%), TOC 
(mg.L
-1
) and hardness (CaCO3 mg.L
-1
) collected from each tank 
during the 28 d in vivo exposure 
Table 4.1: Method performance data for pharmaceuticals in ultra-pure water, 
extracted ASW (500 mL), ASW from exposure tanks (1.5 mL) and 
marine mussels 
Table 4.2: Concentrations (µg.g
-1
 DW) of carbamazepine (CBZ), diclofenac 
(DCF), gemfibrozil (GEM), mefenamic acid (MFA) and 
xv 
trimethoprim (TRM) detected in water-exposed mussel tissue (over 
96 h) 
Table 4.3: Comparison of concentrations of carbamazepine (CBZ), diclofenac 
(DCF), gemfibrozil (GEM), mefenamic acid (MFA) and 
trimethoprim (TRM) detected in raw mussel tissue (µg.g
-1
 DW) 
(n=2), steamed mussel tissue (µg.g
-1
 DW) (n=2) and cooking water 
(µg.g
-1
 WW) (n=1) after steaming 
 
 
  
xvi 
List of Equations 
Eqn. 1.1: Solid-water distribution coefficient 
Eqn. 3.1: Bioaccumulation factor 
Eqn. 3.2: Biomagnification factor 
  
xvii 
List of Abbreviations 
Al2O2: Aluminium oxide 
AOP: Advanced oxidation processes 
APCI: Atmospheric pressure chemical ionisation 
API: Atmospheric pressure interface 
APPI: Atmospheric-pressure photoionisation 
ASW: Artificial seawater 
BAF: Bioaccumulation factor 
BCF: Bioconcentration factor 
BOD: Biological oxygen demand 
BMF: Biomagnification factor 
Caqueous: Chemical concentration in the aqueous phase 
CB: Chemical concentration in the organism 
CD: Chemical concentration in the diet of the organism 
CEC: Chemical of emerging concern 
COD: Chemical oxygen demand 
Csolid: Chemical concentration in the solid 
CWD: Freely dissolved chemical concentration in water 
DAD: Diode array detection 
DMSO: Dimethyl sulfoxide 
DO: Dissolved oxygen 
DOM: Dissolved organic matter 
Dow: Octanol-water distribution coefficient 
DW: Dry weight 
EDC: Endocrine disrupting compound 
EFSA: European food safety authority 
EI: Electron impact 
EIC: Extracted ion chromatogram 
EMEA: European Medicines Evaluation Agency 
EPA: Environmental Protection Agency 
ESI: Electrospray ionisation 
GC: Gas chromatography 
GST: Glutathione S-transferase 
xviii 
H2O2: Hydrogen peroxide 
HBCD: Hexabromocyclododecane 
HCB: Hexachlorobenzene 
HCT: High capacity ion trap 
HPLC: High performance liquid chromatography 
IPHA: Irish Pharmaceutical Healthcare Association 
KD: Solid-water distribution coefficient 
Koc: Normalised organic carbon sorption coefficients 
Kow: Octanol-water partition coefficient 
LC: Liquid chromatography 
LLE: Liquid-liquid extraction 
LOD: Limit of detection 
LOEC: Lowest observed effect concentration 
LOQ: Limit of quantification  
LPME: Liquid phase micro-extraction 
MAE: Microwave-assisted extraction 
MAX: Mixed-mode anion exchange 
MBR: Membrane bioreactor 
MFO: Mixed function oxidase 
MIP: Molecularly imprinted polymer  
MRL: Maximum residue limit 
MS: Mass spectrometry 
MSW: Marine surface water 
MXC: Mixed-mode cation exchange 
NADPH: Nicotinamide adenine dinucleotide phosphate 
NSAID: Non-steroidal anti-inflammatory drug 
OA: Oxolinic acid 
OECD: Organisation for Economic Co-operation and Development 
OSPAR: Oslo-Paris Convention for the Protection of the Marine Environment of 
the North-East Atlantic 
OTC: Oxytetracycline 
PAH: Polycyclic aromatic hydrocarbon 
PCB: Polychlorinated biphenyl 
PE: Population equivalent 
xix 
PEC: Predicted environmental concentration 
PFC: Perfluorinated compound 
pKa: Acid dissociation constant 
PLE: Pressurised liquid extraction 
PNEC: Predicted no effect concentration 
POP: Persistent organic pollutant 
PPCP: Pharmaceutical and personal care product 
PVDF: Polyvinylidene fluoride 
QqLIT: Triple quadrupole linear ion trap 
QqQ: Triple quadrupole 
QSAR: Quantitative structural activity relationship 
QTOF: Quadrupole time of flight 
ROS: Reactive oxygen species 
RSD: Relative standard deviation 
SBSE: Stir-bar sorptive extraction 
SPE: Solid phase extraction 
SPM: Suspended particulate material 
SPME: Solid phase micro-extraction 
SRM: Selected reaction monitoring 
SRT: Solid retention time 
SSRI: Selective serotonin reuptake inhibitor 
STRIVE: Science, Technology, Research and Innovation for the Environment 
S/N: Signal-to-noise 
TOC: Total organic carbon 
TOF: Time of flight 
UDP: Uridine-diphosphate 
UDPGA: Uridine-diphosphate-glucuronic acid 
UGT: Uridine-diphosphate-glucuronosyl transferase 
UPLC: Ultra performance liquid chromatography 
UV: Ultra-violet 
WW: Wet weight 
WWTP: Wastewater treatment plant  
  
 
 
 
 
 
 
 
 
“One of the major problems is what we do to the soil, the air 
and the water. Everything we do, we take in our food.” 
 
-Charlotte Gerson, Food Matters 
 
  
 
1.0 General Introduction 
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1.1 Pharmaceuticals as Environmental Pollutants 
Over the last three decades, public awareness of environmental health issues has 
soared in Ireland due to the increase in funding for environmental research from 
global policy makers such as the Irish Environmental Protection Agency (EPA) and 
the European Union (EU) (Colgan and Donlon, 2010; EUR-OP, 2012). In 
particular, the assessment and monitoring of environment exposure was found to be 
a leading research topic, accounting for 20.8 % of all environmental publications 
released between the years 1995 and 2005 (Tarkowski, 2007). Initially, the 
emphasis of environmental exposure research was on the so called ‘priority 
pollutants’ such as pesticides and industrial intermediates. As environmental 
interest grew and research progressed, so too did the technologies employed, 
resulting in the development of more advanced techniques and the discovery of a 
new group of emerging contaminants, collectively referred to as ‘chemicals of 
emerging concern (CECs)’ (Bhandari, 2009). These compounds include 
pharmaceuticals and personal care products (PPCPs), endocrine disrupting 
compounds (EDCs), perfluorinated compounds (PFCs), surfactants, gasoline 
additives, disinfection by-products, algal and cyanobacterial toxins, organometallic 
compounds, brominated and organophosphate flame retardants, plasticisers and 
nanoparticles (Gros et al., 2006a). 
For the purpose of this thesis, the array of compounds encompassed in the 
scope of PPCPs will be defined to include over-the-counter/prescription 
pharmaceuticals for human and animal use, excluding hormones. Pharmaceuticals 
have a specific structure, mode of action and biological effect which determines 
their function and therapeutic class. Pharmaceuticals can be classified into 
numerous therapeutic classes including anti-inflammatories, antibiotics, 
antipsychotics, antihypertensives, antidiabetics, antihistamines, lipid regulators, 
anticonvulsant, β-blockers, stimulants and statins. Pharmaceuticals were first 
introduced as environmental contaminants by Richardson and Bowron (1985) but, 
their negative environmental effect was only later acknowledged in the late nineties 
when they were described as ‘agents of subtle change’ (Daughton and Ternes, 
1999). As previously mentioned, pharmaceutical concern in the environment is as a 
result of the rapid technological advances in recent years which have enabled the 
3 
improvement of analytical performance in terms of resolution and sensitivity and 
the detection of these now termed CECs.  
Ireland is a leading location for the pharmaceutical industry, housing 9 of 
the 10 largest pharmaceutical companies in the world. The Irish market for 
pharmaceutical products in 2010 was valued at just under €2.3 billion by the Irish 
Pharmaceutical Healthcare Association (IPHA), indicating a high level of 
pharmaceutical consumption in Ireland (IPHA, 2012). Lacey et al. (2008) 
previously reported the presence of pharmaceuticals in Irish wastewater effluent at 
low µg.L-1 concentrations. The release of pharmaceuticals in this concentration 
range has been shown to impact on the quality of the surrounding aquatic 
environment in other European countries and America (Corcoran et al., 2010; 
Huerta et al., 2012). Although hormones are not within the scope of this thesis, it is 
worth mentioning that the release of the hormone medroxyprogesterone acetate in 
Irish industrial wastewaters consequently resulted in the infertility of pigs in 
Holland. This hormone was detected in the pig feed and traced back to 
contaminated wastewater, sourced from a large U.S. pharmaceutical company 
based in Ireland, which was exported to Holland and Belgium to be recycled and 
processed in pig feed (Van Leengoed et al., 2002). The most well-known example 
confirming the negative effects of pharmaceuticals on wildlife resulted in the 
decline of three species of vultures in Asia over the last 20 years. The anti-
inflammatory, diclofenac, was administered to livestock and was reported to have 
caused acute renal failure in vultures preying on their carcasses (Oaks et al., 2004).  
In Europe, a number of policies and directives have been enforced in order 
to protect the environment from exposure to harmful chemicals. The EU Water 
Framework Directives list 33 priority pollutants and 8 other pollutants which must 
be regulated and monitored in all European wastewaters (EU Directives 
2000/60/EC; 2008/105/EC). Pharmaceuticals have remained outside the scope for 
regulation and monitoring under this directive but in the past year, the EU 
Commission has revised the list of priority pollutants and following recent findings, 
has included the regulation of 12 new substances and the monitoring of 3 
pharmaceutical compounds including the anti-inflammatory, diclofenac and the 
hormones, 17α-ethinylestradiol and 17β-estradiol (EU Directive 2013/39/EU). 
These compounds have been added to a ‘watch list’ which are not subject to EU 
standards but are instead closely monitored in EU surface waters for possible future 
4 
addition to the priority list. The Oslo-Paris Convention for the Protection of the 
Marine Environment of the North-East Atlantic (OSPAR) is the only regulatory 
body to have considered pharmaceuticals as a threat to the environment as early as 
2002. This convention monitors environmental conditions and issues standards on 
the release of hazardous and radioactive materials, eutrophication and marine 
biodiversity. Under this legislation, clotrimazole, an antifungal agent, is listed for 
priority action with a number of other pharmaceuticals listed as chemicals of 
possible concern (Table 1.1). 
 
 
Table 1.1: OSPAR list of pharmaceuticals of possible concern to the marine 
environment 
Pharmaceutical compound Class CAS no. 
Chloroquine Antimalarial 54-05-7  
Chloroquine diphosphate Antimalarial 50-63-5  
Chlorpromazine Antipsychotic 50-53-3  
Mitotane Antineoplastic 53-19-0  
Prochlorperazine Antipsychotic/Antiemetic 58-38-8  
Fluphenazine Antipsychotic 69-23-8  
Fluphenazine dihydrochloride Antipsychotic 146-56-5  
Trifluoperazine dihydrochloride Antipsychotic 440-17-5  
Trifluperidol Antipsychotic 749-13-3  
Prochlorperazine edisylate Antipsychotic/Antiemetic 1257-78-9  
Pimozide Antipsychotic 2062-78-4  
Dimetacrine tartrate Antidepressant 3759-07-7  
Niflumic acid Anti-inflammatory 4394-00-7  
Dimetacrine  Antidepressant 4757-55-5  
Niclofolan Anthelmintic 10331-57-4  
Miconazole nitrate Antifungal 22832-87-7  
Timiperone Antipsychotic 57648-21-2  
Midazolam Anxiolitic 59467-70-8  
Diammonium N-ethylheptadecafluoro      
-N-[2-(phosphonatooxy)ethyl] 
octanesulfonamidate 
Chemical auxiliary agent 67969-69-1  
Penfluridol Antipsychotic 26864-56-2  
Terofenamate Anti-inflammatory 29098-15-5  
Flunarizine Antihypertensive 52468-60-7  
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The current list of pharmaceutical compounds deemed harmful to the 
aquatic environment is compiled based on ecotoxicology test results showing acute 
toxicity in the exposed organism. Pharmaceuticals exerting biological effects on 
organisms over time i.e. chronic exposure, are not currently regulated but should be 
considered as just as much of a threat to the aquatic environment. 
 
 
1.2 Sources of Pharmaceuticals in the Aquatic Environment 
Human actions, termed as ‘involuntarily’ and ‘purposefully’, are primarily 
responsible for the release of pharmaceuticals into the environment (Daughton, 
2007). Involuntary actions include pharmaceutical excretion through the body or 
washing of topical medicines down the drain. Human pharmaceuticals are excreted 
into the sewage system as a mixture of the parent compound and metabolites, 
comprising mostly of transformation products and conjugated glucuronides 
(Heberer, 2002). Conjugated compounds have been previously shown to be easily 
cleaved during wastewater treatment, releasing the parent compound into the 
treated wastewater, and subsequently into the environment (Jelic et al., 2011; 
Ternes, 1998). In contrast, purposeful actions include the disposal of unused or out 
of date medicines down the drain or into refuse waste. Medicines disposed of 
inappropriately into refuse waste enter landfill sites where the unchanged bioactive 
compounds can leach into the soil. Agricultural medicines administered to farmed 
animals are also a source of pharmaceutical pollution. Excreted manure, containing 
the metabolite/unchanged pharmaceutical mix, is often used as a fertilizer resulting 
in further exposure of these compounds to soil. Sludge from wastewater treatment 
plants (WWTPs) is also used as a soil fertilizer and may also be a source of 
pharmaceutical contamination in the environment. Soil leaching and groundwater 
recharge, caused by heavy precipitation, are the main modes of transportation for 
pharmaceuticals through the soil and into the aquatic environment. Other sources of 
pharmaceutical pollution of the aquatic environment include industrial spills and 
aquaculture. The origins and pathways of pharmaceuticals into the aquatic and 
terrestrial environment are depicted in Figure 1.1 (Boxall, 2004). 
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Figure 1.1: Sources of pharmaceuticals in the environment (Boxall, 2004) 
 
 
1.3 Drug Metabolism 
The fate of pharmaceuticals in the aquatic environment depends on numerous 
factors, such as the degree of transformation of the parent drug, the structure of the 
newly formed metabolites and the quantity of parent drug and metabolites excreted. 
Pharmacokinetics is the study of the processes by which a drug is absorbed, 
distributed, modified and excreted by the body (Rosenbaum, 2011). Currently, 
pharmaceuticals are designed in such a way that the active ingredient can be 
released at a targeted site to give the required pharmacological effect. In order to 
reach specific sites, pharmaceuticals must possess lipophilic properties to pass 
through the cell membranes of the body. Metabolism is an enzymatic process 
necessary for the transformation of lipophilic compounds to more polar metabolites 
suitable for elimination (Gumbleton, 2005). It is often considered as a deactivating 
process for drugs but for some compounds, known as ‘prodrugs’, metabolism is 
required to release the active parent compound and produce a pharmacological 
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effect (Rautio et al., 2008). Drug metabolism mainly takes place in the liver but 
other organs such as the intestine, lungs and kidneys have the ability to metabolise 
drugs also (Gumbleton, 2005). 
There are two reaction processes involved in the metabolism of compounds 
within the body; Phase I reactions involve the addition or exposure of a reactive 
functional group on the parent molecule and Phase II reactions conjugate the parent 
compound and/or the Phase I metabolite to a highly polar moiety. Phase I reactions 
include oxidation, reduction, hydrolysis, hydration, dethioacetylation and 
isomerisation (Gibson and Skett, 2001). Oxidation is the most common Phase I 
reaction as it performs numerous different types of functionalisation reactions. It is 
mostly controlled by cytochrome P450 enzymes, present in the endoplasmic 
reticulum of liver tissue. Cytochrome P450-catalysed mixed function oxidase 
(MFO) reactions occur in the presence of nicotinamide adenine dinucleotide 
phosphate (NADPH) and an oxidisable drug substrate. Phase II reactions include 
glucuronidation, glycosidation, sulfation, methylation, acetylation, condensation 
and amino acid, glutathione and fatty acid conjugation (Gibson and Skett, 2001). 
The large and diverse group of enzymes involved in Phase II reactions can only act 
on drug substrates in the presence of specific cofactors. For example, 
glucuronidation is the most common Phase II reaction due to the constant presence 
of the uridine-diphosphate (UDP)-glucuronosyl transferase enzyme (UGT), and its 
individual cofactor, UDP-glucuronic acid (UDPGA). The result of Phase I and 
Phase II reactions is the production of highly hydrophilic drug conjugates which are 
soluble in urine and easily eliminated from the kidneys via urine. There are various 
metabolic pathways for drugs, some more dominant than others and some equally 
as important. Phase II conjugation can take place directly for compounds containing 
reactive hydroxyl, carboxyl, amino and sulfhydryl groups (Faed, 1984). The lipid 
regulator, gemfibrozil, is a carboxylic acid containing compound and is primarily 
metabolised by Phase II glucuronidation to form the acyl glucuronide, gemfibrozil 
1-O-β-glucuronide, shown in Figure 1.2 (Ogilvie et al., 2006). Acyl glucuronides 
are highly reactive electrophiles, derived from carboxylic acids (Horng et al., 
2013). Further oxidation of gemfibrozil 1-O-β-glucuronide by hydroxyl groups has 
been reported at positions R1, R2 or R3, also shown in Figure 1.2 (Ogilvie et al., 
2006).  
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Figure 1.2: The primary metabolic pathway of gemfibrozil (Ogilvie et al., 2006) 
 
 
Metabolites of pharmaceuticals cannot be rendered unreactive or harmless 
as in the cases of paracetamol and amitriptyline which are partly metabolised to 
highly reactive compounds (Graham et al., 2013; Rudorfer and Potter, 1997). 
Under experimental conditions, water-exposed rainbow trout were found to 
metabolise pharmaceuticals readily with higher concentrations of metabolites 
detected in fish bile and plasma than the parent drug (Lahti et al., 2011). Besides 
the toxicological concerns, the possibility of uptake and metabolism of 
pharmaceutical compounds in exposed aquatic organisms still warrants further 
investigation. 
 
 
1.4 The Wastewater Treatment Process 
Municipal wastewater consists of the discharge from domestic and industrial 
sources and is made up of approximately 99.9 % water and 0.1 % dissolved and 
suspended solid material (Gray, 2004). The concentration of solid wastewater 
components varies greatly depending on the extent of industrial and agricultural 
influence on the catchment area. The main constituents include micro-organisms, 
biodegradable organic material and non-biodegradable organic material (oil, 
solvents and persistent organic pollutants (POPs)), nutrients, metals and inorganic 
materials (Henze et al., 2002).  
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The collection, treatment and discharge of wastewater is legally required in 
Ireland under the EU directive 91/271/EEC (EPA Ireland, 1997). The main 
objective of WWTPs is to prevent or minimise the risk of ecological impact on 
effluent receiving waters and its surrounding environments by reducing suspended, 
organic and inorganic matter. The functions of individual WWTPs vary and are 
very much dependent on the nature of the receiving waters (Forster, 1985). The 
efficiency of the receiving WWTP is protected under an EU directive concerning 
industrial emissions, which demands the monitoring of industrial and agricultural 
wastewater prior to sewage discharge (EU Directive 2010/75/EU). 
The treatment of municipal wastewater is a sequential process of 
mechanical, biological and chemical processes. A typical layout of a wastewater 
treatment plant is shown in Figure 1.3 (Mjalli et al., 2007). Physical and 
mechanical processes are carried out during preliminary and primary treatment. 
Preliminary treatment aims to prevent plant operational problems by screening 
large objects, debris, wood, grit and oil and by facilitating storm overflow (EPA 
Ireland, 1997). Primary treatment involves the sedimentation of suspended solids in 
large clarifier tanks for sufficient lengths of time. After settling, suspended solids 
and floating organic matter are physically removed from the tank and the 
wastewater is ready for secondary treatment. Biological processes are carried out 
during secondary treatment to remove biodegradable and trace organic constituents, 
colloidal solids and nutrients present in municipal wastewaters (Tchobanoglous et 
al., 2003). Activated sludge treatment is the most common type of secondary 
treatment. This type of treatment consists of two phases, aeration and sludge 
settlement, and aims to reduce the biological oxygen demand (BOD) of the 
wastewater. In suspended growth processes, such as activated sludge treatment, this 
process exposes wastewater to a diversified range of micro-organisms i.e. bacteria, 
protozoa, rotifiers and nematodes, each with distinct trophic levels, forming a 
complete ecosystem (Gray, 2004). These various micro-organisms form ‘flocs’ or 
active microbial biomasses which feed on organic matter and absorb colloidal and 
suspended materials (Horan, 1996). Oxygen diffusers or mechanical aerators, such 
as paddles, encourage high rates of microbial growth and respiration by providing 
aeration and help to keep flocs in suspension enabling maximum contact with 
organic matter in the wastewater (Gray, 2004). The final stage of secondary 
treatment is clarification of the wastewater by settlement. The formation of flocs is 
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Figure 1.3: Schematic diagram of the basic overview of an activated sludge 
wastewater treatment plant (Mjalli et al., 2007) 
 
 
also useful in yielding a clarified effluent as the well-formed flocs settle rapidly 
into a sludge form which is recycled back into the aeration tanks for further BOD 
removal (Horan, 1996). The remainder of solids in the settlement tank exits the 
WWTP and can be used as soil fertiliser or be disposed of in landfills or by 
incineration. At this stage, the treated water is released from the WWTP as effluent 
or undergoes tertiary treatment (EPA Ireland, 1997). 
Where discharges are made to more sensitive waters such as bathing waters 
or shellfish growing areas, more stringent treatments are necessary (EPA Ireland, 
1997). Tertiary treatments are mainly physical in action and are utilised for the 
removal of pathogens, residual suspended solids, dissolved organic matter (DOM) 
and eutrophication causing nutrients such as nitrates and phosphates. Nitrogen, 
primarily removed during the activated sludge treatment due to nitrification and 
denitrification processes, can be removed by the air stripping of ammonia. This 
involves highering the pH of the wastewater to form volatile ammonia gas, which is 
then eliminated following aeration of the tank. Chemical removal of phosphorous is 
a low cost technique which requires the addition of metal salts/lime and the 
subsequent removal of precipitates from the water. Disinfection via ultra-violet 
(UV) treatment is usually the most common final step of the wastewater treatment 
process and is important for the removal of harmful pathogens (Tchobanoglous et 
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al., 2003). The removal of DOM has become an important issue in recent years due 
to the exposure of their negative biological effects on aquatic biota (Farre et al., 
2008b). Advanced wastewater treatments are carried out for the removal of 
dissolved organic and inorganic pollutants using both physical and chemical 
methods. Techniques for their removal include activated carbon, membrane 
filtration and advanced oxidation processes (AOPs) such as ozonation 
(Tchobanoglous et al., 2003). 
 
 
1.5 Pharmaceuticals in the Wastewater Treatment Process 
There are three possible outcomes for pharmaceuticals travelling through the 
WWTP process; persistence throughout the process and release into receiving 
waters, transformation to more hydrophobic compounds and sorption to 
solids/activated sludge and removal after settlement or degradation to less harmful 
compounds. The degree of hydrophobicity of a compound is important when 
assessing their fate in the WWTP as more non-polar compounds adsorb onto 
activated sludge and more polar compounds remain in the water phase, passing 
through the system unchanged and travelling into receiving waters.  
Previous studies have reported low removal efficiencies of pharmaceuticals 
in the conventional activated sludge process by comparing pharmaceutical 
concentrations in the influent to those released in the effluent (Jelic et al., 2011; 
Ternes, 1998). A list of commonly used pharmaceuticals and their removal 
efficiencies in the biological wastewater treatment process has been compiled in 
Table 1.2. From the selected literature, it is clear that removal efficiencies can vary 
as a function of the type of compound being removed. Removal efficiencies for 
antibiotics ranged from 40 to 86 %, anti-inflammatories between 66 and 95 %, with 
the exception of diclofenac, β-blockers between 30 and 95 % and lipid regulators 
generally between 50 and 83 % but for one measurement of gemfibrozil, removal 
efficiencies of <10 % were recorded. Amitriptyline was removed efficiently during 
secondary treatment (>95 % efficiency) unlike carbamazepine and diclofenac, 
which increased in concentration, suggesting the cleavage of glucuronised 
metabolites and conversion back to their original form. The reconversion of 
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Table 1.2: Removal efficiencies of selected pharmaceuticals in the conventional 
activated sludge process 
Pharmaceutical 
class 
Compound % removal Reference 
Antibiotic Trimethoprim 40-50, 60-70 (Jelic et al., 2011; 
Kasprzyk-Hordern et al., 
2009) 
 Ciprofloxacin 86 (Vieno et al., 2007) 
    
Antidepressant Amitriptyline >95 (Kasprzyk-Hordern et al., 
2009) 
Antiepileptic Carbamazepine 7, −44 (Ternes, 1998; Vieno et al., 
2007) 
Anti-
inflammatory 
Diclofenac −34-40 (Kasprzyk-Hordern et al., 
2009; Lishman et al., 2006) 
 Ibuprofen 90, 95 (Lishman et al., 2006; 
Ternes, 1998) 
 Naproxen 66, 85, 93 (Kasprzyk-Hordern et al., 
2009; Lishman et al., 2006; 
Ternes, 1998) 
β-blocker Atenolol 80-95, 63 (Kasprzyk-Hordern et al., 
2009; Vieno et al., 2007) 
 Propranolol 96, 30-75 (Kasprzyk-Hordern et al., 
2009; Ternes, 1998) 
Lipid regulator Gemfibrozil 69, <10, 66 (Jelic et al., 2011; Lishman 
et al., 2006; Ternes, 1998) 
 Bezafibrate 83, 50 (Stumpf et al., 1999; 
Ternes, 1998) 
 
 
glucuronised compounds was previously demonstrated by Ternes et al. (1999) 
while studying the behaviour of estrogens during the activated sludge process. 
Removal efficiencies of WWTPs are also dependent on the treatment 
technology in place, wastewater retention time in each phase of treatment, solid 
retention time (SRT) and weather conditions such as rainfall (Vieno et al., 2007). 
Of all of these parameters, SRT is the most critical in the wastewater treatment 
process as it has been proved that longer SRTs greatly improve the removal 
efficiencies of pharmaceuticals (Clara et al., 2005; Lishman et al., 2006). A longer 
period of activated sludge treatment allows for the growth of diverse bacteria 
capable of further reducing the concentration of persistent pharmaceuticals (Clara et 
al., 2005).  
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Carballa et al. (2004) focused upon sampling wastewater at each stage of 
the treatment process in an attempt to ascertain which treatment step provided the 
highest rate of removal for selected pharmaceuticals. Preliminary and primary 
treatments revealed no reduction in concentrations for the anti-inflammatories, 
ibuprofen and naproxen, and the antibiotic, sulfamethoxazole, however, removal 
efficiencies of between 40-70 % were achieved following biological treatment. Joss 
et al. (2006) carried out a comprehensive study investigating the biodegradation of 
PPCPs after biological treatment and found that only 4 out of 35 compounds were 
degraded by >90 % while 17 compounds were removed by <50 %. The main 
removal mechanism of some persistent pharmaceuticals in biological WWTPs is 
sorption on activated sludge, rather than biodegradation (Kim et al., 2008) Previous 
studies have reported the sorption of pharmaceuticals, such as triclosan, sertraline 
and citalopram, on digested sludge collected from several WWTPs worldwide at up 
to µg.g
-1
 concentrations (Barron et al., 2008; Heidler and Halden, 2007; Jelic et al., 
2011). Other types of biological treatments in operation have not shown removal 
efficiencies for pharmaceuticals significantly greater than those produced after 
activated sludge treatment. Membrane bioreactor (MBR) systems use a suspended 
growth bioreactor, similar to the activated sludge process, but with micro-
/ultrafiltration as an alternative to gravity sedimentation (Harper Jr. et al., 2008). 
With longer SRTs and higher mixed liquor suspended solids concentrations, recent 
reports have only shown slightly higher efficiencies, if any, in comparison to 
similarly operated conventional systems (Clara et al., 2004). A trickling filter did 
not perform as well at removing pharmaceuticals with efficiencies approximately 
12-66 % lower than those yielded by activated sludge treatment (Stumpf et al., 
1999). 
A comprehensive study, carried out by Snyder et al. (2008) evaluated 
advanced WWTP processes individually and in combination for their removal 
efficiency of selected pharmaceuticals. Studies revealed that UV treatment alone 
was not enough to give sufficient removal rates for pharmaceuticals but, when in 
combination with AOPs such as hydrogen peroxide (H2O2), reductions of >90 % 
were reported for the majority of the selected pharmaceuticals. Ozonation was 
another treatment found to be highly effective for the removal of most target 
pharmaceuticals with average removal efficiencies of >90 %. 
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1.6 Pharmaceutical Fate in the Environment 
Designed to be robust and stable, most pharmaceuticals have a polar and non-
volatile nature, making it difficult for their removal in the aquatic environment. 
Pharmaceuticals are predominately released into the aquatic environment with 
treated wastewater effluent but can also be leached through the soil from landfills 
and contaminated sewage sludge and manure used as fertiliser (Boxall, 2004). 
Knowledge concerning the fate of pharmaceuticals is essential when attempting to 
assess the potential risk posed by these micro-pollutants. The regular use and 
continuous introduction of pharmaceuticals into the aquatic environment confers 
some degree of pseudo-persistence (Hernando et al., 2006). To date, over 80 
pharmaceuticals have been detected at substantial concentrations in various 
environmental matrices such as surface waters (Ollers et al., 2001; Roberts and 
Thomas, 2006; Ternes, 1998; Wille et al., 2010), groundwaters (Lapworth et al., 
2012) and soils (Barron et al., 2008). Several processes can occur on compounds in 
the aquatic environment including photochemical degradation, sorption onto solid 
matrices and, of particular importance in this work, dilution and transportation 
within the aquatic environment with potential uptake in biological species, which 
will be covered in more detail in the next section. 
Pharmaceuticals are mainly administered orally and are therefore considered 
resistant to hydrolysis, with previous studies confirming this assumption (Buser et 
al., 1998b; Lam et al., 2004). Photodegradation is the primary pathway for the 
abiotic transformation of pharmaceuticals in the aquatic environment. Two types of 
photolytic reactions can occur; direct absorption of light by the compound, known 
as direct photolysis, or interaction of a reactive intermediate of another species 
produced by its absorption of light, known as indirect photolysis (Andreozzi et al., 
2003). Both reactions cause instability within the compound causing it to degrade 
into numerous photoproducts. With only a small number of published papers on 
this subject to date, research on the photochemical fate of pharmaceutical chemicals 
is limited. Buser et al. (1998b) investigated the photochemical fate of the non-
steroidal anti-inflammatory drug (NSAID), diclofenac, in fortified natural lake 
water and found it was rapidly degraded to <1 % of the initial concentration after 
four days of exposure to natural sunlight. High rates of photodegradation were 
observed in similar experiments where diclofenac was exposed to natural sunlight 
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(Poiger et al., 2001; Schmitt-Jansen et al., 2007). Other pharmaceuticals which 
readily underwent phototransformation included naproxen, sulfamethoxazole, 
ofloxacin, propranolol and fluoxetine (Andreozzi et al., 2003; Lam et al., 2005; 
Packer et al., 2003). In comparison, carbamazepine and clofibric acid were 
observed to have almost negligible rates of phototransformation upon irradiation 
(Andreozzi et al., 2003). The antibiotics, oxolinic acid and ciprofloxacin, were also 
found to degrade at slow rates with oxolinic acid degrading much slower than 
ciprofloxacin (Turiel et al., 2005). This highlights the persistence of antibiotics in 
the aquatic environment and the risk of microbial resistance posed by quinolone 
antibiotics in particular. Photoproducts derived from pharmaceuticals such as 
ciprofloxacin, naproxen and furosemide, have been found to contain the active 
group of the pharmaceutical and may have the potential to be more toxic than the 
parent molecules. Both the parent compound and their degradation products should 
be considered when carrying out environmental risk assessments of 
pharmaceuticals (Isidori et al., 2005; Isidori et al., 2006; Turiel et al., 2005). 
As previously mentioned, sludge from WWTPs and animal manure are 
often applied as agricultural fertiliser over farmed land, introducing both human 
and veterinary pharmaceuticals into the environment. Barron et al. (2009) 
investigated the occurrence of PPCPs in sludge and sludge enriched agricultural 
soils in Ireland. Significant levels of triclosan and carbamazepine were identified in 
dried sludge samples, while lower but still relevant concentrations of triclosan and 
nimesulide were found in the fertilised soil. Pharmaceuticals enter and persist 
within the soil depending on their capacity for sorption, resistance to 
photodegradation and affinity for water, which if high will cause leaching from the 
solid into water systems (Diaz-Cruz et al., 2003). The distribution of 
pharmaceuticals between the aqueous phase and the solid phase is an equilibrium 
process, represented by the solid-water distribution coefficient (KD) whereby; 
 
   KD = Csolid / Caqueous     Eqn. 1.1 
 
Csolid and Caqueous are the pharmaceutical concentrations in the solid and water 
phases, respectively. KD values predict whether a substance will show appreciable 
adsorption or if they will remain in the aqueous phase. Compounds with higher KD 
values are considered more of a possible threat to the soil environment. A previous 
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study on the sorption and fate of 49 pharmaceuticals in biosolid enriched soil 
revealed over two thirds of all selected pharmaceuticals showed low affinity to the 
soil matrix with KD values ≤50 L.kg
-1
 (Barron et al., 2009). Compound properties 
such as KD, octanol-water partition coefficients (logKow) and normalised organic 
carbon sorption coefficients (Koc) have been previously used to interpret sorption 
behaviours of pharmaceuticals, but can only be used as an approximate guide due to 
the complexity of solid matrices and the nature of pharmaceuticals (Carballa et al., 
2008). A more recent solids column study reported the leaching of salbutamol, 
sulfamethoxazole, sulfamethazine, ketoprofen and bezafibrate from sludge and 
spiked soil. Carbamazepine was mostly retained in the soil with low levels leached 
into the aqueous phase. The majority of the other pharmaceuticals, including β-
blockers and trimethoprim, were also highly retained in the soil but, in the case of 
indomethacin, residues were mostly retained in the sludge. Interestingly, the 
majority of pharmaceuticals retained in the sludge or soil were detected at overall 
concentrations approximately 75 % less than those originally spiked suggesting 
high levels of transformation within the solid matrices (Barron et al., 2010). Oppel 
et al. (2004) also reported the high retention of carbamazepine in soil along with 
diazepam and ibuprofen, while clofibric acid was found to seep out with the 
leachate. 
 
 
1.7 Pharmaceutical Occurrence in the Aquatic Environment 
1.7.1 Surface water 
In recent years, monitoring studies have focused on the presence of pharmaceuticals 
in freshwater environments with comparatively little knowledge regarding the 
occurrence, distribution and fate of pharmaceuticals in marine or estuarine 
environments. This may be due to the difficulty of working with a more complex 
matrix or the assumption that pharmaceutical residues are diluted to negligible 
concentrations in the marine environment. Considering the vast number of studies 
on pharmaceutical occurrence in freshwater environments and the scope of this 
thesis, this section will specifically focus on the monitoring of pharmaceuticals in 
marine surface waters only.  
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In a study carried out by Thomas and Hilton (2004), 14 pharmaceuticals 
were monitored in British estuaries of the Thames, the Tyne, the Mersey, the Tees 
and Belfast Lough. The selected pharmaceuticals were chosen based on priority 
lists of the UK Environmental Agency and the OSPAR Commission (Hilton et al., 
2003). From the targeted list, 9 pharmaceuticals were detected in the estuarine 
water samples collected. Ibuprofen and trimethoprim were detected at the highest 
concentrations, measuring at 928 ng.L
-1
 and 569 ng.L
-1
, respectively, and 
clotrimazole was the most frequently detected pharmaceutical with a median 
concentration of 7 ng.L
-1
. A number of other studies have analysed marine water 
samples collected from the North Sea, its estuaries and harbours. In two separate 
studies, clofibric acid was the only pharmaceutical detected in the North Sea at 
concentrations between 1-2 ng.L
-1
 but, further into the River Elbe estuary clofibric 
acid was detected at concentrations of 18 ng.L
-1
, along with diclofenac and 
ibuprofen measuring at 6.2 ng.L
-1
 and 0.6 ng.L
-1
, respectively (Buser et al., 1998a; 
Weigel et al., 2002). A more recent study, carried out by Wille et al. (2010), 
frequently detected residues of salicylic acid, carbamazepine and propranolol in 
marine surface water collected from several Belgian harbours and estuaries, with 
lower and less frequent residues of the antibiotics, trimethoprim and 
sulfamethoxazole, also detected. Further offshore, salicylic acid and carbamazepine 
were detected up to concentrations of 237 ng.L
-1
 and 12 ng.L
-1
, respectively, in the 
Belgian coastal area of the North Sea. Residues of ibuprofen and its metabolites 
were detected in effluent receiving marine waters in Norway at concentrations up to 
7.7 ng.L
-1
 (Weigel et al., 2004). Langford and Thomas (2011) also reported the 
presence of the active metabolites, carbamazepine-10,11-epoxide and simvastatin 
hydroxy carboxylic acid, in marine coastal waters from Oslofjord at concentrations 
greater than their parent compounds, highlighting the need for environmental risk 
assessments of active metabolites. 
Monitoring studies in the Mediterranean Sea revealed the presence of 
pharmaceuticals in the low ng.L
-1
 range. Eight pharmaceuticals, including 
verapamil, atenolol and metolol, were detected in marine surface water collected 
from several bays around the island of Mallorca (Rodriguez-Navas et al., 2013). 
Munaron et al. (2012) deployed passive samplers in French Mediterranean coastal 
waters for a period of 14-28 days and detected the presence of carbamazepine, 
theophilline and terbutaline. Outside of Europe, Comeau et al. (2008) investigated 
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pharmaceutical residues in Canadian marine surface water collected downstream 
from a WWTP. Although low residues of naproxen, gemfibrozil, ibuprofen and 
salicylic acid were detected in the effluent receiving waters, none of these acidic 
compounds were detected in the marine surface waters sampled at an estuary 
further downstream. Recently, a list of 108 PPCPs and alkylphenols were targeted 
in a monitoring study carried out in San Francisco Bay, California. From this list, 
10 pharmaceuticals were detected in the marine waters of all 5 sampling locations 
with carbamazepine, gemfibrozil, sulfamethoxazole, and valsartan among the 
highest concentrations, measuring between 38-92 ng.L
-1
 (Klosterhaus et al., 2013). 
The detection of pharmaceuticals and their metabolites in marine surface waters 
suggests a high level of persistence of these compounds in the aquatic environment. 
 
 
1.7.2 Aquatic biota 
One of the main concerns surrounding pharmaceutical release into surface waters is 
their potential to bioaccumulate in aquatic organisms. Bioconcentration is the 
concentration of a compound in or on an organism through water exposure alone 
whereas bioaccumulation is the uptake of a chemical by an organism through a 
combination of water, food, sediment and air, as occurs in the natural aquatic 
environment (Arnot and Gobas, 2006). There are several elements that can 
influence the bioaccumulation of a pharmaceutical including its physicochemical 
nature, its bioavailability in the aquatic system, biotic factors relating to the 
exposed aquatic organism and the temperature, pH, flow and quality of its residing 
waters (Bremle et al., 1995; Nakamura et al., 2008; Rendal et al., 2011). Kow values 
determine the partition of a compound between octanol and aqueous phases, 
however, due to the ionisation of pharmaceuticals, the octanol-water distribution 
coefficient (Dow) is a more reliable measure for bioaccumulation potential as both 
the neutral and ionised fractions of the compound are considered at a given pH 
(Cunningham, 2008).  
Several studies have investigated the occurrence of pharmaceutical residues 
in wild aquatic species, focusing mainly on accumulation in wild fish species. The 
first of such work was carried out by Brooks et al. (2005) whereby numerous 
antidepressants were screened for in the tissues of wild fish residing in two separate 
effluent dominated streams in the US. Two antidepressants, fluoxetine and 
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sertraline, and their two respective metabolites, norfluoxetine and 
desmethylsertraline, were detected at levels greater than 0.1 ng.g
-1
 wet weight 
(WW) in all tissues, with highest concentrations measured in the liver and brain. 
Additional selective serotonin reuptake inhibitors (SSRIs) and their metabolites 
have also been detected in similar studies carried out more recently in the US, again 
at low ng.g
-1
 concentrations (Chu and Metcalfe, 2007; Schultz et al., 2010). In 
2009, Ramirez et al. (2009) led a national pilot study, to investigate the occurrence 
of PPCPs in fish fillet and liver from effluent-dominated rivers throughout the 
United States. All fish tissues tested positive for norfluoxetine, sertraline, 
diphenhydramine, diltiazem and carbamazepine, with the addition of gemfibrozil 
and fluoxetine detected in the liver. At one particular exposure site, sertraline was 
measured at concentrations up to 545 ng.g
-1
 WW in the liver of the wild white 
sucker fish species. In Sweden, studies on juvenile rainbow trout sampled from 
several sewage effluent outfall sites revealed the presence of ibuprofen, diclofenac, 
naproxen, ketoprofen and gemfibrozil in the fish plasma with gemfibrozil detected 
at the highest concentrations (Brown et al., 2007). More recently, Huerta et al. 
(2013) collected 11 wild fish species from 4 Mediterranean rivers in Spain for 
pharmaceutical and metabolite analysis. From the 20 selected compounds, 9 
pharmaceuticals were detected in fish homogenates and liver tissues. Diclofenac 
was the most recurring compound, detected in 9 % of all samples collected, and 
carbamazepine measured highest at a concentration of 18 ng.g
-1 
in fish liver. 
Bivalves, such as mussels, are natural filter feeders which have been widely utilised 
in POP monitoring programmes because of their high bioaccumulation capacities, 
fixed conditions and high populations in marine waters (Hunt and Slone, 2010; 
Monirith et al., 2003). The uptake of pharmaceuticals, such as antibiotics, has been 
previously observed in mussel species collected from the Bohai Sea in China over a 
period of four years (Li et al., 2012). Most recently, wild ribbed horse mussels 
sampled from five near shore sites in San Francisco Bay were found to contain low 
residues of carbamazepine and sertraline at concentrations up to 2.4 ng.g
-1
 and 0.3 
ng.g
-1
 WW, respectively (Klosterhaus et al., 2013).  
The use of caged sample studies involves the caging of uncontaminated 
species at effluent outfall sites for a number of days. Fick et al. (2010) exposed 
cages of rainbow trout at three different effluent exposure sites for a period of 14 
days. Out of the 25 pharmaceuticals present in the effluent, 16 were detected in the 
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fish plasma. In a similar study, two antidepressants were detected at high ng.L
-1
 
levels in the bile of rainbow trout exposed downstream to a Canadian WWTP for 
14 days (Togunde et al., 2012). With regard to pharmaceutical exposure studies 
using caged mussels, a recent study deployed five cages of blue mussels off the 
Belgian coast. Over a six-month period, five pharmaceuticals were detected in 
mussel tissues including salicylic acid residues, measuring up to 490 ng.g
-1
 dry 
weight (DW)
 
(Wille et al., 2011). In a separate study in North Carolina, the 
antidepressant, fluoxetine, was detected in caged mussel tissues up to 79 ng.g
-1
 
WW after 14 days exposure in a wastewater effluent channel (Bringolf et al., 2010). 
 
 
1.8 Environmental Risk Assessment and Ecotoxicity of 
Pharmaceuticals 
The European Medicines Evaluation Agency (EMEA) is responsible for the 
licensing and registration of medicinal products in the EU. Under the EU Directive 
93/39/EEC, an environmental risk assessment is required prior to drug licensing, to 
determine any significant toxicological risks associated with a drug (Straub, 2002). 
The EMEA risk assessment procedure is carried out over three sections with the 
first involving the calculation of a predicted environmental concentration (PEC) 
value. PEC values are calculated by taking into account the defined daily dose in 
mg per person per day, population size treated, volume of wastewater produced per 
person per day and dilution factor in receiving waters (Huschek et al., 2004). 
Calculated PEC values must be <0.01 µg.L-1 to complete the risk assessment, 
otherwise the investigation proceeds to the next section where the predicted no 
effect concentration (PNEC) value is calculated. This value is based on acute 
toxicity data generated from standardised testing on algae, daphnia or fish. The 
assessment is complete if the PEC/PNEC ratio is <1 but if it exceeds this value, 
completion of the third section is required which may include further testing and 
safety measures such as chronic toxicity testing, modeling environmental fate, field 
studies, specific product labeling and restricted use (Straub, 2002).  
Pharmaceuticals are designed to target specific receptors in humans and 
animals, and thus are extremely potent, even at low concentrations. As previously 
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mentioned, the main concern surrounding pharmaceutical release into surface 
waters is the potential for pharmaceuticals to target similar receptors in non-target 
aquatic species, causing similar effects or side-effects (Fent et al., 2006). Under the 
current regulatory guidelines, environmental toxicity testing of pharmaceuticals 
only requires for standard acute toxicity tests to be carried out unless the 
PEC/PNEC ratio is >1 and further testing is required. Standardised toxicity tests on 
aquatic organisms are generally limited to algae, daphnia and/or fish from 
freshwater environments. This approach increases the uncertainty of the 
environmental impact of chemicals on other freshwater and marine aquatic species 
and even on the tested aquatic species due to intra species variations, such as age 
and gender, resulting in different sensitivities (Jones et al., 2007). Toxic effects 
observed upon exposure of aquatic organisms to environmentally relevant 
pharmaceutical concentrations are listed in Table 1.3. The main effects observed in 
exposed aquatic biota were increased oxidative stress conditions and alterations in 
fish organs, mainly the kidneys. 
 Reactive oxygen species (ROS) are naturally produced in biological systems 
but, in the presence of chemical contaminants, their production is increased (Romeo 
and Giamberini, 2013). In response, a number of antioxidant enzymes are induced 
which have the potential to cause damage to biological tissue resulting in 
biochemical lesions. Oxidative stress is caused by an imbalance in favour of the 
production of ROS instead of their neutralisation by antioxidant defence 
mechanisms (Romeo and Giamberini, 2013). Due to the relationship between 
environmental pollutants and molecular responses of oxidative stress, the use of 
antioxidant enzymes, such as glutathione S-transferase (GST) and glutathione, as 
biomarkers of exposure has been reported to successfully highlight oxidative stress 
in exposed organisms (Hellou et al., 2012). Biomarkers are a more sensitive 
endpoint than standard toxicity tests however, they can lack sensitivity and 
selectivity as response can vary depending on several biotic and abiotic 
factors.Hence, proteomics has recently come forward as a more robust method of 
assessing stress in exposed organisms and potential contamination (Campos et al., 
2012; Schmidt et al., 2013).  
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 Table 1.3: Effects of pharmaceuticals at environmentally relevant concentrations 
on non-target species following chronic exposure studies  
Compound Organism 
Exposed 
concentration 
Exposure 
period 
Toxicity Reference 
Antidepressants Fish WWTP 
effluent 
3 mth Inhibited activity 
of the ATP-
dependent Na/K-
ATPase 
(Lajeunesse et 
al., 2011) 
Carbamazepine Mollusc 1-1000 nM 7 d Increased 
oxidative stress 
(Contardo-Jara 
et al., 2011) 
 Cnidarian 0.1-5 µM 48 h Increased 
oxidative stress 
>30 nM 
(Quinn et al., 
2004) 
 Fish 1-100 µg.L
-1
 28 d Alterations to 
kidney >1 µg.L
-1 
(Triebskorn et 
al., 2007) 
Diclofenac Fish 1-500 µg.L
-1
 28 d Kidney lesions 
and alterations in 
gills 
>5 µg.L
-1
 
(Schwaiger et 
al., 2004) 
 Fish 1-500 µg.L
-1
 28 d Alterations to 
liver, kidney, 
gills & intestine 
>1 µg.L
-1
 
(Triebskorn et 
al., 2004) 
 Fish 0.5-25 µg.L
-1
 21 d Kidney & 
intestinal lesions 
>1 µg.L-1 
(Mehinto et al., 
2010) 
 Fish 1-100 µg.L
-1
 14 d Effects on 
hepatic gene 
expression 
(Cuklev et al., 
2011) 
 Mollusc 1 µg.L
-1
 96 h Increased 
oxidative stress 
(Quinn et al., 
2011) 
 Mollusc 1 µg.L
-1
 14 d Increased 
oxidative stress 
(Schmidt et al., 
2013) 
Gemfibrozil Mollusc 1 µg.L
-1
 96 h Increased 
oxidative stress 
(Quinn et al., 
2011) 
(Schmidt et al., 
2011) 
 Mollusc 1 µg.L
-1
 14 d Increased 
oxidative stress 
(Schmidt et al., 
2013) 
Ibuprofen Mollusc 1-1000 nM 7 d Increased 
oxidative stress 
(Contardo-Jara 
et al., 2011) 
 
 Amphipod 
Crustacean 
1-1x10
6
 ng.L
-
1
 
2 h Behavioural 
activity changes 
 >10 ng.L
-1
 
(De Lange et 
al., 2006) 
Metaprolol Fish 1-100 µg.L
-1
 28 d Alterations to 
liver >1 µg.L
-1
 
(Triebskorn et 
al., 2007) 
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Computerised models using quantitative structural activity relationships 
(QSARs) have also been employed to assess the potential risk posed by 
pharmaceuticals. QSARs compare pharmaceuticals to similar, previously tested, 
compounds based on their structure and composition to predict toxicity data 
(Perkins et al., 2003). Due to the lack of ecotoxicological data, QSAR models have 
proved useful by providing reasonable environmental risk data on the chronic 
toxicity of pharmaceuticals in surface waters (Sanderson et al., 2003). A previous 
study ranked 2986 different pharmaceuticals relative to the risk they pose to algae, 
daphnids and fish using a QSAR model. Cardiovascular pharmaceuticals ranked the 
most hazardous therapeutic class with daphnids and algae found to be the most and 
least susceptible species to change following pharmaceutical exposure (Sanderson 
et al., 2004). 
 
 
1.9 Pharmaceutical Exposure to Humans 
Unbeknownst to us, human health can also be exposed to pharmaceuticals through 
food and drinking water. The widespread use of veterinary medicines in 
aquaculture and livestock has generated great concern of developing antibiotic 
resistance. This may be the reason as to why antibiotics are the most investigated 
compounds when it comes to assessing the potential risk of pharmaceutical 
exposure to humans via trophic level transfer. In Canada, a ‘Total Diet Study’ was 
carried out to test the presence of veterinary drugs in fresh and canned fish and 
shrimp produced for human consumption. Results confirmed the exposure of 
humans to low ng.g
-1
 concentrations of some banned and upapproved veterinary 
drug residues via consumption of these farmed seafoods (Tittlemier et al., 2007). 
The European Food Safety Authority (EFSA) conducts an annual report on the 
monitoring of veterinary pharmaceutical residues in live animals and animal 
products from 27 member states (EFSA, 2013). The most recent report detailed the 
results from the year 2011 with tested animals and animal produce including 
bovines, pigs, sheep and goats, horses, poultry, rabbit, farmed game, wild game, 
aquaculture, milk, eggs and honey. For antibiotics, 0.2 % of just over 400,000 
tested samples were deemed non-compliant, with the highest reoccurrence in 
honey. Other drugs such as NSAIDs and steroids were also detected in less than 0.7 
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% and 0.1 % of tested samples, respectively. The potential for human health risks 
due to exposure to contaminated seafood and animal produce are not confined 
geographically to one location due to global trade, making this a worldwide issue 
(Sapkota et al., 2008). 
Pharmaceutical residues found in drinking water are mostly polar 
compounds with a weak binding affinity to soil particles which enable them to pass 
through the soil to the groundwater. The presence of pharmaceuticals in 
groundwater is a cause for concern as groundwater is often reused and recycled as 
potable water. As previously mentioned, pharmaceuticals have been detected in 
drinking water supplies at low ng.L
-1
 concentrations providing direct entry for 
pharmaceuticals into the human body (Benotti et al., 2009; Focazio et al., 2008; 
Heberer et al., 2000; Stan and Heberer, 1997). The extent of exposure to humans 
has been deemed as negligible in most cases, citing ‘no appreciable risk to humans 
exist’ but the risk of chronic exposure to pharmaceuticals needs to be further 
assessed (Cunningham et al., 2009; Schwab et al., 2005). 
 
 
1.10 Pharmaceutical Analysis of Environmental Samples 
Since the initial detection of pharmaceuticals in the environment, instrumentation 
has advanced considerably, enabling the quantification of pharmaceuticals at part 
per trillion levels in very complex matrices. Within this review, the objective of this 
section was to highlight the most recent advances and current approaches in the 
methods carried out for the analysis of pharmaceuticals in the natural aquatic 
environment, covering both water and aquatic biota samples. 
Most recently, the need for more efficient sample preparation and 
instrumental methods of analysis has resulted in the development of numerous 
multi-class detection methods for pharmaceuticals (Ferrer et al., 2010; Gracia-Lor 
et al., 2011; Gros et al., 2006b; Petrovic et al., 2006; US EPA, 2007). These 
methods vary in procedure and technique but the basic sample preparation steps, 
depicted in Figure 1.4, are fundamental to all methods of analysis for 
pharmaceuticals in solid and aqueous samples (Comerton et al., 2009; Reemtsma 
and Quintana, 2006).  
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Figure 1.4: Sample preparation and analysis of pharmaceuticals in aqueous and 
biotic matrices (Reemtsma and Quintana, 2006) 
 
 
Water samples include wastewater influent and effluent, marine water, 
freshwater groundwater and drinking water. Solid samples include biological tissue, 
soil and sludge but, within this review, we will discuss the techniques carried out to 
date on aquatic biological tissues only.  
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1.10.1 Water analysis 
In order to minimise any initial losses of analytes, certain approaches are taken for 
sample collection and pre-treatment. Water samples are filtered soon after 
collection, typically with glass fibre filters (0.2-1.2 µm), to remove suspended 
particulate matter (SPM) present in the sample and reduce the clogging of 
extraction sorbents (Jjemba, 2008). Adjustment of sample pH is carried out to 
determine analyte speciation and promote interactions with the solid phase 
extraction (SPE) sorbent, enhancing analyte recovery (Comerton et al., 2009).  
For complex environmental samples, extraction is required to isolate and 
pre-concentrate target analytes, reduce or remove unwanted matrix components and 
overall, increase method sensitivity. A wide range of multi-class pharmaceuticals 
have been found to be reasonably extracted from aqueous samples and pre-
concentrated using a technique known as SPE (Gros et al., 2006a; Li et al., 2006). 
Currently the most common sample preparation technique in environmental 
analysis, SPE is less time consuming, less wasteful and more sensitive than the 
traditionally used liquid-liquid extraction (LLE) (Pichon, 2000; Wu et al., 2010). 
Two basic approaches to SPE are off-line i.e. extraction is separate to the analyte 
separation step and the SPE sorbent is usually packed in disposable cartridges, and 
on-line i.e. extraction is coupled with the analyte separation step by means of 
packing the sorbent into a pre-column in the injection loop of a high performance 
liquid chromatography (HPLC) system (Pichon, 2000). Off-line SPE can be time 
consuming and laborious but, in comparison to on-line SPE, the risk of 
contamination from sorbent reuse is eliminated and costs are somewhat reduced. 
Both off-line and on-line SPE techniques yield comparable values for precision and 
sensitivity (Trenholm et al., 2009) but, for the vast majority of methods, off-line 
SPE is the method of choice (Gros et al., 2009; Petrovic et al., 2010). 
A large variety of off-line SPE sorbents are commercially available with 
selection based on the nature of the analyte and the sample matrix type. Mixed-
mode SPE sorbents have emerged onto the market with the advantage of displaying 
both hydrophobic and ion exchange properties and allowing for multi-class analysis 
of pharmaceuticals in aqueous samples. The most popular of these new polymeric 
sorbents are Oasis HLB, a copolymer of divinylbenzene and vinylpyrrolidone, 
manufactured by Waters, and Strata-X, a polydivinylbenzene resin containing 
piperidone groups, manufactured by Phenomenex. These sorbents have shown the 
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highest extraction efficiencies for numerous pharmaceuticals of varied classes 
(Cahill et al., 2004; Gomez et al., 2007; Lacey et al., 2008; Roberts and Bersuder, 
2006). Other mixed-mode cartridges used for pharmaceutical extraction include 
Oasis MXC (mixed-mode cation exchange) (Batt et al., 2008; Castiglioni et al., 
2005; Kasprzyk-Hordern et al., 2008) and Oasis MAX (mixed-mode anion 
exchange) (Laven et al., 2009; Sousa et al., 2011) both manufactured by Waters. 
Following extraction, analytes retained on SPE sorbents will remain stable until 
further analysis, once stored at −20 °C (Baker and Kasprzyk-Hordern, 2011). 
More recently, molecularly imprinted polymers (MIPs) were developed to 
overcome the problem of poor recovery of polar analytes. This highly selective 
extraction technique only recognises molecules matching the shape and functional 
group position of the template in the polymer (Buszewski and Szultka, 2012). 
Although there have been several studies which have utilised MIPs for 
pharmaceutical extraction from environmental water samples (Beltran et al., 2007; 
Gros et al., 2008; Sun et al., 2008; Zorita et al., 2008), this is not a practical method 
for the analysis of multi-class pharmaceuticals. Sorptive extraction methods have 
also been used for the extraction of low-level pharmaceutical residues from 
complex water samples and include solid phase micro-extraction (SPME) (Araujo 
et al., 2008; Rodriguez et al., 2004; Wen et al., 2006) and stir-bar sorptive 
extraction (SBSE) (Luo et al., 2011; Quintana et al., 2007; Van Hoeck et al., 2009). 
Low detection limits were also determined for NSAIDs using liquid phase micro-
extraction (LPME) in conjunction with LC-MS/MS and gas chromatography-mass 
spectrometry (GC-MS) analysis (Es'haghi, 2009; Quintana et al., 2004). Although 
alternative techniques to SPE may be speedier, more cost efficient and less 
wasteful, higher sensitivity and precision values are achieved when using SPE for 
the extraction of multi-class pharmaceuticals (Fatta et al., 2007). 
Highly sensitive methods are required to determine the low levels of 
contaminants present in complex environmental samples. Hyphenated techniques, 
such as GC-MS and LC-MS, combine chromatographic separation with 
spectrometric detection and produce a highly sensitive analytical technique with 
high specificity. The traditional GC-MS approach is suitable for the analysis of 
thermally stable and volatile analytes, hence, a lengthy derivatisation procedure is 
required prior to pharmaceutical analysis. Such an approach is unfavourable as not 
only is it time consuming but, it also increases the level of variability of the method 
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(Fatta et al., 2007). For these reasons, LC-MS has been extensively employed for 
the identification and quantification of a wide range of multi-class pharmaceuticals 
in environmental samples (Buchberger, 2011; Wu et al., 2010).  
LC is most commonly used in reverse phase with the mobile phase 
consisting of an aqueous phase (water) and an organic phase (usually acetonitrile or 
methanol). The aqueous phase often has the addition of a volatile additive such as 
ammonium acetate or formic acid to enhance ionisation efficiencies of basic and 
acidic pharmaceuticals, respectively. Ultra performance liquid chromatography 
(UPLC) is a new technique which exploits sub 2 µm particle-packed columns to 
produce faster and more resolved separations of pharmaceuticals (Wille et al., 
2012). Numerous analytical methods have been developed using UPLC and 
separations of up to 70 pharmaceutical residues in less than 7 mins have been 
reported (Batt et al., 2008; Farre et al., 2008a; Gracia-Lor et al., 2011; Kasprzyk-
Hordern et al., 2007; Kasprzyk-Hordern et al., 2008; Petrovic et al., 2006). Limits 
of detection (LODs) were in the low ng.L
-1
 range when combined with an MS 
detector, similar to conventional HPLC analysis. 
Mass spectrometry has been the detection technique of choice for the 
analysis of pharmaceutical residues in aqueous samples for many years. Over the 
past two decades, LC-MS technologies have greatly advanced in reliability, 
sensitivity and selectivity with detection limits in the ng.L
-1
 range and lower. 
Electrospray ionisation (ESI) is the most commonly used atmospheric pressure 
ionisation interface for the coupling of LC with mass spectrometry, compared to 
atmospheric pressure chemical ionisation (APCI) and atmospheric-pressure 
photoionisation (APPI) (Krauss et al., 2010). A drawback associated with LC is the 
co-elution of unwanted matrix constituents with analytes of interest resulting in a 
decrease in ionisation efficiencies. The use of internal standards has somewhat 
overcome this problem but, depending on costs, availability and variability of the 
matrix, standard addition has proved to be just as effective (Botitsi et al., 2007; Van 
De Steene et al., 2006). 
Quadrupole mass analysers set up in tandem are most frequently used for 
routine target analysis of complex environmental samples due to their relatively 
low cost and ability to fragment ions necessary for the accurate identification of 
analytes (Comerton et al., 2009). The most common types of quadrupole mass 
analysers used are the triple quadrupole (QqQ) mass analyser and the ion trap, with 
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typical limits of detection for pharmaceuticals in contaminated waters measuring in 
the low ng.L
-1
 concentration range (Petrovic et al., 2005). These analysers offer 
high sensitivity and selectivity in selected reaction monitoring (SRM) mode for 
target analysis (Zwiener and Frimmel, 2004). For the accurate mass screening of 
both known and unknown compounds, the time-of-flight (TOF) and orbitrap mass 
analysers are applied due to their high resolving power, high mass accuracy and 
high sensitivity, down to the femtogram range (Krauss et al., 2010). However, these 
techniques are much more expensive to run and have not been carried out as often 
in environmental analysis (Nurmi and Pellinen, 2011; Radjenović et al., 2007). 
Recently, a new type of hybrid instrument combining the detection and 
identification capabilities of two different mass spectrometers has emerged. Triple 
quadrupole linear ion trap (QqLIT) (Bueno et al., 2007; Gros et al., 2012; Huerta-
Fontela et al., 2010; Jelic et al., 2009), quadrupole time of flight (QTOF) (Farre et 
al., 2008a; Ibanez et al., 2009; Magner et al., 2010; Petrovic and Barceló, 2006) 
and linear ion trap orbitrap (Cahill et al., 2012; Hogenboom et al., 2009) have the 
abilities to unequivocally identify pharmaceuticals in complex environmental 
matrices due to their full-scan product-ion spectrum and high resolution exact mass 
measurement of both precursor and product ions. In order to avoid the reporting of 
false positives of pharmaceutical residues in complex environmental matrices, the 
European Union Commission Decision 2002/657/EC requires the detection of at 
least four identification points for LC-MS/MS analysis. This can be achieved with 
the detection of one precursor ion and two daughter ions or two precursor ions each 
with one daughter ion (EU Decision 2002/657/EC, 2002). 
LC in tandem with spectrophotometric detection, such as UV detection, 
diode array detection (DAD) and fluorescence are less expensive techniques which 
have been also previously utilised in the analysis of pharmaceuticals in 
environmental waters (Benito-Pena et al., 2006; Garcia et al., 2009; Kim et al., 
2013; Seifrtova et al., 2008). However, the need for higher sensitivities in more 
complex environmental matrices is required, and the wider availability of mass 
spectrometers has resulted in a decrease in studies utilising these techniques. 
A combination of both LC-MS and GC-MS techniques is recommended for 
the reliable confirmation and measurement of a wider range of compound 
properties (Comerton et al., 2009). GC-MS is generally carried out using electron 
impact (EI) ionisation with previous studies reporting LODs for pharmaceuticals in 
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the low ng.L
-1
 concentration range in environmental waters (Reddersen and 
Heberer, 2003; Togola and Budzinski, 2008). 
 
1.10.2 Biota analysis 
Prior to clean-up and extraction, biotic samples are de-shelled/deboned, if required, 
and dissected. Tissues are usually separated and pooled before homogenisation. 
Depending on the method, extraction can then be carried out or frozen samples can 
be freeze-dried, ground down to a powder and sieved prior to extraction. In 
comparison to studies on water, sediment and food, relatively fewer studies have 
investigated the presence of pharmaceutical residues in aquatic species. In most 
cases, the methods developed for sediment and food matrices can be easily adapted 
for the analysis of aquatic biota. In solid samples, soxhlet extraction has been 
replaced by alternative methods which use significantly less volumes of organic 
solvent. The most common extraction techniques carried out on aquatic biota 
include LLE (Brooks et al., 2005; Dussault et al., 2009; Klosterhaus et al., 2013; 
Nallani et al., 2011) followed by less solvent consuming techniques such as 
pressurised liquid extraction (PLE) (Chu and Metcalfe, 2007; Ramirez et al., 2007; 
Schultz et al., 2010; Wille et al., 2011) and SPME (Togunde et al., 2012; Zhou et 
al., 2008). Microwave-assisted extraction (MAE) with micellar media is another 
extraction technique recently developed and previously employed for the 
quantification of six pharmaceuticals in mussel tissue (Cueva-Mestanza et al., 
2008). Following extraction of pharmaceuticals from solid samples, further clean-
up of the aqueous extract may be required using extraction methods such as SPE. 
A recent review, carried out by Huerta et al. (2012), compiled a list of 
previously applied analytical techniques for pharmaceutical analysis in biological 
tissues. From this list, LC-MS/MS was the most widely applied technique with the 
QqQ mass analyser utilised for the majority of studies and the QqLIT also utilised 
in two of the reported studies for the analysis of pharmaceuticals in both fish and 
molluscs (Contardo-Jara et al., 2011; Schultz et al., 2010). Most of the LODs 
reported using LC-MS/MS techniques were at concentrations <1 ng.g
-1
. More 
recent studies not included in the review have analysed wild marine mussels for up 
to 104 PPCPs by LC-QqQ analysis (Klosterhaus et al., 2013), combined UPLC 
with a QqQ mass analyser for the quantification of 11 pharmaceuticals in caged 
blue mussels (Wille et al., 2011), detected a range of multi-class pharmaceuticals in 
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the tissues of wild fish analysed by LC-QqLIT (Huerta et al., 2013; Togunde et al., 
2012) and quantified 5 pharmaceuticals in wild marine mussels from the 
Mediterranean Sea using an orbitrap mass analyser (Bueno et al., 2013). Besides 
MS detection, other techniques previously used in tandem with LC for the detection 
of pharmaceuticals in biota include UV, DAD and fluorescence detection (Cueva-
Mestanza et al., 2008; Fernandez-Torres et al., 2011; Schroder and Machetzki, 
2007). Although these methods of analysis measured LODs at low ng.g
-1
 
concentrations, these measurements were still slightly higher than those produced 
by LC-MS/MS analysis. GC-MS has also been utilised in the detection of 
diclofenac and antidepressants in fish tissues (Brooks et al., 2005; Nakamura et al., 
2008; Schwaiger et al., 2004). There are a number of recently developed analytical 
techniques for the detection of pharmaceuticals in aquatic biota, however, there is 
still a need for more sensitive, reproducible and transferable methods which can be 
applied to a range of aquatic species. 
 
 
1.11 Conceptual Framework 
The research carried out in this thesis is encompassed in a large scale EPA Science, 
Technology, Research and Innovation for the Environment (STRIVE) project 
entitled ‘The assessment and potential human impact of exposure to environmental 
contaminants on marine and freshwater bivalves’. The objective of this project was 
to combine chemical and biological analysis in an attempt to assess with an 
integrated approach the extent and effects of pharmaceutical pollution in the aquatic 
environment with the ultimate aim of developing a simple bioassay for fast, reliable 
identification and toxicological assessment of pharmaceuticals in environmental 
samples. An overview of the project in its entirety is presented in Figure 1.5, with 
the work undertaken in this thesis outlined under the chemical analysis section. 
Pharmaceuticals have recently gained more attention and concern due to 
their possible toxicity and potential to cause adverse effects in marine organisms. 
Additionally, the potential for direct human exposure via ingestion of contaminated 
seafood needs to be investigated further, given the limited evidence thus far.  
 
32 
 
Figure 1.5: Overview of the objectives and ultimate aim of the research project 
including both chemical and biological analysis 
 
 
Information regarding the presence of pharmaceuticals in aquatic ecosystems is 
urgently required in order to assess their fate and effects and the risks posed to the 
marine environment and human health. Therefore, the main objectives of this thesis 
were as follows: 
 To optimise and validate analytical methods for the quantification of 
pharmaceuticals in aqueous samples, such as wastewater effluent and 
marine surface waters, and aquatic biota samples from the Irish aquatic 
environment. 
 To investigate the occurrence and distribution of selected pharmaceuticals 
in the Irish marine environment. 
 To assess the potential for pharmaceuticals to bioaccumulate in an aquatic 
food web via trophic level transfer. 
 To determine the potential for human exposure to pharmaceuticals via 
dietary intake of contaminated seafood.  
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Abstract 
Reports concerning the quantitative analysis of pharmaceuticals in marine 
ecosystems are somewhat limited. It is necessary to determine pharmaceutical fate 
and assess any potential risk of exposure to aquatic species and ultimately, seafood 
consumers. In the work presented herein, analytical methods were optimised and 
validated for the quantification of five pharmaceutical residues in wastewater 
effluent, receiving marine waters and marine mussels (Mytilus spp.). Selected 
pharmaceuticals included two non-steroidal anti-inflammatory drugs (diclofenac 
and mefenamic acid), an antibiotic (trimethoprim), an antiepileptic (carbamazepine) 
and a lipid regulator (gemfibrozil). This chapter also presents the results of an in 
situ study in which caged Mytilus spp. were deployed at three sites on the Irish 
coastline over a one-year period. For aqueous samples, pharmaceutical residues 
were determined using solid phase extraction (SPE) and liquid chromatography-
tandem mass spectrometry (LC-MS/MS). The extraction of pharmaceuticals from 
mussel tissues used an additional pressurised liquid extraction (PLE) step prior to 
SPE and LC-MS/MS. Limits of quantification (LOQs) ≤225 ng.L-1 were achieved 
in wastewater effluent, ≤38 µg.L-1 in marine surface water and ≤29 ng.g-1 in marine 
mussels. Method linearity was achieved for pharmaceuticals in each matrix with 
correlation coefficients of R
2≥0.976. All five selected pharmaceuticals were 
quantified in wastewater effluent and marine surface waters. This work has 
demonstrated the susceptibility of the Mytilus spp. to pharmaceutical exposure 
following the detection of pharmaceutical residues in the tissues of this mussel 
species at measurable concentrations. 
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Aims and Objectives 
 Develop and validate analytical methods for the quantification of selected 
pharmaceuticals in sewage effluent, marine surface water and marine 
mussels using pressurised liquid extraction (PLE) and solid phase extraction 
(SPE) techniques with liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) analysis. These pharmaceuticals include two non-steroidal 
anti-inflammatory drugs (diclofenac and mefenamic acid), an antibiotic 
(trimethoprim), an antiepileptic (carbamazepine) and a lipid regulator 
(gemfibrozil). 
 Set up an in situ experiment exposing caged mussels to three sites (two 
impacted sites and one control site) along the Irish coastline to investigate 
the occurrence of the selected pharmaceuticals in marine mussels. 
 Apply developed methods to samples of 24-h composite effluent, marine 
surface water and marine mussels, collected monthly over a 12-month 
period, to determine the prevalence and relative distribution of selected 
pharmaceuticals in the marine environment.  
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2.1 Introduction 
Current knowledge on the distribution pathways and fate of pharmaceuticals in the 
aquatic environment is somewhat limited and has emerged as an environmental 
issue. Unlike other environmental contaminants, pharmaceuticals have many 
physicochemical and biological properties which must be taken into account when 
predicting or assessing their fate in the environment. Human pharmaceuticals are 
excreted into the sewage system as a mixture of the parent compound and 
metabolites, comprising mostly of transformation products and conjugated 
glucuronides (Heberer, 2002). Conjugated compounds have been found to be easily 
cleaved during wastewater treatment, releasing the parent compound into the 
treated wastewater, and subsequently into the environment (Jelic et al., 2011; 
Ternes, 1998). Veterinary medicines also enter the environment, mainly via 
medicated fish feed and agricultural soil leaching (Boxall, 2004; Heberer, 2002). 
Although susceptible to further degradation or transformation in the environment, 
their continuous introduction into receiving waters in reality confers some degree of 
pseudo-persistence (Hernando et al., 2006). The seemingly ubiquitous presence of 
pharmaceuticals in the aquatic environment has been reported worldwide over the 
past decade or so, with over 80 pharmaceuticals and their metabolites detected at 
µg.L
-1
 concentrations in municipal sewage effluent and surface waters and at ng.L
-1
 
concentrations in groundwater and drinking water (Fatta-Kassinos et al., 2011; 
Heberer et al., 2000; Lapworth et al., 2012; Roberts and Thomas, 2006; Stan and 
Heberer, 1997; Thomas and Hilton, 2004). In order to investigate their fate, the 
quantitative determination of pharmaceuticals in aquatic ecosystems is necessary. 
One of the main concerns surrounding pharmaceutical release into surface 
waters is their potential for bioaccumulation in aquatic organisms. The polar nature 
of most pharmaceuticals make them directly bioavailable to filter feeding 
organisms. Bivalves, such as mussels, are natural filter feeders which have been 
previously utilised in POP monitoring programmes because of their high 
bioaccumulation capacities, fixed location and high populations in marine waters 
(Hunt and Slone, 2010; Monirith et al., 2003). The uptake of pharmaceuticals has 
been previously observed in wild mussel species collected from the Mediterranean 
Sea, San Francisco Bay and the Bohai Sea in China (Bueno et al., 2013; 
Klosterhaus et al., 2013; Li et al., 2012). The use of caged sample studies allows 
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for the measurement of exposure levels as a function of time, making it easier to 
assess and compare the extent of pollution between contaminated sites. With regard 
to pharmaceutical exposure studies using caged mussels, recent studies carried out 
by Bringolf et al. (2010) and Wille et al. (2011) have involved the exposure of 
caged Mytilus spp. to effluent contaminated surface waters and the detection of 
salicylic acid, carbamazepine and fluoxetine in exposed mussel tissues. 
There is comparatively larger knowledge of the fate of pharmaceuticals in 
the human body and during wastewater treatment processes, (Debska et al., 2004; 
Fent et al., 2006) but little research has been performed regarding pharmaceutical 
fate studies after effluent release into surface waters, particularly in the marine 
environment. Pharmaceuticals in the environment need to be quantified by means 
of in situ studies in order to assess the prevalence of pharmaceutical residues 
present in ‘real’ environmental matrices. Numerous effects on the reproduction and 
growth of non-target aquatic species have been observed following toxicity studies 
of pharmaceuticals at environmentally relevant concentrations (Huerta et al., 2012; 
Quinn et al., 2011; Schmidt et al., 2011). Besides toxicity to aquatic species, trace 
pharmaceutical concentrations have been previously detected in drinking water in 
Greece and the US (Benotti et al., 2009; Heberer et al., 2002) and in packaged 
seafood (Tittlemier et al., 2007; EFSA, 2013). The presence of pharmaceuticals in 
water and seafood may potentially act as risk to the consumer either through direct 
effect or indirectly through potential antimicrobial resistance (Cabello, 2006). In 
order to study the possible environmental and human health risks posed by these 
contaminants at environmentally relevant concentrations, information regarding 
their occurrence in the aquatic environment, particularly in aquatic species, is 
urgently required. 
Based on pharmaceutical sales data from Ireland (HSE, 2010) and the UK 
(NHS, 2010) and the results from previous monitoring studies carried out in 
wastewater effluent (Hilton and Thomas, 2003; Lacey et al., 2008; Lacey et al., 
2012), five pharmaceuticals were chosen from four different therapeutic classes: an 
antiepileptic (carbamazepine); two NSAIDs (diclofenac and mefenamic acid); a 
lipid regulator (gemfibrozil); and an antibiotic (trimethoprim). The chemical 
structures of these compounds and their physicochemical properties are given in 
Table 2.1. To the author’s knowledge, this study was the first to quantify a range of 
pharmaceuticals in effluent, marine surface waters and marine mussels across a 
one-year period. 
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Table 2.1: Chemical structure, class and physicochemical properties (Bones et al., 2006; Brown et al., 2007) of selected pharmaceutical compounds 
Trimethoprim Diclofenac Carbamazepine Mefenamic acid Gemfibrozil 
  
 
   
     
     
     
     
Antibiotic Anti-inflammatory Antiepileptic Anti-inflammatory Lipid regulator 
Mr 290.32 Mr 296.15 Mr 236.27 Mr 250.34 Mr 241.28 
pKa 6.60 pKa 4.15 pKa 13.90 pKa 4.20 pKa 4.80 
LogKow 0.65 LogKow 3.91 LogKow 2.30 LogKow 4.16 LogKow 3.56 
pH 7.5 pH 8.0 pH 7.5 pH 8.0 pH 7.5 pH 8.0 pH 7.5 pH 8.0 pH 7.5 pH 8.0 
LogDow 0.55 0.63 LogDow 0.56 0.06 LogDow 2.30 2.30 LogDow 0.86 0.36 LogDow 0.86 0.36 
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2.2 Experimental 
2.2.1 Reagents and chemicals 
LC-MS grade acetonitrile and water, and analytical grade acetone, acetonitrile, 
ethyl acetate and methanol, were purchased from Fisher Scientific (Cheshire, UK). 
Dichloromethane, dichlorodimethylsilane, ammonium hydroxide solution, acetic 
acid and sulphuric acid were purchased from Aldrich (Gillingham, UK). Analytical 
grade carbamazepine (≥98 %), diclofenac sodium salt (≥98 %), gemfibrozil (≥99 
%) and mefenamic acid (≥99 %) were obtained from Sigma-Aldrich (Steinheim, 
Germany) and trimethoprim (≥98 %) was ordered from Fluka (Buch, Switzerland). 
Ultra-pure water was obtained from a Millipore Milli-Q water purification system 
(Bedford, MA, USA). 
Stock solutions (1000 mg.L
-1
) of individual analytes were prepared in 
methanol and stored in a freezer at −20 °C and in the dark, for optimum stability. 
Working mixed standards were prepared weekly in either water or, where required, 
in 80:20 v/v 13 mM ammonium acetate in water/acetonitrile. 
 
 
2.2.2 Sampling locations, procedures and experimental conditions 
Blue mussels (Mytilus spp.) were sourced in the west of Ireland (Lettermullen, Co. 
Galway), from a Class A bivalve mollusc production area, designated by the Sea-
Fisheries Protection Authority of Ireland under EC Regulation 854/2004. Animals 
chosen for this study were of the same size class (4-6 cm) and were collected in 
March pre-spawning. Mussels were placed on wet seaweed and transported to the 
laboratory in a cooler box. Shells were wiped free of debris and seaweed and the 
animals were depurated over seven days in a large tank of artificial seawater 
(ASW). ASW consisted of Peacock Seamix (NaCl 65.5 %, MgSO4 8.25 %, MgCl2 
6 %, CaCl2 3 %, KCl 1.6 %, insolubles 0.05 %, H20 15.6 %) dissolved in 
dechlorinated tap water to a salinity of 33 g.kg
-1
 at 13 °C (±1 °C). Mesh cages (1 m 
x 0.5 m) were constructed and divided into two sections to reduce the loss of 
mussels in the event of the cage tearing (images shown in Figure 2.1 (a) & (b)).
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Figure 2.1 (a) & (b): Images of the constructed mesh cages filled with Mytilus spp. 
mussels before deployment 
 
 
Each cage was filled with 2×300 mussels, which, over time, were found to attach 
themselves to the inside wall of the cage. As shown in Figure 2.2, cages were 
deployed at a control site (CON) and two effluent exposure sites off the east 
(EXP1) and west (EXP2) coasts of Ireland. 
 
 
 
Figure 2.2: Map of Ireland showing sampling locations CON, EXP1 and EXP2  
EXP1 
EXP2 
CON 
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CON was located in a Class A defined enclosed bay, approximately 0.3 km 
off the west coast of Ireland. EXP1 was set up on the east coast of Ireland, 
approximately 100 m downstream from a wastewater effluent outfall pipe which 
discharges into a lower river estuary (see Figure 2.3 (a) & (b)). WWTP1 is a 
secondary treatment facility that also carries out tertiary treatment i.e. UV 
disinfection, from the months of May to September. It has a population equivalent 
(PE) of approximately 1.7 million and an average outflow of 500,000 m
3
.day
-1
. 
 
 
 
 
Figure 2.3 (a): Satellite view of EXP1 with locations of effluent outfall and mussel 
cage marked (GoogleMaps, 2012) (b): Mussel cage tied to bridge and WWTP1 and 
effluent outfall observed in background 
 
 
EXP2 was located in a shallow bay on the west coast of Ireland, above a 
wastewater effluent diffuser pipe, approximately 0.4 km south of WWTP2 (see 
Figure 2.4 (a) & (b)). WWTP2 is a secondary treatment facility with a PE of 
approximately 110,000 and an average outflow of 49,000 m
3
.day
-1
. A year-long 
cage experiment was carried out from March 2011 to March 2012. Mussels (n=45) 
were sampled monthly alongside grab samples of surrounding marine surface 
waters and 24-h composite effluent samples from each WWTP.   
Mussel 
cage 
Effluent 
outfall 
WWTP1 
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Figure 2.4 (a): Satellite view of EXP2 and the effluent outfall pipe where the 
mussel cage hangs from (GoogleMaps, 2012) (b): Buoy from which mussel cage 
hangs and under which lies the effluent outfall pipe for WWTP2 (observed in 
background) 
 
 
Silanised amber Winchester glass bottles (2.5 L) were used to collect marine 
surface waters and effluent samples. When it was not possible to use this approach 
such as in the case of marine surface water from EXP2, samples were first collected 
in a pre-washed stainless steel bucket and then transferred into a silanised, amber 
Winchester glass bottle. All samples were transported to the laboratory in a cooler 
box. Mussels were de-shelled, pooled and frozen at −80 °C. Aqueous samples were 
stored at 4 °C and extracted onto SPE cartridges within 72 h of collection. 
 
 
2.2.3 Sample pre-treatment, extraction and clean-up 
2.2.3.1 Glassware preparation and silanisation 
All glassware was pre-cleaned with 50:50 (v/v) methanol/water solution and 
silanised using a 10 % (v/v) dichlorodimethylsilane solution in dichloromethane. 
This was followed by two rinses with dichloromethane, methanol and ultra-pure 
water respectably in that order. Glassware was cleaned with 50:50 solution of 
methanol/water followed by 100 % ultra-pure water between silanisation washes. 
Effluent 
outfall and 
mussel cage 
WWTP2 
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2.2.3.2 Effluent and marine surface water 
The analytical method previously established for WWTP influent and effluent 
(Lacey et al., 2008) was re-optimised for the determination of pharmaceutical 
residues in effluent and also applied to marine surface water. Effluent and marine 
surface water samples (2.5 L) were first filtered through a 1.2 µm glass fibre filter 
(GF/C diameter 70 mm, Whatman, Kent, UK) and adjusted to pH 4 using dilute 
sulphuric acid. Samples were split into 500 mL aliquots and any necessary spiking 
was carried out at this stage (one sample left unspiked, three samples spiked at 1, 2 
and 3 µg.L
-1
, respectively, with a 1 mg.L
-1
 pharmaceutical mix). For the extraction 
of pharmaceuticals, Strata-X SPE cartridges (6 mL, 200 mg, Phenomenex, 
Cheshire, UK) were first conditioned with 6 mL methanol and 6 mL ultra-pure 
water before loading of the sample. Cartridges were then rinsed with 6 mL of ultra-
pure water and dried for 30 min. Sample extracts were eluted with 3x3 mL ethyl 
acetate/acetone (50:50) and dried under nitrogen while heated to 40 °C with a 
Turbovap LV (Zymark Corporation, Hopkington, MA, USA). Samples were 
reconstituted in 250 µL of 13 mM ammonium acetate with 20 % acetonitrile and 
filtered with 0.2 µm polyvinylidene fluoride (PVDF) syringe filters (Whatman, 
Kent, UK) before LC-MS/MS analysis. All samples were stored at −20 °C before 
analysis. 
 
2.2.3.3 Marine mussels 
For marine mussels, the same method as above was carried out with the addition of 
a PLE step prior to SPE. Previously developed methods for solids extraction were 
investigated and tailored further for the analysis of pharmaceuticals in marine 
bivalves (Lacey et al., 2008; Wille et al., 2011). Prior to extraction, mussels were 
frozen at −80 °C, freeze-dried, homogenised and sieved to 125 µm. PLE was 
performed on a Dionex ASE
®
 200 (Dionex Corp., Sunnyvale, CA, USA). A 
cellulose filter (19.8 mm, Dionex Corp.) was placed on the bottom of a 33 mL 
stainless steel extraction cell. Each cell was filled with 20 g of activated neutral 
aluminium oxide (Al2O3) (Sigma Aldrich, Steinheim, Germany). A mixture of 1 g 
of freeze-dried biotic sample with 10 g of ottawa sand (20-30 mesh, Fisher 
Scientific, Cheshire, UK) was placed on top of the Al2O3 and any necessary spiking 
was carried out at this stage (for method performance and external calibration 
curves). The remaining dead volume of the cell was filled with sand. A 
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combination of acetonitrile/water (3:1) was used as the extraction solvent. 
Extraction was carried out at 60 °C for three cycles of each 5 min. The solvent 
extracts (≈55 mL) were dried under nitrogen while heated to 40 °C with a Turbovap 
LV to a final volume less than 10 mL and further diluted to 200 mL with ultra-pure 
water. The diluted extract was further extracted by SPE, reconstituted and analysed 
by LC-MS/MS following the procedure described above for effluent and marine 
surface water samples in Section 2.2.3.2. 
 
 
2.2.4 Instrumental conditions 
Separations were carried out with an Agilent 1200 LC system (Agilent 
Technologies, Palo Alto, CA, USA) consisting of a binary solvent manager, 
autosampler, UV detector and Waters Sunfire C18 column (3.5 µm, 150 mm×2.1 
mm, Waters Corp., MA, USA) and guard column (3.5 µm, 2.1 mm×10 mm, Waters 
Corp., MA, USA). Mobile phases were 80:20 v/v 13 mM ammonium acetate in 
water (pH 6.2) /acetonitrile (A) and 100 % acetonitrile (B) with a flow rate of 0.3 
mL.min
-1
 and a gradient profile as follows: 0-2 min was 100 % A; 2-3 min B was 
raised to 50 %; 3-9 min B was raised to 80 % and then adjusted to 100 % for a 
further 5 mins. Re-equilibration time was 15 min and injection volumes were 10 
µL. A Bruker Daltonics Esquire HCT Ion Trap mass spectrometer equipped with an 
atmospheric pressure interface-electrospray ionisation (API-ESI) source was used 
for pharmaceutical identification and quantification. Nitrogen, used as a nebulising 
and desolvation gas, was provided by a high purity nitrogen generator, available on 
site through tap, and helium (99.999 %) (Air Products Plc, Crewe, UK) was used as 
a collision gas. The LC-MS/MS system was controlled using Bruker Compass 
HyStar version 3.2. Mass spectrometric analysis was carried out in SRM mode, 
measuring the fragmentation of the ions produced from each analyte. The optimal 
mass spectrometric conditions (Table 2.2) were determined by direct infusion using 
a Cole-Parmer 74900 Series syringe pump set to deliver 300 μL.h-1 of analyte 
solution from a 500 μL glass syringe. The nebuliser pressure and drying gas flow 
were increased slightly after optimisation to account for the higher flow rates set for 
sample analysis. 
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Table 2.2: Electrospray ionisation tandem mass spectrometric conditions 
Electrospray ionisation conditions 
 Negative ion mode Positive ion mode 
Capillary (V) 3150 2825 
End plate offset (V) −500 −500 
Dry gas flow (N2, L.min
-1
) 20 20 
Nebuliser pressure (psi) 8 8 
Dry gas temperature (°C) 300 300 
Mass spectrometric conditions 
 Negative ion mode Positive ion mode 
Skimmer (V) −15 36 
Capillary exit (V) −70 130 
Trap drive 20 24 
Oct RF 100 200 
Lens 1 2.3 −1.5 
Lens 2 35 −32 
 
 
2.2.5 Method performance 
Quantities of linearity, LOD, limit of quantification (LOQ), percentage recovery, 
ion suppression and precision (both instrumental and method) were investigated for 
all target ions allowing for reliable confirmation of analytes. Instrumental linearity 
was evaluated using linear regression analysis measuring peak height versus 
concentration. LOD was determined by the lowest concentration of an analyte 
which produced a signal-to-noise (S/N) ratio of approximately 3:1. LOQ was 
determined as the analyte concentration to give a S/N ratio of 10:1. Both LOD and 
LOQ were calculated using the S/N ratios of three low-level spiked samples (n=9). 
Instrumental retention time precision was carried out for n=11 replicate injections 
of a 1 mg.L
-1
 standard and n=6 replicates of the same standard used to determine 
peak height precision. Reproducibility studies were carried out by spiking sample 
matrices (n=6) pre-extraction to concentrations of 0.5 µg.L
-1
 for ultra-pure water, 
marine surface water and wastewater effluent (500 mL) and 0.25 µg.g
-1
 for marine 
mussels (1 g). Percentage recoveries were calculated using this data by comparison 
to final extracts of the unspiked matrix (n=3) reconstituted in 250 µL of mobile 
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phase A containing the expected 100 % recovery concentration. Ion suppression 
and enhancement was also investigated by comparing aqueous and mussel sample 
extracts spiked post-extraction to an analyte mixture of the same concentration 
prepared in mobile phase A. Calibration curves (n=12 in triplicate) were 
constructed in each matrix to assess method performance. 
 
 
2.3 Results and Discussion 
2.3.1 Sample preparation 
Few studies to date have investigated the presence of pharmaceutical concentrations 
in marine species such as blue mussels (Cueva-Mestanza et al., 2008; Klosterhaus 
et al., 2013; Wille et al., 2011). Soxhlet extraction methods have been replaced by 
alternative methods which use significantly less volumes of organic solvent such as 
PLE and microwave-assisted extraction (MAE). Several recent studies have utilised 
PLE to investigate the presence of pharmaceuticals in soil, sediment and aquatic 
biota (Barron et al., 2008; Huerta et al., 2013; Jelic et al., 2009; Wille et al., 2011). 
This technique was selected and used in conjunction with a modified SPE method 
previously developed for pharmaceutical extraction from effluent (Lacey et al., 
2008).  
Prior to PLE, the freeze-dried biotic tissue was ground with a pestle and 
mortar and sieved to a particle size of approximately 125 µm. Smaller particle size 
allows for greater surface area exposure and shorter diffusion distances of analytes 
from sample to extraction solvent (Bjorklund et al., 2000). Larger sample remains 
(≤20 %), unable to pass through the sieve, were discarded. For PLE optimisation, 
various extraction solvents were tested initially (1:1 methanol/water, 1:1 
methanol/water with 1 % formic acid, 1:1 acetonitrile/water, 3:1 acetonitrile/water, 
3:1 acetonitrile/water with 1 % formic acid). A mixture of 3:1 acetonitrile/water 
provided the best recovery. Second, the optimal temperature (60, 80 and 100 °C), 
static time (5 and 10 min), and number of cycles (2 and 3) were investigated. Three 
cycles of 5 min were found to be optimal for the extraction of the target analytes. 
Slightly higher recoveries were observed for all compounds, particularly at 60 °C 
compared to 100 °C. The flush volume was also evaluated starting at the 
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manufacturers recommendation of 60 % and increasing to 100 % which showed 
higher recoveries overall. Next, the addition of Al2O3 to the extraction cell was 
evaluated. Al2O3 inhibits the co-extraction of lipids and other hydrophobic matrix 
constituents and was tested by addition of several different quantities (10, 15 and 20 
g) to the cell. Cleaner abstracts were obtained with the higher quantity of 20 g of 
Al2O3 added to the cell. For fine powdery samples, such as freeze-dried biotic 
tissue, it is recommended to mix the sample with dispersion agents, such as 
diatomaceous earth and sodium sulphate, to prevent clogging and allow for 
improved contact between the analyte and solvent (Runnqvist et al., 2010). 
Therefore, various quantities of Ottawa sand (2.5, 5 and 10 g) were pre-mixed with 
the sample and transferred to the cell which was then filled to the top with sand. 
The higher the quantity of sand mixed through the sample, the slightly higher 
recovery of analytes observed, therefore, 10 g of sand was mixed with the samples. 
The sample mass itself was tested by analysing the freeze-dried and sieved biotic 
tissue (0.5, 1 and 2 g) spiked at 250 ng.g
-1
. Golet et al. (2002) found that increasing 
the sample size of soil and sewage sludge samples resulted in lower analyte 
recoveries and turbid extracts, explaining why cleaner extracts with higher analyte 
recoveries were achieved with 1 g of sample in comparison to 2 g. Due to the 
complexity of biotic samples, further clean-up was required following PLE in order 
to achieve low matrix interference. Extraction of pharmaceuticals from the diluted 
PLE extract is most commonly carried out using SPE.  
Strata-X SPE cartridges have previously been used for the extraction of 
acidic, basic and neutral pharmaceutical mixes in effluent, surface waters and 
marine mussels (Hilton and Thomas, 2003; Lacey et al., 2008; Wille et al., 2011). 
The analytical method previously established by Lacey et al. (2008) was re-
validated here for the determination of pharmaceutical residues in all aqueous and 
marine mussel samples. Minor adjustments were made to assess any improved 
method performance including SPE eluting/reconstitution solvent, LC run time, 
mobile phase composition and gradient conditions. Higher recoveries have been 
reported for saline samples such as marine surface water when using larger post-
load washing volumes (Wille et al., 2010; Wu et al., 2010) but, when evaluated, 
there was no overall increase in recovery with washing volumes greater than 6 mL. 
Eluting solvents were also re-investigated here as a means of increasing percentage 
recovery of analytes from a more complex matrix and in comparison to methanol, 
50:50 (v/v) ethyl acetate/acetone exhibited marginally higher recoveries on average. 
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2.3.2 Analytical method development 
Due to the limited volatility of the investigated analytes and their polar nature, 
which would require derivatisation prior to analysis with GC-MS, LC-MS/MS was 
the method of analysis chosen for this study. For pharmaceutical analysis using 
reversed-phase HPLC, water and acetonitrile are commonly used mobile phase 
solvents. Additives (in this case ammonium acetate) are normally used to facilitate 
efficient ESI through increasing ionic strength. A 13 mM ammonium acetate 
solution in a mixture of acetonitrile and water was selected as a suitable mobile 
phase. Separate analyses using negative and positive ionisation modes were 
employed to maximise peak definition and quantitative reliability. Direct infusion 
of each standard was carried out initially in full scan mode to determine an 
abundant precursor ion. In negative mode ESI-MS, [M–H]- precursor ions were 
produced for diclofenac, gemfibrozil and mefenamic acid and [M+H]
+
 precursor 
ions were produced for carbamazepine and trimethoprim in positive mode ESI-MS. 
SRM was carried out under both positive and negative ion modes. Selected 
transitions, shown in Table 2.3, were monitored for the quantification and 
confirmation of each analyte. The fragmentation amplitude was set at 0.5 in 
negative mode and 0.6 in positive mode with isolation width set at 2.0 m/z for all 
analytes. A selection of EICs of each pharmaceutical, occurring at their highest 
concentrations in either effluent, marine surface waters or marine mussels, are 
shown in Figure 2.5. 
 
 
Table 2.3: Precursor, quantification and confirmation ions (m/z) for each 
pharmaceutical and their corresponding fragmentation amplitudes 
Compound 
Precursor 
 ion 
ESI 
mode 
Quantification 
 ion 
Confirmation 
ion 
Fragmentation 
amplitude 
Carbamazepine 237  + 194 192 0.6 
Diclofenac 294  − 250 236 0.5 
Gemfibrozil 249  − 121 127 0.5 
Mefenamic acid 240  − 196 223 0.5 
Trimethoprim 291  + 123 230 0.6 
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Figure 2.5: EICs of the most concentrated occurrence of selected pharmaceuticals 
in samples of wastewater effluent, marine surface water and marine mussels 
collected from exposure sites 
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2.3.3 Instrumental and method performance 
Method performance results for individual pharmaceuticals in ultra-pure water, 
effluent, marine surface water and mussel tissue are shown in Table 2.4. Upon 
investigation of instrumental precision, retention times varied ≤1.3 % for all 
analytes in each matrix. For aqueous samples, correlation coefficients of ≥0.987 
(n≥8) were achieved for most analytes, except mefenamic acid (R2≈0.98), over the 
ranges of 0.025 to 5 µg.L
-1
 using negative ESI-MS/MS mode and 0.005 to 2.5 µg.L
-
1
 using positive ESI-MS/MS mode. LOQs were as low as 15 to 225 ng.L
-1
 and 3 to 
38 ng.L
-1 
in effluent and marine surface water, respectively. Due to the complexity 
and high salt content of marine surface water, pharmaceutical detection in this 
matrix is difficult and has not been reported to a wide extent. Method performance 
results correlated with previous data reported for the analysis of 13 pharmaceuticals 
in natural sea water (Wille et al., 2010). Recoveries of analytes ranged from 62 to 
99 % in effluent and 56 to 110 % in marine surface water for n=6 replicates of a 1 
µg.L
-1
 standard mix with relative standard deviations (RSDs) ≤11 %. Signal 
suppression was observed for all analytes in marine surface water and for all 
analytes except gemfibrozil in effluent. The signal enhancement of gemfibrozil in 
effluent is in stark contrast to the signal suppression of gemfibrozil in marine 
surface water. At 56 %, gemfibrozil underwent the highest matrix induced 
suppression out of the five pharmaceuticals in marine surface water but, signal was 
not greatly reduced as recoveries >100 % were achieved. Most noticeable in the 
effluent matrix was the signal suppression observed for the pharmaceuticals in 
positive ESI-MS mode, i.e. trimethoprim and carbamazepine, at 63-65 %. In 
contrast, these compounds were the least suppressed analytes in the marine surface 
water matrix. The high salt content of marine surface waters suggests that salt 
residues may still be present in the sample extract and co-eluting with the selected 
analytes. As can be seen from Table 2.4, the method developed allows for 
quantification of the target analytes in ultra-pure water also. Recoveries between 79 
and 98 % were achieved for all pharmaceuticals in ultra-pure water, highlighting 
the influence of complex matrices, such as effluent and marine surface water, on 
ion suppression or enhancement. 
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Table 2.4: Method performance data for pharmaceuticals in ultra-pure water (500 mL), wastewater effluent (500 mL), marine surface water (500 
mL) and marine mussel tissue (1 g) 
Compound  Ultra-pure water  Effluent 
 
tr* 
(min) 
n=12 
LOQ  
(ng.L
-1
) 
n=9
a
 
R
2 
 
n≥24b 
Recovery 
(%) 
n=6 
 
LOQ 
(ng.L
-1
) 
n=9
a
 
R
2 
 
n≥24b 
Recovery 
(%) 
n=6 
Trimethoprim 5.9 2 0.993 84±3  49 0.993 88±6 
Diclofenac 8.1 5 0.997 98±8  225 0.991 70±9 
Carbamazepine 8.2 2 0.991 93±9  15 0.995 99±7 
Mefenamic acid 9.0 6 0.999 96±10  219 0.976 62±8 
Gemfibrozil 11.5 8 0.999 79±7  35 0.995 66±11 
Compound Marine surface water  Marine mussels (DW) 
 
LOQ 
(µg.L-1) 
n=9
a
 
R
2 
 
n≥24b 
Recovery 
(%) 
n=6 
 
LOQ  
(ng.g
-1
) 
n=9
a
 
R
2 
 
n≥24b 
Recovery 
(%) 
n=6 
Trimethoprim 3 0.987 56±4  4 0.985 91±9 
Diclofenac 22 0.995 110±11  29 0.990 83±8 
Carbamazepine 4 0.995 86±5  6 0.987 100±5 
Mefenamic acid 29 0.977 91±7  23 0.990 104±12 
Gemfibrozil 38 0.995 108±5  18 0.993 100±20 
*
Average time recorded for each pharmaceutical in marine mussel tissues 
a 
Three data points carried out in triplicate 
b 
Eight data points carried out in triplicate 
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Marine mussels (1 g, n=12 in triplicate) were spiked in the extraction cell, 
after mixing with sand, with a standard mixture resulting in final concentrations of 
5-5000 ng.g
-1
 of each pharmaceutical (solvent volume added ≤250 µL). Linearity 
was achieved for analytes in negative mode from 10 to 5000 ng.g
-1
 (R
2≥0.990) and 
in positive mode from 5 to 2500 ng.g
-1
 (R
2≥0.985). All analytes were quantifiable at 
concentrations of between 4 and 29 ng.g
-1
. These performance results are 
comparable to previously reported results for the same and similar pharmaceuticals 
investigated in marine mussels (Cueva-Mestanza et al., 2008; Wille et al., 2011) 
and other solid matrices such as sludge (Barron et al., 2008) and fish (Ramirez et 
al., 2007) (Table 2.5). Method recoveries were in the range of 83 to 104 % with 
precision varying ≤20 % for n=6 replicates of a 250 ng.g-1 standard mix. Signal 
suppression ranged from 25 to 44 % for analytes in marine mussel tissue with the 
signal for gemfibrozil again exhibiting the greatest suppression.  
In order to minimise the matrix effect on the quantification of ions using 
external calibration, standard addition (n=4, unless otherwise stated) was performed 
in effluent and marine surface water samples. However, for the quantification of 
pharmaceuticals in marine mussels, external calibration curves were prepared in 
matrix-matched samples to avoid lengthy processing times for larger amounts of 
samples. For quality control of the method, an injection of starting mobile phase 
was run between each sample with no carry over observed.  
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Table 2.5: Comparison of method performance results for pharmaceuticals in solid matrices from selected literature using LC-MS analysis 
 
Mussel tissue (DW)  Mussel tissue (DW)   Fish tissue (WW)  Sludge (DW) 
 
Results  Wille et al. (2011)  Ramirez et al. (2007)  Barron et al. (2008) 
Compounds Linearity 
 
LOQ 
(ng.g
-1
) 
 Linearity 
 
LOQ 
(ng.g
-1
) 
 Linearity 
 
LOQ 
(ng.g
-1
) 
 Linearity 
 
LOD 
(ng.g
-1
) 
Carbamazepine >0.98 6  >0.99 1  >0.99 0.1  >0.99 3 
Diclofenac >0.99 29  >0.99 25  
  
 >0.99 7 
Gemfibrozil >0.99 18  
  
 >0.99 0.9  >0.98 2 
Mefenamic acid >0.99 23  
  
 
  
 
  
Trimethoprim >0.98 4  >0.99 1  >0.99 2.6  >0.98 50 
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2.3.4 Application to wastewater effluent, marine surface waters and caged 
Mytilus spp. exposed along the Irish coast 
The developed methods were applied to 24-h composite effluent samples (WWTP1 
and WWTP2), marine surface water grab samples and marine mussel samples (CON, 
EXP1 and EXP2). Samples from CON, EXP1 and WWTP1 were collected over a 12-
month period. Due to rough sea weather and the consequential loss of a cage, a 
shorter exposure was carried out at EXP2, where marine mussels were sampled for 
three months and effluent and marine surface water samples were collected from 
WWTP2 and EXP2 for four months. 
 
2.3.4.1. Wastewater effluent 
As can be deduced from Figures 2.6 and 2.7, pharmaceutical residues were 
quantified in Irish wastewater effluent entering Irish surface waters. All five of the 
selected pharmaceuticals were detected in >85 % of effluent samples collected from 
each exposure site. Effluent discharged from WWTP2 was found to contain the 
highest concentrations of pharmaceutical residues, except for carbamazepine, with 
>1 µg.L
-1
 measured for at least one sampling point over the four month period. 
Diclofenac and mefenamic acid were measured at environmentally relevant 
concentrations of 2.63 µg.L
-1
 and 2.80 µg.L
-1
, respectively, from WWTP2 and 
carbamazepine measured at concentrations up to 3.16 µg.L
-1
 from WWTP1 (See 
Appendix). In comparison, WWTP1 caters for 15-fold more people than WWTP2 
but pharmaceutical concentrations detected over the same four months (May to 
August 2011) were found to be slightly lower from WWTP1. This may be as a result 
of the tertiary treatment carried out on the wastewater at WWTP1 from May to 
September. UV treatment has been shown to partially remove some antibiotics in 
drinking water but this is at a UV dose approximately 100 times greater than that 
typically supplied for effluent disinfection (Adams et al., 2002) therefore, 
pharmaceutical residues in UV treated effluent may be slightly reduced but not 
completely eliminated. When compared to the concentrations of pharmaceutical 
residues present in the effluent throughout the year, no obvious reduction in 
pharmaceutical concentrations was observed for UV treated effluent collected from 
WWTP1. 
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Figure 2.6: Cumulative pharmaceutical concentrations (µg.L
-1
) detected in effluent from WWTP1 and marine surface water from EXP1 and 
WWTP flow rates (May 2011-April 2012) 
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Figure 2.7: Cumulative pharmaceutical concentrations (µg.L
-1
) detected in effluent from WWTP2 and marine surface water from EXP2 and 
WWTP flow rates (May 2011-August 2011) 
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In comparison to pharmaceutical concentrations detected in effluent from 
WWTPs worldwide, slightly higher levels were reported in the effluent from the 
selected Irish WWTPs in this study, in line with observations from previous Irish 
wastewater studies. Lacey et al. (2012) reported the presence of diclofenac, 
mefenamic acid, trimethoprim and carbamazepine in the effluent from WWTP1 at 
concentrations up to 0.5 µg.L
-1
, 9.1 µg.L
-1
, 0.6 µg.L
-1 
and 6.5 µg.L
-1
, respectively. 
Furthermore, gemfibrozil was measured up to 0.1 µg.L
-1 
in influent but was not 
detected in the treated effluent. This study revealed similar orders of concentration 
for the same compounds in effluent sampled from the same WWTP however, 
gemfibrozil concentrations were detected in the effluent and measured from <LOD-
0.65 µg.L
-1
. Although population equivalents of the other secondary WWTPs 
studied by Lacey et al. (2012) were approximately half that of WWTP2, diclofenac 
residues were recorded in their effluents at concentrations up to 3 µg.L
-1
.  
 
2.3.4.2. Marine surface water 
The pseudo-persistence of pharmaceuticals in the aquatic environment was 
observed with the continuous detection of pharmaceutical residues in marine 
surface waters, at slightly lower concentrations than those detected in effluent. The 
antiepileptic, carbamazepine, had the highest concentration in marine surface 
waters, measuring at 1.41 µg.L
-1
 at EXP1. Trimethoprim was repeatedly detected at 
both exposures with much higher concentrations of up to 0.87 µg.L
-1
 detected at 
EXP2. Residues of diclofenac and mefenamic acid varied in their concentrations 
each month but measured highest at EXP2 with concentrations of 0.55 µg.L
-1
 and 
0.61 µg.L
-1
, respectively. The lipid regulator, gemfibrozil, was the least detected 
pharmaceutical in marine surface water but was measured at concentrations of up to 
0.64 µg.L
-1
 at EXP2. The highest pharmaceutical concentrations in marine surface 
waters were detected at EXP2, with the exception of carbamazepine (See 
Appendix). None of the selected analytes were detected in marine surface water 
samples from the CON site. 
A selection of monitoring studies has been performed previously in 
European estuarine and marine surface waters. In a study carried out by Thomas 
and Hilton (2004), 14 pharmaceuticals were monitored in British estuaries of the 
Thames, the Tyne, the Mersey, the Tees and Belfast Lough. From the targeted list, 
nine pharmaceuticals were detected in the estuarine water samples collected. 
Ibuprofen and trimethoprim were determined at the highest concentrations, 
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measuring at 928 ng.L
-1
 and 569 ng.L
-1
, respectively, and clotrimazole was the most 
frequently detected pharmaceutical with a median concentration of 7 ng.L
-1
. A 
number of other studies have analysed marine water samples collected from the 
North Sea, its estuaries and harbours (Buser et al., 1998; Langford and Thomas, 
2011; Weigel et al., 2002; Weigel et al., 2004). Eight pharmaceuticals were 
previously determined in Belgian coastal waters, with concentrations of salicylic 
acid and carbamazepine measured most frequently at concentrations up to 860 ng.L
-
1
 (Wille et al., 2010). Monitoring studies in the Mediterranean Sea revealed the 
presence of eight pharmaceuticals, including verapamil, atenolol and metolol in the 
low ng.L
-1
 range. In comparison to previous monitoring studies, pharmaceutical 
residues determined in marine surface waters from EXP1 and EXP2 here are 
therefore similar to those previously detected in British and Belgian estuaries but, 
overall, are higher than the average pharmaceutical concentrations detected in other 
European marine surface waters. 
The presence of high pharmaceutical concentrations in Irish WWTP effluent 
is likely to be the reason for the higher than average pharmaceutical concentrations 
measured in Irish marine surface waters. The cumulative pharmaceutical 
concentrations in effluent and marine surface water from both EXP1 and EXP2 
exposure sites are shown in Figures 2.6 and 2.7, respectively. Most notably, higher 
concentrations of pharmaceutical residues in marine surface waters were 
determined during periods of higher effluent outflow. Insufficient data does not 
allow for the determination of the dilution factor at each sampling site, but, as 
observed from the results, the short distances of the sites (outlined in Section 2.2.2) 
from the effluent outfall pipes did not allow for significant dilution of the 
pharmaceutical concentrations. Other factors may also explain these high 
pharmaceutical concentrations in marine waters including the restriction of access 
to sampling sites at high tide, requiring sample collection to be carried out at low 
tide, and the continuous flow of effluent from the outfall pipe, regardless of tidal 
patterns. That said, in some cases, pharmaceuticals in marine surface waters were 
determined at higher concentrations than those in the WWTP effluent. 
Pharmaceutical measurements were based on one sample of effluent and marine 
surface water collected from each site over 1-2 days each month, depending on 
weather conditions. The pharmaceutical concentrations in the effluent should not be 
taken as the exact same concentrations exposed to the marine surface water 
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sampled during the same month. Higher loads of certain pharmaceuticals may occur 
over time depending on human consumption. 
Effluent and marine surface water analysis was carried out previously on 
samples collected approximately 700 m downstream of the effluent outfall pipe for 
WWTP1 between the months of July to September 2010. In comparison to the 
samples collected at EXP1, the pharmaceutical residues measured in the marine 
surface water samples were almost 100 times lower. These results reveal the extent 
of dilution of the pharmaceuticals at less than 1 km from the effluent outfall pipe. 
Effluent outfall pipes built further out at sea encourages dilution of environmental 
contaminants and reduced risk of chronic exposure to non-target aquatic organisms. 
 
2.3.4.3. Marine mussels 
The accumulation of a large number of pharmaceuticals in solid media such as 
sludge was the focus of recent work in our laboratory. These studies support some 
of the findings shown here for pharmaceutical occurrence in wastewaters and their 
potential for uptake in mussels (Barron et al., 2008; Barron et al., 2009; Barron et 
al., 2010). Besides the physicochemical properties of pharmaceutical compounds, 
the potential for pharmaceuticals to bioaccumulate in aquatic biota also depends on 
several biological factors such as age, species, diet, habitat and reproductive cycle 
(Meredith-Williams et al., 2012). The uptake of pharmaceuticals in biological 
tissue may be possible due to a small portion of unionised species of the 
compounds remaining in the aqueous phase, which has a greater affinity for 
lipophilic matter. With a pKa of 6.6, trimethoprim is the only pharmaceutical of 
those selected not to be completely ionised in marine surface water at pH 8.0. This 
may be the reason why a very low but constant concentration of trimethoprim was 
detected in exposed mussel tissue. Residues of trimethoprim in the Mytilus spp. 
from EXP1 were quantified at concentrations of 9.22 ng.g
-1
 and 7.28 ng.g
-1
 DW 
(See Table A.2 of Appendix) for the respective months of October and November, 
during which time tertiary treatment was not carried out on the wastewater. 
Carbamazepine and mefenamic acid were also detected in mussel tissues from both 
exposure sites, but at <LOQ levels. Although mefenamic acid and carbamazepine 
have slightly higher LOQ values, their concentrations in surrounding marine waters 
were on average slightly higher than those detected for trimethoprim and thus, their 
presence in mussel tissues may be as a result of the uptake of residual levels, 
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although this may also be the case for trimethoprim. It is important to note that the 
mussels were not depurated before analysis, therefore, remains in the mussel 
digestive tract were included in the measurements. Selected pharmaceuticals had a 
broad range of temporal variability and particularly in the cases of gemfibrozil and 
mefenamic acid, residues dropped below detectable levels in marine surface waters. 
This may be due to the higher salt content in marine waters causing these 
pharmaceuticals to become less soluble, and ultimately, ‘salt out’ of solution. None 
of the selected analytes were detected in marine mussel samples collected from the 
CON site.  
In a similar recent study, five cages of blue mussels were deployed off the 
Belgian coast. Over a six-month period, five pharmaceuticals were detected in 
mussel tissues including  salicylic acid residues, measuring up to 490 ng.g
-1
 DW
 
(Wille et al., 2011). Whilst salicylic acid was determined in the mid ng.g
-1
 range, 
mostly lower and fluctuating concentrations of all other pharmaceuticals including 
carbamazepine, ofloxacin, propranolol and paracetemol were observed. In a 
separate study in North Carolina, the antidepressant, fluoxetine, was detected in 
caged mussel tissues up to 79 ng.g
-1
 WW after 14 days exposure in a wastewater 
effluent channel. Fluoxetine was also detected in mussels caged approximately 100 
m downstream from the effluent outfall pipe at concentrations of 9.8 ng.g
-1
 WW 
where residues in surrounding waters measured up to 7.3 ng.L
-1
 (Bringolf et al., 
2010). The presence of oestrogens in Irish seawater and their potential for uptake in 
marine mussels was only recently investigated. Although low ng.L
-1
 levels of 
oestrone were detected in marine surface waters, no uptake was determined in 
exposed mussel tissues due to high levels of interference from the co-extraction of 
matrix components (Ronan and McHugh, 2013). Most recently, wild marine 
mussels were collected from several diversely impacted areas in the Mediterranean 
Sea with traces of carbamazepine measuring up to 3.5 ng.g
-1
 DW in mussels 
residing from wastewater exposed waters (Bueno et al., 2013). Similarly, wild 
ribbed horse mussels were collected from five near shore sites in San Francisco Bay 
and analysed for the presence of up to 104 PPCP residues. Carbamazepine and 
gemfibrozil were detected in the surrounding marine surface waters at 
concentrations between 38-92 ng.L
-1
 but, mussels collected from the same sites 
were found to contain only very low residues of carbamazepine at concentrations 
up to 2.4 ng.g
-1
 WW (Klosterhaus et al., 2013). Uptake of pharmaceuticals has been 
previously confirmed in other wild aquatic species such as fish (Brooks et al., 2005; 
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Fick et al., 2010; Huerta et al., 2013; Togunde et al., 2012) with glucuronised 
parent compounds measuring at higher concentrations to the unmetabolised 
compounds in one particular study (Lahti et al., 2011). The cost and limited 
availability of glucuronised pharmaceutical compounds did not allow for further 
investigation into the bioaccumulation of metabolites within the mussel. 
Wild mussels were observed at EXP1 and a considerable number of crab 
and oyster pots were observed in close proximity to the effluent outfall pipe at 
EXP2. The presence of pharmaceuticals in the caged mussels suggests a possibility 
for pharmaceutical uptake in wild species and potential exposure to humans via 
ingestion. The measurement of pharmaceuticals in aquatic species that are 
important in terms of human consumption, such as mussels, is very useful in 
estimating the human exposure and dietary intake of these pharmaceuticals. 
 
 
2.4 Conclusions 
For the first time, the spatial occurrence of five targeted pharmaceuticals in the 
aquatic environment was monitored over a 12-month period. Analytical techniques 
such as PLE, SPE and LC-MS/MS were combined, optimised and applied to 
wastewater effluent, marine surface water and Mytilus spp. samples collected from 
two impacted sites and a control site on the Irish coastline. The presence of all five 
targeted pharmaceuticals was confirmed in the low µg.L
-1
 in effluent and in the 
high ng.L
-1
 in exposed marine surface water. Residues of carbamazepine measured 
highest in exposed marine surface water at concentrations up to 1.41 µg.L
-1
. Three 
of the five detected pharmaceuticals in marine surface waters were also found to 
occur in exposed Mytilus spp., with residues of trimethoprim measuring at 
concentrations up to 9.22 ng.g
-1
 DW. This study has confirmed the uptake of 
pharmaceuticals in marine bivalves at measurable quantities and also highlights the 
inability of mussels to act as reliable bioindicators of pollution for the selected 
pharmaceuticals due to temporal variations observed in the data. These findings 
will contribute to pharmaceutical fate studies and aid in the assessment of 
ecological and health risks posed by these contaminants in the natural aquatic 
environment. 
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Abstract 
The potential for pharmaceuticals to bioaccumulate in aquatic species, such as fish, 
via trophic level transfer was investigated. Selected pharmaceuticals included two 
non-steroidal anti-inflammatory drugs (diclofenac and mefenamic acid), an 
antibiotic (trimethoprim), an antiepileptic (carbamazepine) and a lipid regulator 
(gemfibrozil). An in vivo experiment was carried out in a flow-through system in 
which juvenile rainbow trout were fed marine mussels (Mytilus spp.) collected from 
a highly polluted site exposed to wastewater effluent for a period of 28 days. The 
analytical methods previously developed for ultra-pure water and marine mussels 
were applied to carbon filtered municipal water and mussel feed samples, 
respectively. The pharmaceutical extraction method applied to marine mussels was 
further optimised for fish liver samples with limits of quantification (LOQs) ≤53 
ng.g
-1
 and correlation coefficients of R
2≥0.988 achieved. Trimethoprim was the 
only pharmaceutical to be quantified in the wild Mytilus spp. at concentrations of 
6.68 ng.g
-1
 DW. After feeding, none of the selected pharmaceuticals were detected in 
the fish liver samples collected from the exposed rainbow trout. Hence, the 
potential for pharmaceuticals, in particular trimethoprim, to biomagnify via trophic 
level transfer is unlikely, however, bioaccumulation of pharmaceutical residues 
may have occurred at concentrations measuring below the method detection limits. 
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Aims and Objectives 
 Develop and validate an analytical method for the detection and 
quantification of selected pharmaceuticals in fish tissues using pressurised 
liquid extraction (PLE) and solid phase extraction (SPE) techniques with 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. 
These pharmaceuticals include an antiepileptic (carbamazepine), two non-
steroidal anti-inflammatory drugs (NSAIDs) (diclofenac and mefenamic 
acid), a lipid regulator (gemfibrozil) and an antibiotic (trimethoprim). 
 Set up an in vivo experiment exposing juvenile rainbow trout to 
pharmaceuticals via ingestion of effluent exposed marine mussels over a 28-
day period. 
 Apply new and previously developed methods for pharmaceutical extraction 
and analysis to carbon filtered municipal supply water, marine mussels and 
fish tissues collected from this in vivo exposure. 
 Investigate the bioaccumulation of pharmaceuticals in juvenile rainbow 
trout through trophic level transfer via dietary exposure to contaminated 
mussel tissue feed. 
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3.1 Introduction 
One of the many concerns surrounding pharmaceutical release into surface waters 
is their potential to bioaccumulate in aquatic biota via trophic level transfer. 
Bioaccumulation is the uptake of a chemical by an organism through a combination 
of water, food, sediment and air. As shown in Chapter 2, uptake of pharmaceuticals 
in aquatic biota can occur at low, environmentally relevant concentrations and the 
question remains if bioaccumulation of pharmaceuticals through the food chain is 
also a possibility. The best known occurrence of pharmaceutical bioaccumulation 
and exposure through the food chain caused the mass mortality of three vulture 
species in Asia. Following the consumption of dead livestock containing the anti-
inflammatory pharmaceutical, diclofenac, thousands of vultures suffered renal 
failure leading to their unfortunate demise (Oaks et al., 2004). 
There have been few studies that have addressed the issue of 
bioaccumulation of pharmaceuticals in aquatic biota. Bioaccumulation can be 
expressed in terms of a bioaccumulation factor (BAF), which is the ratio of the 
chemical concentration in the organism (CB) to the concentration of the freely 
dissolved chemical in the water column (CWD), shown in Equation. 3.1 (Gobas and 
Morrison, 2000); 
 
BAF = CB / CWD   Eqn. 3.1 
 
However, bioaccumulation of a chemical in an organism can also occur via dietary 
exposure. When this route of uptake is assessed, a biomagnification factor (BMF) is 
used as the endpoint (OECD, 2012) and is calculated as the ratio of the chemical 
concentration in the organism (CB) to the concentration in the organisms diet (CD), 
shown in Equation. 3.2 (Gobas and Morrison, 2000);  
 
BMF = CB / CD   Eqn. 3.2 
 
Biomagnification occurs when the chemical concentration in an organism is greater 
than that in the organisms diet, due to dietary uptake (Gobas and Morrison, 2000). 
Low biomagnification factors cannot be disregarded as they can often highlight 
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low-level bioaccumulation of a compound in an organism which may be of 
significance at higher trophic levels. 
The earliest study on the bioaccumulation of pharmaceuticals through the 
food chain involved the feeding of juvenile fish and shrimp with medicated brine 
shrimp (Artemia franciscana) containing the popular aquaculture antibiotics, 
sulfamethazole and trimethoprim (Chair et al., 1996). Bioaccumulation of these 
antibiotics was observed in both fish and shrimp tissues after feeding with 
trimethoprim detectable up to 80-h post-dosage. Konwick et al. (2006) exposed 
juvenile rainbow trout to nine triazole fungicides (dual-use pesticides and 
pharmaceuticals) via commercial feed spiked at concentrations of 23-35 µg.g
-1
 
WW. Bioaccumulation in fish occurred after the first day of feeding however, due 
to high rates of elimination in fish, no triazole residues were detected after two days 
of depuration and BMF values were determined as <0.1. Another study, carried out 
by Nie et al. (2008) and translated by Daughton and Brooks (2011), compared the 
concentrations of ciprofloxacin in carp via water uptake and dietary intake. 
Interestingly, feeding alone resulted in the highest concentrations of the antibiotic 
accumulated in the fish in comparison to water uptake and dual exposure. The few 
studies carried out to date have focused on the accumulation of pharmaceuticals 
over one trophic level. Vernouillet et al. (2010) investigated the increase of the 
antiepileptic drug, carbamazepine, at successive trophic levels in the food chain. 
The green algae, Pseudokirchneriella subcapitata, were exposed to 150 mg.L
-1
 
carbamazepine and fed to the crustacean, Thamnocephalus platyurus, which was in 
turn fed to the cnidarians, Hydra attenuata. The results revealed trophic level 
transfer of carbamazepine was highest between the algae and crustacean with only 
trace residues of the antiepileptic detected in the exposed cnidarian. Considering 
bioaccumulation studies of other water pollutants at more environmentally relevant 
concentrations, Haukas et al. (2010) investigated the bioavailability of the 
brominated flame retardant, hexabromocyclododecane (HBCD), to ragworm by 
exposure through naturally contaminated sediment and mussel feed. Both sediment 
and mussel tissues used in this experiment were collected from a highly impacted 
area with concentrations measuring up to 85 µg.g
-1
 DW and 7 ng.g
-1
 WW, 
respectively. After 28 days of exposure, no HBCD residues were detected in 
ragworm exposed to contaminated sediment but, HBCD residues measuring 
between 7-12 ng.g
-1
 were detected in the ragworm exposed to contaminated mussel 
tissue feed. Despite the higher levels of HBCD contamination in the sediment, 
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trophic transfer was found to be a more important mechanism for HBCD 
bioaccumulation in the benthic food web. 
Thus far, indirect exposure of humans to pharmaceuticals via drinking water 
(Benotti et al., 2009; Focazio et al., 2008; Heberer et al., 2000; Stan and Heberer, 
1997) and dietary intake (Tittlemier et al., 2007; EFSA, 2013) have been shown to 
be possible but, the extent to which drugs can travel through the food chain and 
ultimately pose as a threat to human health remains relatively unknown. From the 
five pharmaceuticals selected in this study, carbamazepine and trimethoprim are the 
only pharmaceuticals previously investigated for their potential to bioaccumulate in 
aquatic organisms via dietary exposure. Previous studies confirmed high 
bioaccumulation of carbamazepine at lower trophic levels but low risk of exposure 
to organisms higher up in the food chain (Vernouillet et al., 2010). Trimethoprim 
was found to bioaccumulate in exposed fish and shrimp species with residues 
persisting for longer than three days post-dosage, which is of concern with respect 
to human consumption (Chair et al., 1996). To the author’s knowledge, this study 
was the first to investigate the potential for bioaccumulation of pharmaceuticals in 
fish via dietary exposure to wild bivalves collected from an impacted site. 
 
 
3.2 Experimental 
3.2.1 Reagents and chemicals 
LC-MS grade acetonitrile and water, and analytical grade acetone, acetonitrile, 
ethyl acetate and methanol, were purchased from Fisher Scientific (Cheshire, UK). 
Dichloromethane, dichlorodimethylsilane, ammonia solution, acetic acid and 
sulphuric acid were purchased from Aldrich (Gillingham, UK). Analytical grade 
carbamazepine (≥98 %), diclofenac sodium salt (≥98 %), gemfibrozil (≥99 %) and 
mefenamic acid (≥99 %) were obtained from Sigma-Aldrich (Steinheim, Germany) 
and trimethoprim (≥98 %) was ordered from Fluka (Buch, Switzerland). Ultra-pure 
water was obtained from a Millipore Milli-Q water purification system (Bedford, 
MA, USA). 
Stock solutions (1000 mg.L
-1
) of individual analytes were prepared in 
methanol and stored in a freezer at −20 °C, in the dark, for optimum stability. 
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Working mixed standards were prepared weekly in either water or, where required, 
in 80:20 v/v 13 mM ammonium acetate in water/acetonitrile. 
 
 
3.2.2 Sampling and experimental design 
The facilities at Shannon Aquatic Toxicology Laboratory were used for the set-up 
of this exposure. Juvenile rainbow trout were sourced from a pond system fish farm 
facility in Roscrea, Co.Tipperary. Fish (approx. 50±15 g) were acclimatised for 13 
days in one large tank of carbon filtered municipal supply water and fed 
commercial fish feed, in the form of pellets, at 1-2 % of total fish weight daily. A 
flow-through system was set up for nine 70 L aerated and covered tanks, using the 
same water supply set at a flow rate of 0.2 L.min
-1
 (see images in Figure 3.1 (a) & 
(b)). This set-up included three tanks for control, three tanks for mussel control and 
three tanks for contaminated mussel exposure, organised randomly, as shown in 
Figure 3.2. Organisation for Economic Co-operation and Development (OECD) 
Guideline No. 305 was followed for the set-up and running of this exposure with 
any exceptions noted (OECD, 2012).  
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Figure 3.1 (a) & (b): Flow-through system connected to 9 x 70 L tanks. Fish 
and air stones visible in each labelled tank. 
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Figure 3.2: Set-up of labelled fish tanks for in vivo exposure  
 
 
Six fish were weighed (see Table 3.1 for individual weights) and transferred 
into each tank to acclimatise for a further 24 h to reduce stress levels before 
exposure initiation. Water (500 mL) and fish (n=3) were sampled from the 
acclimation tank before the first day of exposure (t0) as a control and from each of 
the nine exposure tanks after 14 days of feeding (t14) and after 28 days of feeding 
(t28). An additional nine fish were sampled from the acclimation tank for method 
performance studies. Silanised amber Winchester glass bottles (500 mL) were used 
to collect water samples from each tank which were then stored in the fridge at 4 
°C. Fish were caught with a net and sampled individually. Fish were sacrificed, 
length and weight measurements were recorded and blood (≈1 mL), sampled from  
 
 
Table 3.1: Weights (g) of juvenile rainbow trout in each tank measured pre-
exposure 
Tank Fish weights (g) Mean weight (g) 
A 47, 53, 46, 58, 52, 49 51 
B 52, 60, 54, 46, 49, 50 52 
C 51, 54, 54, 60, 60, 52 55 
D 46, 54, 50, 57, 44, 50 50 
E 46, 44, 46, 46, 58, 61 50 
F 43, 41, 43, 48, 47, 58 47 
G 48, 48, 41, 44, 50, 60 49 
H 43, 49, 41, 43, 59, 51 48 
I 57, 58, 52, 51, 57, 47 54 
 
D 
Mussel 
Control 
H 
Mussel 
Exposed 
C 
Control 
I 
Mussel 
Exposed 
B 
Control 
E 
Mussel 
Control 
G 
Mussel 
Exposed 
F 
Mussel 
Control 
A 
Control 
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the caudal vein, was placed in a vial for later biomarker analysis. The liver (average 
weight of 0.5 g), kidney (average weight of 0.8 g) and fillet (average weight of 12 g 
×2) of fish were collected at each sampling time point, dissected and placed in 
labeled vials or plastic bags. All samples were transported back to the laboratory on 
dry ice and frozen at −80 °C. Aqueous samples were stored at 4 °C and extracted 
by SPE within 24 h of collection. 
 
 
3.2.3 Food preparation and feeding 
Blue mussels (Mytilus spp.) were sourced from a Class A bivalve mollusc 
production area, under EC Regulation 854/2004, off the west coast of Ireland and 
used as feed for the fish in the mussel control tanks. Fish in the mussel exposure 
tanks were fed blue mussels collected from one of the most highly impacted sites 
off the coast of Ireland, representative of a worst-case effluent exposure site. 
Pharmaceutical residues were previously detected in caged mussels exposed to the 
contaminated marine surface waters at this site and were expected to be present in 
the wild mussels residing at this site for a longer period of time. The animals 
chosen for this study were of the same size class (4-6 cm) and were collected at the 
end of August, before the spawning period in September. After collection, mussels 
were transported back to the laboratory in a cooler box, wiped free of debris, de-
shelled, chopped into small pieces, weighed into feed bags for each day of exposure 
and stored at −80 °C. Bagged mussel feed was removed from the freezer, cut into 
small frozen pellets and fed to the corresponding tank. All tanks were fed daily at 2 
% the total fish weight in the tank. From t1 to t14, each tank contained 
approximately 300 g (6×50 g) of fish and received 6 g of feed. After sampling at 
t14, each tank received 3 g of feed until t28. For the control tanks, fish were fed 
commercial fish feed in the form of pellets at the same quantities fed to the fish in 
the mussel control and exposure tanks. Fish faeces were removed approximately 6 
h after feeding by siphoning from the tank bottom. 
 
 
3.2.4 Sample pre-treatment, extraction and clean-up 
3.2.4.1 Glassware preparation and silanisation 
All glassware, including the exposure tanks, was pre-cleaned and silanised using 
97 
the method described in Section 2.2.3.1. 
 
3.2.4.2 Carbon filtered municipal water 
The optimised analytical method applied to ultra-pure water samples (Section 
2.2.3.2) was also applied to the carbon filtered municipal water samples collected 
from each tank. Briefly, samples (500 mL) were filtered, adjusted to pH 4 and 
extracted onto Strata-X SPE cartridges (6 mL, 200 mg, Phenomenex, Cheshire, 
UK). Samples were eluted with ethyl acetate:acetone (50:50), evaporated and 
reconstituted in 250 µL starting mobile phase before LC-MS/MS analysis. 
 
3.2.4.3 Marine mussels 
For marine mussels, the analytical method optimised described in Section 2.2.3.3 
was applied. Prior to sample extraction, mussels were frozen at −80 °C, freeze-
dried, homogenised and sieved to 125 µm. PLE was carried out on 1 g of freeze-
dried mussel tissue. Sample extracts were dried down to <10 mL and diluted to 200 
mL with ultra-pure water before undergoing SPE. Samples were reconstituted in 
250 µL of mobile phase A and analysed by LC-MS/MS. 
 
3.2.4.4 Fish liver 
The analytical method for marine mussels was also applied to fish liver tissues with 
some minor adjustments. Prior to sample extraction, fish livers were frozen at –80 
°C, freeze-dried, pooled according to tank and sampling time, homogenised and 
sieved to 125 µm. PLE was carried out using the same conditions as in Section 
2.2.3.3 but with different sample measurements added to the extraction cell. The 
activated neutral Al2O3 (20 g) (Sigma Aldrich, Steinheim, Germany) was placed in 
the cell followed by a mixture of freeze-dried fish liver sample (0.4 g) mixed with 
10 g of ottawa sand (20-30 mesh, Fisher Scientific, Cheshire, UK). The remaining 
dead volume of the cell was filled with sand. PLE was carried out as before and 
sample extracts were dried down to <10 mL and diluted to 200 mL with ultra-pure 
water. Samples underwent SPE and sample reconstitution to 200 µL before LC-
MS/MS analysis.  
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3.2.4.5 Fish fillet 
After freeze-drying, the fish fillet was too tough to be ground to a fine powder and 
could not be processed any further. The fish skin was not removed from the fillet 
before freeze-drying and may have been the reason the fillet did not freeze-dry 
sufficiently. 
 
 
3.2.5 Instrumental conditions 
The Agilent 1200 LC system (Agilent Technologies, Palo Alto, CA, USA) 
consisted of a binary solvent manager, autosampler, UV detector and Waters 
Sunfire C18 column (3.5 µm, 150 mm×2.1 mm, Waters Corp., MA, USA) and guard 
column (3.5 µm, 2.1 mm×10 mm, Waters Corp., MA, USA). Operating conditions 
were as previously described in Section 2.2.4. A Bruker Daltonics Esquire HCT Ion 
Trap mass spectrometer equipped with an API-ESI source was used for 
pharmaceutical identification and quantification. Nitrogen was used as a nebulising 
and desolvation gas (on site tap) and helium (99.999 %) (Air Products Plc, Crewe, 
UK) was used as a collision gas. Ionisation and mass spectrometric conditions (see 
Table 2.2) were optimised by direct infusion using a syringe pump (Cole-Parmer 
74900 Series) to deliver 300 μL.h-1 of analyte solution. The nebuliser pressure and 
drying gas flow were increased slightly after optimisation to account for the higher 
flow rates set for sample analysis. Mass spectrometric analysis was carried out in 
SRM mode for selected transitions (see Table 2.3). 
 
 
3.2.6 Method performance  
Method performance in ultra-pure water and marine mussels was previously carried 
out and discussed in Section 2.2.5. Method performance data for fish liver was 
obtained by replicating the optimised method for marine mussels, as described in 
Section 2.2.3.3, with a change in the sample mass added to the PLE extraction cell. 
Calibration curves (n=3) were constructed in fish liver tissues (0.4 g), sourced from 
rainbow trout bought from a local fishmonger, to assess method performance. Fish 
liver was spiked with the selected pharmaceuticals at concentrations from 5 to 5000 
ng.g
-1
. LOD (S/N ratio=3:1) and LOQ (S/N ratio=10:1) were calculated using 
triplicate injections of three low-level spiked samples. Precision, reproducibility 
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and recovery studies were carried out by spiking sample matrices (n=6) pre-
extraction to pharmaceutical concentrations of 0.5 µg.g
-1
 DW. Recovery was 
calculated by comparing spiked extracts to final extracts of the unspiked matrix 
(n=3) reconstituted in 200 µL of mobile phase A containing the expected 100 % 
recovery concentration. Ion suppression and enhancement was also investigated by 
comparing sample extracts spiked post-extraction to a 1 mg.L
-1
 analyte mixture 
prepared in mobile phase A. None of the target analytes were detected in solvents, 
reagents, ultra-pure water or fish liver tissue used for the method performance 
studies. All sample and standard measurements were carried out in triplicate unless 
otherwise stated.  
 
 
3.3 Results and Discussion 
3.3.1 Fish liver sample preparation  
Prior to PLE, the freeze-dried biotic tissue was ground with a pestle and mortar and 
sieved to a particle size of approximately 125 µm. Most of the sample was ground 
to a fine powder with very few larger remains in the sieve (<5 %). PLE was based 
on the method previously optimised for marine mussels with slight modifications. 
Extraction solvents were tested using 1:1 methanol/water, 1:1 acetonitrile/water, 
3:1 acetonitrile/water and 3:1 acetonitrile/water with 1 % formic acid). A mixture 
of 3:1 acetonitrile/water again provided the best recovery. The optimal temperature 
(60 °C), static time (5 min), number of cycles (3) and flush volume (100 %) 
remained the same as those for the PLE method for marine mussels. Next, the 
addition of various quantities of Al2O3 (10, 15 and 20 g) added to the extraction cell 
and the quantities of ottawa sand (2, 4 and 10 g) mixed with the sample were 
evaluated. Higher quantities of Al2O3 (20 g) and ottawa sand (10 g) achieved 
slightly higher recoveries and S/N ratios. The sample mass itself was tested by 
analysing the sieved freeze-dried biotic tissue (0.1, 0.2 and 0.4 g) spiked at 500 
ng.g
-1
. Due to the small size of fish liver samples, the higher sample mass of 0.4 g 
was made up of three fish liver tissues combined. Higher analyte recoveries were 
achieved with 0.4 g of sample in comparison to 0.1 g. The PLE extract was further 
cleaned up using Strata-X SPE cartridges. The analytical method applied to marine 
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mussels was used for the extraction of pharmaceuticals from fish liver tissues. 
Eluting solvents were re-investigated here as a means of increasing percentage 
recovery of analytes from a more complex matrix. Both methanol and 50:50 (v/v) 
ethyl acetate/acetone exhibited similar results with ethyl acetate/acetone achieving 
slightly higher recoveries on average.  
 
 
3.3.2 Instrumental and analytical method performance 
Method performance results for individual pharmaceuticals in ultra-pure water, 
marine mussel tissue and fish liver are shown in Table 3.2. Instrumental precision 
measured ≤1.3 % for retention time of all analytes in ultra-pure water, marine 
mussel tissues and fish liver tissues. As results for ultra-pure water and marine 
mussels have been previously discussed in Section 2.3.3, this section will focus on 
the results of the method performance when applied to fish liver samples. Fish liver 
samples (0.4 g, n=11 in triplicate) were spiked in the extraction cell, after mixing 
with sand, with a standard mixture resulting in final concentrations of 5-5000 ng.g
-1
 
of each pharmaceutical (solvent volume added <250 µL). Linearity was achieved 
for analytes in negative mode from 10 to 2500 ng.g
-1
 (R
2≥0.992) and in positive 
mode from 5 to 1000 ng.g
-1
 (R
2≥0.988). LOQs ≤53 ng.g-1 were achieved for 
analytes in fish liver. Method recoveries were in the range of 41 to 97 % with 
precision varying ≤18 % for n=6 replicates of a 500 ng.g-1 standard mix. Signal 
suppression ranged from 32 to 68 % for analytes in fish liver tissue with the signal 
for acidic compounds exhibiting the greatest suppression.  
 In order to minimise the matrix effect on the quantification of ions, 
calibration curves were prepared in each sample matrix and run before and after 
each series of samples. For quality control of the method, an injection of starting 
mobile phase was run between each sample with no carry over observed. EICs of 
pharmaceuticals spiked in fish liver at 250 ng.g
-1
 are shown in Figure 3.3. 
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Table 3.2: Method performance data for pharmaceuticals in ultra-pure water (500 mL), marine mussel tissue (1 g) and fish liver (0.4 g) 
*
Average time recorded for each pharmaceutical in marine mussel tissues 
a 
Three data points carried out in triplicate 
b 
Eight data points carried out in triplicate 
 
Compound  
 
Ultra-pure water 
 
Marine mussels 
 
Fish liver 
 
tr * 
(min) 
SRM 
transitions 
LOQ 
(ng.L
-1
) 
n=9
a
 
R
2 
 
n≥24b 
Recovery 
(%) 
n=6 
 LOQ  
(ng.g
-1
) 
n=9
a
 
R
2 
 
n≥24b 
Recovery 
(%) 
n=6 
 LOQ  
(ng.g
-1
) 
n=9
a
 
R
2 
 
n≥24b 
Recovery 
(%) 
n=6 
Trimethoprim 5.9 291→123 (+) 
291→230 (+) 
2 0.993 84±3  4 0.985 91±9  4 0.990 97±18 
Diclofenac 8.1 294→250 (−) 
294→236 (−) 
5 0.997 98±8  29 0.990 83±8  53 0.992 52±8 
Carbamazepine 8.2 237→194 (+) 
237→192 (+) 
2 0.991 93±9  6 0.987 100±5  8 0.988 54±5 
Mefenamic acid 9.0 240→196 (−) 
240→223 (−) 
6 0.999 96±10  23 0.990 104±12  44 0.996 42±6 
Gemfibrozil 11.5 249→121 (−) 
249→127 (−) 
8 0.999 79±7  18 0.993 100±20  49 0.999 41±6 
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Figure 3.3: EICs of selected pharmaceuticals (250 ng.g
-1
 DW) spiked in fish liver   
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3.3.3 Application to marine mussels sampled from a wastewater effluent 
exposure site 
The method previously developed for the analysis of pharmaceuticals in marine mussel 
tissues was applied to the identification of pharmaceuticals in both the marine mussels 
collected from the pristine site off the west coast of Ireland and the effluent exposed 
marine mussels collected from the highly contaminated site off the east coast of 
Ireland. As expected, no pharmaceuticals were detected in the marine mussels 
collected from the pristine site and used as feed in the mussel control tanks. Similar to 
the results obtained for pharmaceutical residues in the caged mussels (Table 2.7), 
residues of trimethoprim were quantified in the tissues of the wild effluent exposed 
mussels at 6.68 ng.g
-1
 DW. An EIC of trimethoprim residues detected in the wild 
marine mussel tissues is shown in Figure 3.4. None of the other selected 
pharmaceuticals were detected in the wild marine mussels. 
 
 
 
Figure 3.4: EIC of trimethoprim in wild marine mussel tissue sampled from a 
wastewater effluent exposure site 
 
 
Although trimethoprim was the only pharmaceutical quantified in the effluent 
exposed mussel tissue, this does not rule out the presence of the other selected 
pharmaceuticals in the contaminated mussel tissue considering the ubiquitous presence 
of the same pharmaceutical residues in surrounding marine waters at concentrations up 
5 10 15 20 25 Time [min]
0
1
2
3
4
5
4x10
Intens.
dub mo6_2-C,8_01_10281.d: EIC 123.1±0.2 +MS2(291.1)
Trimethoprim 
m/z transition: 291→123 
104 
to 1.41 µg.g
-1
 (see Tables 2.6 (a), (b) & (c)). If there is a potential for pharmaceuticals 
to bioaccumulate and even biomagnify through the food chain, pharmaceuticals too 
low to be quantified in marine mussels using this analytical method may be detected or 
even quantified in the tissues of organisms at higher trophic levels, feeding on the 
exposed marine mussel tissues over time. 
 
 
3.3.4 Application to fish tissues collected from juvenile rainbow trout feeding on 
contaminated marine mussel tissue for 28 days 
The developed methods were applied to the identification of pharmaceutical residues in 
fish liver following a 28-day in vivo exposure. Fish and carbon filtered municipal water 
were sampled from each of the nine tanks at t14 and t28 in an attempt to evaluate the 
potential for selected pharmaceuticals to bioaccumulate in specific tissues of rainbow 
trout feeding on contaminated mussel tissue. Fish liver and fillet were collected from 
each fish sample however, pharmaceutical analysis was only carried out on the fish 
liver due to problems with the freeze-drying of the fillet. Due to the small sample size 
after freeze-drying, fish livers (n=3) sampled from fish collected from the same tank at 
the same time were combined prior to PLE and analysed as one sample via triplicate 
injections on the LC-MS/MS. One sample of carbon filtered water was also collected 
per tank at each sampling time and analysed via triplicate injections on the LC-
MS/MS. Water pH, temperature, dissolved oxygen (DO) content, total organic carbon 
(TOC) and hardness were measured throughout the 28-day in vivo experiment on the 
days marked in Table 3.3. Average results for each parameter are shown in Table 3.4. 
From the results in Section 3.3.3, it can be accepted that juvenile rainbow trout were 
exposed to environmentally relevant concentrations of trimethoprim through a diet of 
naturally contaminated marine mussels. However, following analysis of liver tissues 
from the exposed juvenile rainbow trout, no pharmaceutical residues were detected in 
the fish liver sampled at t0, t14 or t28. There were also no pharmaceutical residues 
detected in the liver tissues of the rainbow trout fed uncontaminated mussel tissue or 
commercial fish feed. 
105 
Table 3.3: Days on which water measurements, such as temperature (°C), pH, DO (%), TOC (mg.L
-1
) and hardness (CaCO3 mg.L
-1
), 
were collected 
Parameter  Time (days)  
 
 t0 t1 t2 t3 t4 t5 t6 t7 t8 t9 t10 t11 t12 t13 t14 t15 t16 t17 t18 t19 t20 t21 t22 t23 t24 t25 t26 t27 t28 
Temperature (°C)  √ √ √ √ 
  
√ √ √ √ √   √ √ √ √ √   √ √ √ √ √   √ √ 
pH  √ √ 
 
√ 
  
√ 
 
√  √   √  √  √   √  √  √   √ √ 
DO (%)  √ 
 
√ √ 
  
√ √ 
 
 √   √  √  √     √  √   √ √ 
TOC (mg.L
-1
)  
 
√ 
       
     √              √ 
Hardness (CaCO3 mg.L
-1
)  √ 
        
     √              √ 
 
 
Table 3.4: Average measurements of temperature (°C), pH, DO (%), TOC (mg.L
-1
) and hardness (CaCO3 mg.L
-1
) collected from each 
tank during the 28 d in vivo exposure 
Parameter  Tanks 
 
 Control Mussel Control Mussel exposure 
 
 A B C D E F G H I 
Temperature (°C)  14.7±1.7 14.7±1.7 14.7±1.4 14.8±1.6 14.7±1.5 14.7±1.5 14.8±1.6 14.8±1.7 14.5±.5 
pH  7.1±0.5 7.2±0.5 7.2±0.4 7.1±0.5 7.2±0.5 7.3±0.3 7.3±0.5 7.3±0.5 7.2±0.3 
DO (%)  92±6 91±6 89±6 89±9 96±4 95±6 92±6 93±4 95±3 
TOC (mg.L
-1
)  1.3±0.2 
  
1.4±0.2 
  
1.2±0.2 
  
Hardness (CaCO3 mg.L
-1
)  149.5±6.3 
  
148.9±7 
  
148.5±6.4 
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The experimental design of this study was similar to that carried out by 
Haukas et al. (2009) in that it was based on an organisms ability to graze on lower 
trophic species and the feed administered was collected from an impacted site in the 
natural aquatic environment assumed to contain environmentally relevant 
concentrations of the contaminants. The test compound HBCD has a logKow value 
higher than the selected pharmaceuticals, at approximately 5.6, therefore, it has a 
higher affinity for solid matrices and is most likely removed by adsorption to 
sludge during wastewater treatment (Barron et al., 2009). However, when this 
compound is released with industrial wastewaters, directly into the aquatic 
environment, its potential for bioaccumulation and trophic level transfer in aquatic 
organisms was found to be high (Haukas et al., 2009). Jaffe (1991) proposed that 
dietary exposure of pharmaceuticals in the environment and biomagnification could 
be relevant for compounds with logKow>6. Considering most pharmaceuticals are 
polar non-volatile compounds with low logKow values, biomagnification of 
pharmaceuticals in aquatic ecosystems is not likely, however, low bioaccumulation 
and trophic level transfer of pharmaceuticals may still occur within food webs. 
Low-level residues of trimethoprim were quantified in the mussel tissue 
feed but not in the fish liver, implying the antibiotic was either readily metabolised 
in the fish tissues or eliminated at a higher rate than the uptake rate. The latter 
explanation seems more feasible based on the results from previous exposure 
studies which highlight the long residence times of trimethoprim in fish species 
after exposure and its low biotransformation in the renal tubule and liver in rats and 
humans (Chair et al., 1996; Liu et al., 2012). Unlike the bioaccumulation study of 
trimethoprim carried out by Chair et al. (1996), bioaccumulation of trimethoprim in 
fish via trophic level transfer was not observed in this experiment. However, this is 
most likely due to the environmentally relevant and much lower concentrations 
exposed to the fish which may have been too low to measure in the fish liver. 
Although trimethoprim was not detected in the exposed fish tissues, it cannot be 
concluded that bioaccumulation did not occur, as trimethoprim residues can only be 
detected as low as the detection limits set for this analytical method i.e. <1 ng.L
-1
. 
Carbamazepine was not detected in the contaminated mussel feed, 
previously shown to be exposed to marine surface waters contaminated with this 
compound at concentrations up to 1.41 µg.L
-1
. However, trace residues of 
carbamazepine have been previously detected in mussel tissue collected from the 
same exposure site but, at a different time of year (see Tables 2.6 (a), (b) & (c)). 
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Studies have shown carbamazepine to have a low propensity to bioconcentrate in 
fish (Huggett et al., 2004; Ramirez et al., 2007; Zhou et al., 2008) but, when 
exposed to green algae then fed to the crustacean, T. platyurus, high 
bioaccumulation of the compound was reported via dietary exposure (Vernouillet et 
al., 2010). This trophic level study also reported very low bioaccumulation of 
carbamazepine in the cnidarian, H. attenuata, following exposure to the compound 
via the food chain (Vernouillet et al., 2010). Biochemical biomarkers such as Phase 
I (cytochrome P450-3A4) activity and oxidative stress were monitored during this 
exposure to provide an insight into the biotransformation capacities of each species. 
In comparison to unexposed control species, Phase I activity was inhibited in the 
exposed algae and crustacean but, was induced by 433 % in exposed cnidarians. 
This implies low biotransformation of carbamazepine within all species except the 
H. attenuata spp. which explains the low bioaccumulation measurements made for 
carbamazepine in the cnidarians. Previous exposure studies support the induction of 
biotransformation enzymes in the cniadarian, H. attenuata, in the presence of 
carbamazepine (Quinn et al., 2004). The metabolism of pharmaceuticals in aquatic 
organisms has not been previously studied in great detail, but in the case of fish, 
both Phase I and II metabolism have been found to occur (Lahti et al., 2011). Major 
metabolites of three acidic compounds (diclofenac, ibuprofen and naproxen) were 
detected in the bile of exposed rainbow trout at concentrations greater than the 
parent compounds, suggesting efficient biotransformation of the studied 
pharmaceuticals in fish. As highlighted by these previous studies, aquatic species at 
lower trophic levels may not possess a metabolic system as efficient or complex as 
their predators, increasing their susceptibility to pharmaceutical bioaccumulation.  
 
 
3.4 Conclusions 
In this study, PLE, SPE and LC-MS/MS methods were optimised and validated for 
the identification and quantification of five pharmaceuticals in fish liver tissues. 
Linearities for this method were ≥0.988 and LOQs ≤53 ng.g-1 were achieved. This 
analytical method and the methods previously optimised for pharmaceutical 
analysis in marine mussels and ultra-pure water were applied to samples collected 
from a 28 d in vivo exposure investigating the uptake of pharmaceutical residues in 
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juvenile rainbow trout via dietary intake of wild marine mussels. Despite the 
presence of trimethoprim residues in the tissues of the Mytilus spp., no 
pharmaceutical residues were detected in the fish liver tissues or the carbon filtered 
municipal water supplied to the fish tanks, after 28 days of feeding. It cannot be 
concluded that trimethoprim was not bioaccumulated in the fish tissues as residues 
may have been too low to be detected by the analytical method. The monitoring of 
pharmaceutical metabolites is suggested for future studies assessing the risk of 
pharmaceutical exposure to aquatic species via dietary intake. 
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Abstract 
The effect of cooking (by steaming) on pharmaceutical residues present in marine 
mussels (Mytilus spp.) was investigated to determine any potential difference in 
human exposure risk. Selected pharmaceuticals included two non-steroidal anti-
inflammatory drugs (diclofenac and mefenamic acid), an antibiotic (trimethoprim), 
an antiepileptic (carbamazepine) and a lipid regulator (gemfibrozil). A preliminary 
in vivo exposure experiment was set up in the laboratory in which mussels were 
exposed either directly by injection (10 ng) or daily through spiked artificial 
seawater (ASW) over 96 h. The solid phase extraction (SPE) and liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) method, optimised for 
marine surface water in Chapter 2.0, was applied to ASW samples. Limits of 
quantification (LOQs) ≤46 ng.L-1 were achieved for extracted cooking water and 
ASW, ≤64 µg.L-1 for ASW in exposure tanks, and ≤29 ng.g-1 for mussel tissue. 
Method linearities were achieved for pharmaceuticals in each matrix with 
correlation coefficients of R
2≥0.977. A selection of exposed mussels was cooked 
(via steaming) and analysed using the optimised method to observe any effect on 
detectable concentrations of parent pharmaceuticals present. An overall increase in 
pharmaceutical residues in the exposed mussel tissue and cooking water were 
observed after cooking.  
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Aims and Objectives 
 Develop and validate analytical methods for the quantitation of selected 
pharmaceuticals in artificial seawater (ASW) using solid phase extraction 
(SPE) and liquid chromatography-tandem mass spectrometry (LC-MS/MS). 
These pharmaceuticals include an antiepileptic (carbamazepine), two non-
steroidal anti-inflammatory drugs (NSAIDs) (diclofenac and mefenamic 
acid), a lipid regulator (gemfibrozil) and an antibiotic (trimethoprim). 
  Set up a preliminary experiment exposing marine mussels in vivo to the 
pharmaceutical mix via direct injection or water exposure for a 96-h period.  
 Apply previously developed methods for pharmaceutical extraction and 
analysis to ASW, cooking water and marine mussels samples collected from 
this preliminary exposure. 
 Following the steaming of 96-h exposed mussels, examine the net changes 
of pharmaceutical residues in the mussel tissue after cooking. 
 Compare the effect of cooking on mussels exposed to elevated 
pharmaceutical concentrations to those exposed to effluent impacted marine 
surface waters. 
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4.1 Introduction 
Studies have shown that chemicals present in the aquatic environment have the 
ability to be absorbed by humans. The Fourth National US Report on Human 
Exposure to Environmental Chemicals published the exposure levels of 250 
chemicals, such as heavy metals, polychlorinated biphenyls (PCBs), chlorinated 
pesticides, phytoestrogens, and triclosan, in blood and urine samples from over 
6000 participants (US Department of Health and Human Services, 2009). 
Pharmaceuticals are designed to have a biological effect at low levels and exposure 
of humans to these compounds through the environment may act as a serious health 
risk either through direct effect or indirectly through potential antimicrobial 
resistant species. It is therefore of interest to determine possible routes of exposure 
that may pose as a threat to human health.  
The presence of pharmaceuticals in drinking water has been previously 
reported at low ng.g
-1
 concentrations in countries such as the U.S. and Germany 
(Benotti et al., 2009; Focazio et al., 2008; Heberer et al., 2002).  However, levels of 
pharmaceutical residues found in drinking water are usually much lower than those 
detected in foodstuffs as most pharmaceutical residues in drinking water are 
sourced from environmental contamination alone. Food safety appears to be more 
of a concern for regulatory authorities in the E.U. following the reports of 
contaminated foodstuffs in the news, such as the presence of the hormone 
medroxyprogesterone acetate in pig feed in Belgium and Holland and antibiotics in 
shrimp imported from Asia (Holmstrom et al., 2003; Van Leengoed et al., 2002). 
Yearly residue monitoring programmes are carried out by the EU on various 
foodstuffs such as meat, meat products and aquaculture in a bid to improve the 
quality of consumed food (EFSA, 2013).  
Due to their widespread use in aquaculture and livestock, veterinary drug 
residues, in particular antibiotics, are among the most commonly reported chemical 
contaminants in foodstuffs in the EU (Kleter et al., 2009). Most veterinary drug 
residues occur in food as a result of the direct administration of pharmaceuticals to 
farmed animals and seafood in an effort to reduce disease outbreak and promote 
growth efficiency (Turnipseed and Andersen, 2008). Besides exposure to dispensed 
veterinary drugs, seafood in particular is also exposed to contaminants present in 
the aquatic environment which may potentially accumulate in their tissues. 
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Most raw seafood is thermally treated by cooking before consumption but, 
little information is available regarding the potential effects of these treatments on 
pharmaceutical residue content. At present, studies on the effect of thermal 
treatments have only been applied to veterinary antibiotic residues, mainly in fish 
and crustacean species. Kitts et al. (1992) carried out one of the first thermal 
treatment studies on OTC residues in salmon with reductions of approximately 30 
% measured in fried salmon fillet. The effect of cooking on the residues of two 
quinolones, oxolinic acid (OA) and flumequine, was also investigated in salmon 
and reported residue persistence during baking and boiling and leakage from 
contaminated tissue to uncontaminated tissues (Steffenak et al., 1994). Uno et al. 
(2002; 2006a; 2006b; 2010) investigated the persistence of the residues of OA and 
OTC in shrimp and prawns, reporting residue elimination to be incomplete with 
reductions measuring between 20-60 % in the muscle and shell. The reduction of 
the antibiotics, ormetoprim, sulfadimethoxine and OTC, after cooking were also 
reported at approximately 50 % from raw catfish fillet (Huang et al., 1997; Xu et 
al., 1996). The transfer of biologically active compounds to humans is of major 
concern and may occur through mechanisms as simple as the consumption of 
seafood products containing pharmaceutical residues. 
Marine blue mussels are natural filter feeders, filtering approximately 1.8 
L.h
-1
 (Clausen and Riisgard, 1996). Dissolved or suspended contaminants present in 
the water column may result in uptake within the mussel and potential exposure to 
humans via dietary exposure. Pharmaceutical residues were detected in caged and 
wild marine mussel tissues in Chapters 2 and 3 and have also been detected in 
mussels used in monitoring studies in Belgium, China and the U.S. (Bringolf et al., 
2010; Klosterhaus et al., 2013; Li et al., 2012; Wille et al., 2011).  
A preliminary experiment was set up whereby marine mussels were exposed 
in vivo to a pharmaceutical mixture (carbamazepine, diclofenac, gemfibrozil, 
mefenamic acid and trimethoprim) via direct injection or water exposure. This 
study was carried out to investigate if cooking will decrease pharmaceutical 
residues to negligible levels, in the event that pharmaceuticals are present in the raw 
marine mussels. No previous studies exist on the effect of thermal treatment on 
pharmaceutical residues, other than veterinary antibiotics, in biological tissues.   
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4.2 Experimental 
4.2.1 Reagents and chemicals 
LC-MS grade acetonitrile and water, and analytical grade acetone, acetonitrile, 
ethyl acetate and methanol, were purchased from Fisher Scientific (Cheshire, UK). 
Dichloromethane, dichlorodimethylsilane, dimethyl sulfoxide, ammonium 
hydroxide solution, acetic acid and sulphuric acid were purchased from Aldrich 
(Gillingham, UK). Analytical grade carbamazepine (≥98 %), diclofenac sodium salt 
(≥98 %), gemfibrozil (≥99 %) and mefenamic acid (≥99 %) were obtained from 
Sigma-Aldrich (Steinheim, Germany) and trimethoprim (≥98 %) was ordered from 
Fluka (Buch, Switzerland). Ultra-pure water was obtained from a Millipore Milli-Q 
water purification system (Bedford, MA, USA). 
A stock solution of the analyte mix, including carbamazepine, diclofenac, 
gemfibrozil, mefenamic acid and trimethoprim, was prepared in dimethyl sulfoxide 
(DMSO) at a concentration of 10,000 mg.L
-1
. Working mixed standard solutions 
were prepared by appropriate dilution of the stock solutions in DMSO. Stock 1,000 
mg.L
-1
 standards were also prepared for each pharmaceutical in methanol for 
method performance and quantification purposes. Working mixed standards were 
prepared weekly in either methanol or, where required, in 80:20 v/v 13 mM 
ammonium acetate in water/acetonitrile. All solutions were stored in a freezer at 
−20 °C and in the dark for optimum stability. 
 
 
4.2.2 Sampling and experimental design 
Blue mussels (Mytilus spp.) were collected in the west of Ireland (Lettermullen, Co. 
Galway), from a Class A bivalve mollusc production area, designated by the Sea-
Fisheries Protection Authority of Ireland under EC Regulation 854/2004. The 
animals chosen for this study were of the same size class (4-6 cm) and were 
between summer spawning periods. The mussels were transported back to the 
laboratory in a cooler box, wiped free of debris and seaweed and acclimatised over 
3.5 days in a large tank of ASW. ASW consisted of Peacock Seamix (NaCl 65.5 %, 
MgSO4 8.25 %, MgCl2 6 %, CaCl2 3 %, KCl 1.6 %, insolubles 0.05 %, H20 15.6 
%) dissolved in dechlorinated tap water to a salinity of 33 g.kg
-1
 at 13 °C (±1 °C).  
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Figure 4.1 (a) & (b): Images of the in vivo experimental set-up exposing 
pharmaceuticals to Mytilus spp. via direct injection and water uptake 
 
 
Preliminary experiments were set up in four silanised glass tanks (15 L total 
volume) containing ASW under semi-static conditions (24-h ASW renewal).  
Mussels were exposed to 1 mg.L
-1
 of a pharmaceutical mixture via direct 
injection into the haemolymph of the mussel or via water uptake. Each tank was 
supplied with an air stone to maintain dissolved oxygen concentrations and covered 
with a black plastic cover, shown in Figure 4.1 (a) & (b). For the direct injection 
exposure, 10 ng of a 1 mg.L
-1
 pharmaceutical mixture in DMSO was injected into 
the adductor muscle of the mussel following the protocol described by Schmidt et 
al. (2011). For the water uptake exposure, mussels were exposed to 1 mg.L
-1
 of 
each selected pharmaceutical with water replenishment and fresh chemical addition 
occurring daily. To fortify 10 L ASW at this concentration, 1 mL of the 10,000 
mg.L
-1
 stock solution was added directly into the exposure tank on Day 1. The 
volume of ASW and stock solution added to the tank for Days 2, 3 and 4 were 
reduced to 6,666 mL and 0.66 mL, respectively, to compensate for the reduction in 
mussels sampled after 24 hours of exposure (t24h) and maintain the same volume of 
ASW per mussel throughout the experiment. The mixture was stirred immediately 
with a glass rod for 1 min to hasten equilibration of pharmaceuticals throughout the 
tank. Forty mussels were attached to two tiles and placed at the bottom of each tank 
after spiking and the pH was recorded (7.95±0.02). Solvent control tanks were 
prepared in parallel with each exposure and DMSO concentrations corresponding to 
those in the exposure tanks were used. Fresh ASW was supplied to all tanks daily 
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and spiked as necessary. Mussels were not fed during acclimatisation and exposure. 
Water temperature and salinity were measured (WTW Cond 1970i meter with a 
TetraCon 325 probe) at the mussel collection site and for each exposure tank daily. 
The experiment was carried out over 96 h and conducted under 10 h of light per 
day. ASW (500 mL) was sampled from the acclimatisation tank before the 
exposure commenced and from each tank (1.5 mL) at t1h, t24h and t96h of the 
exposure. The concentration of compounds in water over a 19-h period was 
monitored during Day 2 of the water exposure experiment. ASW (1.5 mL) was 
collected in silanised amber vials at t2min, t1h, t3h, t7h and t19h and frozen immediately 
at −20 °C until analysis. At t2min, t24h and t96h, mussels were sampled from each 
tank, de-shelled and the visceral mass was dissected and frozen at −80 oC. For 
statistical analysis, 10 mussels were sampled from each tank at t2min and again at 
t24h and 20 mussels were sampled at t96h.  
The frozen visceral mass collected at t96h was halved and allowed to defrost 
at room temperature. Following a basic cooking recipe, mussels were steamed in 
approximately 50 mL of ultra-pure water in a silanised glass pot, as shown in 
Figure 4.2, at 100 °C for 15 minutes, removed and allowed to cool (Mussel Industry 
Council of North America, 2009). After cooling, cooked mussels were frozen again 
 
 
 
Figure 4.2: The steaming of water-exposed mussels collected at t96 
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at –80 °C until analysis. The remaining cooking water was diluted up to 250 mL 
before undergoing SPE and LC-MS/MS analysis. From the experiment described in 
the previous chapter, mussel samples collected from EXP1 in October 2011 were 
also cooked, following the same procedure, to investigate the effect of cooking on 
pharmaceutical residues present in the mussel tissues at environmentally relevant 
concentrations.  
 
 
4.2.3 Sample pre-treatment, extraction and clean-up 
4.2.3.1 Glassware preparation and silanisation 
All glassware, including the exposure tanks, was pre-cleaned and silanised using 
the method described in Section 2.2.3.1. 
 
4.2.3.2 Artificial sea water 
The optimised analytical method applied to effluent and marine surface water 
samples (Section 2.2.3.2) was also applied to artificial seawater samples. Briefly, 
samples were filtered, adjusted to pH 4 and extracted onto Strata-X SPE cartridges 
(6 mL, 200 mg, Phenomenex, Cheshire, UK). Samples were eluted with ethyl 
acetate:acetone (50:50), evaporated and reconstituted in 250 µL starting mobile 
phase before LC-MS/MS analysis. 
 
4.2.3.3 Marine mussels 
For marine mussels, the analytical method optimised and discussed in Section 
2.2.3.3 was applied to all cooked and uncooked mussel samples collected. Prior to 
sample extraction, both cooked and uncooked mussels were frozen at −80 °C, 
freeze-dried, homogenised and sieved to 125 µm. PLE was carried out on 1 g of 
freeze-dried mussel tissue. Sample extracts were dried down to <10 mL and diluted 
to 200 mL with ultra-pure water before undergoing SPE and sample reconstitution 
prior to LC-MS/MS analysis. 
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4.2.4 Instrumental conditions 
The Agilent 1200 LC system (Agilent Technologies, Palo Alto, CA, USA) 
consisted of a binary solvent manager, autosampler, UV detector and Waters 
Sunfire C18 column (3.5 µm, 2.1 mm×150 mm, Waters Corp., MA, USA) and guard 
column (3.5 µm, 2.1 mm×10 mm, Waters Corp., MA, USA). Operating conditions 
were as previously described in Section 2.2.4. A Bruker Daltonics Esquire HCT Ion 
Trap mass spectrometer equipped with an API-ESI source was used for 
pharmaceutical identification and quantification. Nitrogen was used as a nebulising 
and desolvation gas (on site tap) and helium (99.999 %) (Air Products Plc, Crewe, 
UK) was used as a collision gas. Ionisation and mass spectrometric conditions (see 
Table 2.2) were optimised by direct infusion using a syringe pump (Cole-Parmer 
74900 Series) to deliver 300 μL.h-1 of analyte solution. The nebuliser pressure and 
drying gas flow were increased slightly after optimisation to account for the higher 
flow rates set for sample analysis. Mass spectrometric analysis was carried out in 
SRM mode for selected transitions (see Table 2.3). 
 
 
4.2.5 Method performance 
Calibration curves (n=3) were constructed in ASW (500 mL and 1.5mL) to assess 
method performance. Method performance in marine mussels was previously 
discussed in Section 2.2.5. ASW (500 mL, n=12 in duplicate) was spiked with the 
selected pharmaceuticals at concentrations from 5 to 5000 ng.L
-1
. For ASW (1.5 
mL, n=12 in triplicate) collected from each tank during the exposure, ASW was 
spiked at concentrations measuring from 5-5000 µg.L
-1
. LOD (S/N ratio=3:1) and 
LOQ (S/N ratio=10:1) were calculated using triplicate injections of three low-level 
spiked samples. Precision, reproducibility and recovery studies were carried out by 
spiking sample matrices (n=6) pre-extraction to pharmaceutical concentrations of 
0.5 µg.L
-1
. Recovery was calculated by comparing spiked extracts to final extracts 
of the unspiked matrix (n=3) reconstituted in 250 µL of mobile phase A containing 
the expected 100 % recovery concentration. Ion suppression and enhancement was 
also investigated by comparing sample extracts spiked post-extraction to a 1 mg.L
-1
 
analyte mixture prepared in mobile phase A. None of the target analytes were 
detected in solvents, reagents, ultra-pure water, ASW or marine mussel tissue 
(sampled from Lettermullan, Co. Galway) used for method performance studies. 
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All sample and standard measurements were carried out in triplicate unless 
otherwise stated.  
 
 
4.3 Results and Discussion 
4.3.1 Instrumental and analytical method performance 
Upon investigation of instrumental precision, retention times varied ≤1.3 % for all 
analytes in each matrix. Despite high levels of salt in the ASW matrix, correlation 
coefficients of greater than 0.990 (n≥8) were achieved for all analytes over the 
ranges of 10 to 2500 ng.L
-1
 in negative ESI-MS/MS mode and 5 to 1000 ng.L
-1
 in 
positive ESI-MS/MS mode. All analytes were quantifiable at concentrations as low 
as 2 to 46 ng.L
-1
 in ASW. Method performance in ASW correlates to data for 
marine surface water in Chapter 2.0 and to that reported by Wille et al. (2010) for 
the analysis of 13 pharmaceuticals in natural sea water. The % recovery of each 
analyte in ASW using the combined SPE and LC-MS/MS method was 45 to 87 % 
for n=6 replicates of a 1 µg.L
-1
 standard mix (RSD≤12 %) (Table 4.1). An 
investigation into the matrix effects of ASW was carried out by comparison of 
extracts spiked post-extraction (1 µg.L
-1
) to a standard in mobile phase A. Signal 
suppression of <29 % was observed for all analytes in ASW, with gemfibrozil 
subject to the most suppression. For ASW (1.5 mL) collected from each tank during 
the exposure, instrumental correlation coefficients of R
2≥0.977 and LOQs ≤64 
µg.L
-1
 were achieved for concentrations measuring from 5 to 2500 µg.L
-1
. Ion 
suppression ranged from 7 to 26 % for all pharmaceuticals except gemfibrozil, 
which underwent a signal enhancement of 7 %. Recoveries of between 79-98 % 
were achieved for analytes in ultra-pure water (cooking water) with LOQs 
measuring up to 8 ng.L
-1
. Method performance in marine mussels has been 
previously discussed in Section 2.3.3. All method performance results for 
individual pharmaceuticals in ultra-pure water, ASW (1.5 mL), extracted ASW 
(500 mL) and marine mussel tissue are shown in Table 4.1.  
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Table 4.1: Method performance data for pharmaceuticals in ultra-pure water, extracted ASW (500 mL), ASW from exposure tanks (1.5 mL) and 
marine mussels 
Compound  Ultra-pure water  Artificial sea water (500 mL) 
 
tr* 
(min) 
n=12 
LOQ 
(ng.L
-1
) 
n=9
a
 
R
2 
 
n≥24b 
Recovery 
(%) 
n=6 
 
LOQ 
(ng.L
-1
) 
n=9
a
 
R
2 
 
n≥24b 
Recovery 
(%) 
n=6 
Carbamazepine 8.2 2 0.991 93±9  4 0.994 87±4 
Diclofenac 8.1 5 0.997 98±8  46 0.992 63±7 
Gemfibrozil 11.5 8 0.999 79±7  16 0.996 45±12 
Mefenamic acid 9.0 6 0.999 96±10  24 0.989 49±3 
Trimethoprim 5.9 2 0.993 84±3  2 0.992 70±4 
Compound Artifical sea water (1.5 mL)  Marine mussels (DW) 
 
LOQ 
 (µg.L
-1
) 
n=9
a
 
R
2 
 
n≥21c 
Ion suppression 
 (%) 
n=3 
 
LOQ  
(ng.g
-1
) 
n=9
a
 
R
2 
 
n≥24b 
Recovery 
 (%) 
n=6 
Carbamazepine 7 0.991 13±5  6 0.987 100±5 
Diclofenac 16 0.998 26±7  29 0.990 83±8 
Gemfibrozil 64 0.999 −7±15  18 0.993 100±20 
Mefenamic acid 37 0.997 7±4  23 0.990 104±12 
Trimethoprim 2 0.977 9±3  4 0.985 91±9 
*
Average time recorded for each pharmaceutical in marine mussel tissues 
a 
Three data points carried out in triplicate 
b 
Eight data points carried out in triplicate 
c
 Seven data points carried out in triplicate
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In order to minimise the matrix effect on the quantification of ions, 
calibration curves were prepared in each sample matrix and ran before and after 
each series of samples. For quality control of the method, an injection of starting 
mobile phase was run between each sample with no carry over observed.  
 
 
4.3.2 Application to marine mussels exposed in vivo via direct injection or 
water exposure 
The developed methods were applied to the identification of pharmaceutical 
residues in marine mussels and ASW collected during a preliminary 96 h in vivo 
exposure. Ten mussels and 1.5 mL aliquots of ASW were sampled from each of the 
four tanks at t2min, t24h and t96h in an attempt to evaluate the potential of selected 
pharmaceuticals to bioconcentrate within the tissues of mussels over time. Five 1.5 
mL aliquots of ASW were also collected from the water exposure tank over 19 h to 
investigate any reduction in pharmaceutical concentration over time. Due to small 
sample volumes, marine mussel samples were analysed in duplicate and ASW 
samples were determined via triplicate injections on the LC-MS/MS. 
This preliminary exposure experiment was carried out to ascertain any 
possibility for pharmaceutical uptake by mussels through direct injection and water 
exposure. For the direct injection exposure, pharmaceutical concentrations of ≈10 
ng (using a 1 mg.L
-1
 standard in DMSO) were injected into the adductor muscle of 
the mussel, as previously described by Schmidt et al. (2011). No pharmaceuticals 
were detected in the injected mussel tissue or ASW. This may be due to the natural 
detoxification abilities of mussels, but is more likely to be related to the method 
detection limits given the concentration administered. Therefore, larger 
pharmaceutical concentrations than normally observed in environmental waters 
(Fatta-Kassinos et al., 2011; Wille et al., 2010) were exposed to the mussels in the 
water tank to ensure analytical method measurement reliability. Environmental 
exposure to pharmaceutical concentrations >1 mg.L
-1
 are generally considered rare, 
but have been previously reported in effluent from an Indian WWTP serving 
several drug manufacturers (Larsson et al., 2007). Upon fortification with 
pharmaceuticals, most analyte concentrations did not reach equilibrium in the ASW 
until 3 h after spiking. That said, after this initial stabilising period, concentrations 
were significantly less than the spiking level and continued to decline over time, 
124 
 
Figure 4.3: Pharmaceutical concentrations in ASW (n=1) from water exposure tank 
spiked at approximately 1 mg.L
-1
 and measured over 19 h 
 
 
as shown in Figure 4.3. Therefore, and as tanks were silanised before use, reduced 
pharmaceutical concentrations are most likely due to a combination of uptake 
within the mussels, photolysis, microbial transformation and sequestration via 
sorption to the mussel shell, although this is difficult to determine definitively. 
As can be deduced from Table 4.2, all pharmaceuticals were detected in the 
mussel tissues sampled from the water exposure tank from as soon as 2 min post-
exposure. Mussels were originally placed on tiles in the acclimation tank and 
directly transferred to the exposure tank with minimum handling, where they were 
observed to have their siphons extended almost immediately, indicating feeding 
activity. EICs of the most concentrated occurrence of selected pharmaceuticals in 
the water-exposed marine mussel samples are shown in Figure 4.4. No 
pharmaceutical residues were detected in the mussels and ASW collected from the 
acclimation tank and solvent control tanks.  
400.00
500.00
600.00
700.00
800.00
900.00
1000.00
0 5 10 15 20
C
o
n
ce
n
tr
at
io
n
 (
µ
g
.L
-1
)
Time (h)
Diclofenac
Mefenamic acid
Gemfibrozil
Trimethoprim
Carbamazepine
125 
Table 4.2: Concentrations (µg.g
-1
 DW) of carbamazepine (CBZ), diclofenac 
(DCF), gemfibrozil (GEM), mefenamic acid (MFA) and trimethoprim (TRM) 
detected in water-exposed mussel tissue over 96 h 
Time Pharmaceutical concentrations detected in mussel tissue (µg.g
-1
 DW) 
 
CBZ DCF GEM MFA TRM 
t2min 4.3±0.1 7.2±1.0 2.4±0.5 9.4±1.0 2.6±0.1 
t24h 12.8±1.1 13.5±2.4 1.0 ±0.0 11.7±1.0 18.8±0.9 
t96h 12.1±0.4 1.3±0.2 0.4±0.0 1.6±0.5 21.7±1.4 
 
 
It is generally assumed that organic compounds with logKow ≥3 have the 
potential to bioconcentrate within biotic tissues (Huerta et al., 2012). However, 
bioconcentration depends on numerous factors relating to the compound i.e. 
physicochemical nature and bioavailability, the aquatic organism i.e. rates of 
metabolism and uptake and depuration kinetics (Van Der Oost et al., 2003), and its 
residing waters i.e. quality and pH (Bremle et al., 1995; Nakamura et al., 2008; 
Rendal et al., 2011). Due to the ionisable nature of most pharmaceutical 
compounds, logDow is a more reliable quantity in this case as it takes into account 
the pH of the ASW. Trimethoprim is mostly ionised under experimental conditions 
but, with the second highest logDow value (0.63) after carbamazepine, it was found 
to be the most bioconcentrated pharmaceutical detected in the mussel tissue at the 
end of the 96 h exposure. On the contrary, gemfibrozil has only a slightly lower 
logDow value of 0.36 and was the least concentrated pharmaceutical measured in 
the mussel tissue at t96h. Similarly, diclofenac and mefenamic acid also display 
positive logDow values and were poorly bioconcentrated in the mussel tissue. Low 
bioavailability due to limited solubility or adsorption to shell surfaces for less polar 
compounds may be one reason for this observed trend in results. There is also the 
possibility that the pharmaceuticals were detoxified and metabolised within the 
mussel and therefore immeasurable using a SRM-based method. A glucuronidated 
metabolite cleaving enzyme, β-glucuronidase, has been previously extracted from 
marine molluscs, such as the large periwinkle (Littorina littorea) and the limpet 
(Patella vulgata), suggesting the presence of Phase II enzymatic activity 
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Figure 4.4: EICs of the most concentrated occurrence of selected pharmaceuticals 
in the water-exposed marine mussel samples 
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in invertebrates (Dodgson et al., 1953). Exposure to two carboxylic acid containing 
drugs (diclofenac and gemfibrozil) was found to significantly increase expression 
of the Phase II detoxification enzyme GST in marine and freshwater mussels at 
environmentally relevant concentrations (Quinn et al., 2011; Schmidt et al., 2011). 
Acyl glucuronides are reactive electrophilic metabolites, responsible for the 
elimination of carboxylic acid containing drugs (Horng et al., 2013). From the 
selected pharmaceuticals in this study, diclofenac, gemfibrozil and mefenamic acid 
contain carboxylic acid moieties and are primarily released in their acyl 
glucuronated form in the bile of humans, rats and fish (Grillo et al., 2012; Kallio et 
al., 2010; Lahti et al., 2011; Mano et al., 2007). If mussels share similar metabolic 
pathways to fish, this may explain the lower concentrations of the three acidic 
pharmaceuticals detected in the mussel tissue sampled at t96h.  
An overall reduction in mussel residues was observed for all 
pharmaceuticals except trimethoprim after 96 h. A reported study carried out by Le 
Bris and Pouliquen (2004) highlighted the ability of blue mussels to bioaccumulate 
two antibiotics, OTC and OA, over an eight hour in vivo exposure. Reductions in 
concentrations during exposure were observed between six to eight hours for OTC 
in the viscera and gills and between two to four hours for OA in the gills. The 
mussels may have undergone a detoxification process whereby the rate of 
elimination is greater than the rate of uptake, resulting in an overall loss in 
contaminant concentration within the mussel. As mentioned previously, 
metabolism within the mussel must also be considered. An in depth metabolic 
pathway study in the mussel model is required to account for any definite losses 
through biotransformation. 
 
 
4.3.3 Effect of cooking on pharmaceutical residues in marine mussel tissue 
As clearly observed in Figure 4.5, steaming of the water-exposed mussels resulted 
in an overall increase of pharmaceutical concentrations in the mussel tissue. 
Diclofenac, gemfibrozil and mefenamic acid residues in the mussel tissue increased 
by more than a factor of 20 and in the case of mefenamic acid, concentrations 
increased from 1.6 µg.g
-1
 in the raw mussel to 89.6 µg.g
-1
 after cooking (Table 4.3). 
The basic compound, trimethoprim, was the only pharmaceutical to undergo a 
reduction of 23 %, similar to results for other antibiotics, such as OTC and OA,  
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Figure 4.5: Pharmaceutical concentrations (µg.g
-1 
DW) detected in mussel tissue 
extracts before (n=2) and after cooking (n=2). Water-exposed mussels sampled at 
t96h were steamed and compared to uncooked mussels also sampled at t96h. 
 
 
which were reduced in shrimp muscle after baking (Uno et al., 2006a; Uno et al., 
2006b). Carbamazepine, a neutral compound, underwent the least change in 
concentration, with an increase of 12 % after cooking. Previous work in our 
laboratory has shown that temperatures of 450 
o
C in activated sludge drying 
processes perform only moderate transformation of this pharmaceutical residue in 
particular and remarkable stability in soils was also demonstrated during a two 
week leaching experiment (Barron et al., 2008; Barron et al., 2010). Studies 
exposing carbamazepine to aquatic species such as, H. attenuata, have reported the 
induction of biotransformation enzymes within the organism (Quinn et al., 2004; 
Vernouillet et al., 2010). Interestingly, significant increases in concentrations after 
cooking were only observed for acidic compounds. 
As shown in Table 4.3, the steaming of the mussels exposed in vivo resulted 
in the detection of all selected pharmaceuticals in the cooking water, indicating 
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leakage or extraction from the mussel tissue when heated. Carbamazepine and 
trimethoprim had the highest concentrations detected in the cooking water at 5.2 
µg.g
-1
 and 4.4 µg.g
-1
 WW, respectively. Considering their higher logDow values, 
this is not entirely unsurprising as water displays similar properties to organic 
solvents when heated under pressure to subcritical point (100-374 °C) and has been 
previously used as an extraction solvent for various environmental contaminants 
such as PAHs, PCBs and pesticides (Smith, 2002). Therefore, the presence of less 
polar pharmaceutical residues in the cooking water might be expected. 
 
 
Table 4.3: Comparison of concentrations of carbamazepine (CBZ), diclofenac 
(DCF), gemfibrozil (GEM), mefenamic acid (MFA) and trimethoprim (TRM) 
detected in raw mussel tissue (µg.g
-1
 DW) (n=2), steamed mussel tissue (µg.g
-1
 
DW) (n=2) and cooking water (µg.g
-1
 WW) (n=1) after steaming 
 
Pharmaceutical concentrations (µg.g
-1
) 
 
CBZ DCF GEM MFA TRM 
Uncooked mussels 12.1±0.4 1.3±0.2 0.4±0.0 1.6±0.5 21.7±1.4 
Cooked mussels 13.6±0.5 37.6±0.3 8.5±0.8 89.6±9.5 16.7±0.8 
Cooking water 5.2 0.3 0.1 0.9 4.4 
 
 
Significant increases in the production of GST in mussels exposed to low 
concentrations of acidic pharmaceuticals (Quinn et al., 2011; Schmidt et al., 2011) 
suggests a strong possibility of metabolic activity within the mussels. As previously 
mentioned, acidic compounds were found to undergo biotransformation to their 
glucuronated metabolites in fish bile (Lahti et al., 2011). Although not an acidic 
compound, carbamazepine has been found to undergo primary amine 
glucuronidation in human tissues (Staines et al., 2004) and trimethoprim 
metabolites were subsequently conjugated with glucuronides in metabolic studies 
carried out in pigs (Mengelers et al., 1997). Glucuronides are generally stable and 
can undergo deconjugation experimentally by harsh enzyme or chemical digestions 
but, in the case of acyl glucuronides in particular, these display instability (via 
cleavage) at mild temperatures and hydrolysis at pH>5 (Horng et al., 2013; 
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Skonberg et al., 2008; Trontelj, 2012). The observed increases in concentration of 
diclofenac, gemfibrozil and mefenamic acid in the cooked mussels may be as a 
result of the reconversion of acyl glucuronides to the parent compound after such 
thermal treatment. However, this would need to be confirmed in further studies as 
these metabolites were not available to analytical grade standards. The increase in 
concentration of carbamazepine in the mussel tissue after cooking was very low in 
comparison to the more acidic pharmaceuticals, however, this may be due to the 
higher stability of the formed amide linkage in n-glucuronides in comparison to the 
more reactive ester linkage in acyl glucuronides (Nassar et al., 2004). The 
reconversion of glucuronised parent compounds has been observed previously for 
estrogens following activated sludge treatment in WWTPs (Ternes et al., 1999). 
The presence of glucuronidase activity during secondary treatment is considered a 
rational explanation for the increase in concentration of numerous pharmaceuticals, 
including carbamazepine, in the discharged effluent of WWTPs (Jelic et al., 2012). 
Previous studies investigating the effect of cooking on pharmaceuticals have 
only determined veterinary antibiotics, such as OTC, OA and flumequine, directly 
exposed to farmed crustaceans and fish via medicated feed, with reported 
reductions, if any, less than 60 % after cooking (Huang et al., 1997; Kitts et al., 
1992; Steffenak et al., 1994; Uno, 2002; Uno et al., 2006a; Uno et al., 2006b; Uno 
et al., 2010; Xu et al., 1996). No previous studies on the effect of cooking on 
human pharmaceuticals in aquatic biota exist. Other environmental contaminants, 
such as metals, hexachlorobenzene (HCB) and polycyclic aromatic carbons (PAH), 
have been measured in fish, specifically hake, and mussel tissues at increased levels 
after undergoing several cooking processes (Kalogeropoulos et al., 2012; Perello et 
al., 2008; Perello et al., 2009).  
As mentioned previously, pharmaceutical residues in the natural aquatic 
environment are most often detected at concentrations in the high ng.L
-1
 to low 
µg.L-1 range. Marine mussel samples collected in October 2011 from the effluent 
exposure site, EXP1, described in Chapter 2, were found to contain residues of 
trimethoprim at 9.22 ng.g
-1 
(Table 2.6 (b)). These environmentally contaminated 
mussel samples were cooked (n=2) and both mussel tissue extracts and cooking 
water (n=1) were analysed via triplicate injection on the LC-MS/MS. No 
pharmaceutical residues were detected in either sample after steaming. 
Trimethoprim residues in mussels exposed to elevated pharmaceutical 
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concentrations were not significantly reduced after steaming but, in comparison, 
trimethoprim residues detected in naturally exposed marine mussels were so low, 
they were completely eliminated after steaming. 
 
 
4.4 Conclusions 
In this study, PLE, SPE and LC-MS/MS methods were optimised and validated for 
the identification and quantification of five pharmaceuticals popularly prescribed in 
Ireland, in ultra-pure water, ASW and Mytilus spp. tissues. Linearities in each 
matrix were ≥0.977 and LOQs ≤46 ng.L-1 were achieved for extracted cooking 
water and ASW, ≤64 µg.L-1 for unprocessed ASW, and ≤29 ng.g-1 in Mytilus spp. 
tissues. Application of these analytical methods to samples collected from a 
preliminary 96 h in vivo exposure, investigating the uptake of elevated 
pharmaceutical concentrations in mussel tissues, revealed the bioconcentration of 
selected pharmaceuticals in water-exposed mussel tissue only, at up to 21.7 µg.g
-1
 
DW. Domestic cooking by steaming resulted in an overall increase in 
pharmaceutical residues in the contaminated mussel tissue and cooking water. 
Mussels exposed to effluent impacted marine surface waters were found to contain 
low-level residues of the antibiotic trimethoprim but, these residues were 
eliminated after steaming. The potential risk of pharmaceutical exposure to humans 
through the food chain is low when pharmaceuticals are present in foods at 
environmentally relevant concentrations. However, this work has highlighted the 
possibility for pharmaceutical residues in food, particularly acidic compounds, to 
increase in concentration after thermal treatment and potentially pose a risk to 
human health via ingestion of farmed fish or animals regularly administered 
medication at high doses. 
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5.1 Summary 
Pharmaceuticals have been previously detected in the aquatic environment, 
particularly in freshwater environments, and have been reported to exert specific 
biological effects on aquatic organisms exposed in vivo. However, knowledge on 
the occurrence, fate and effects of pharmaceuticals in the marine environment is 
still lacking and their potential to bioaccumulate and biomagnify in aquatic 
organisms and potentially pose a threat to human health is relatively unknown. 
Therefore, the main goal of this thesis was to investigate the prevalence of selected 
pharmaceuticals in the Irish marine environment with the optimisation of novel 
analytical methods for their determination in various environmental matrices, such 
as wastewater effluent, marine surface waters, bivalves and fish. Additionally, the 
potential for trophic level transfer of pharmaceuticals through the food chain and 
human exposure via ingestion of contaminated seafood was also addressed. The 
main outputs of this thesis are as follows: 
 
 
 
Figure 5.1 Schematic overview of the main outputs of this thesis 
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Preliminary risk assessment 
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The research carried out investigates the occurrence of pharmaceuticals in 
the Irish aquatic environment and their potential to bioaccumulate and pose a risk to 
human health via dietary intake of contaminated seafood. The current literature on 
the presence of pharmaceuticals in the aquatic environment focuses on residues 
detected in wastewater and freshwater and to date the occurrence and fate of 
pharmaceuticals in the natural marine environment is still unknown. For this 
reason, Chapter 1.0 reviews the presence of pharmaceuticals in the marine 
environment with a focus on previous monitoring studies conducted in marine 
surface water and marine biota and recent trends in analytical techniques. 
For the first time, a year-long monitoring study was carried out to determine 
the spatial occurrence of five targeted pharmaceuticals in the Irish marine 
environment (Chapter 2.0). Analytical techniques such as PLE, SPE and LC-
MS/MS were combined, optimised and applied to wastewater effluent, marine 
surface water and Mytilus spp. samples collected from two impacted sites and a 
control site along the Irish coastline. The presence of all five targeted 
pharmaceuticals was confirmed at concentrations in the low µg.L
-1
 range in effluent 
and in the high ng.L
-1
 range in exposed marine surface water. Three of the five 
detected pharmaceuticals in marine surface waters were also found to occur in 
exposed Mytilus spp., with residues of trimethoprim measuring at concentrations up 
to 9.22 ng.g
-1
 DW. This study has confirmed the uptake of pharmaceuticals in 
marine bivalves at measurable quantities. The presence of very low antibiotic 
residues in the aquatic environment has been shown to cause antimicrobial 
resistance in natural bacteria which could be of concern for potential consumers 
(Kummerer, 2009). Thus, for the remaining work (Chapters 3 & 4), the possibility 
of pharmaceutical uptake in exposed biota was assessed and the potential for 
exposure to humans via dietary intake was also investigated. 
Pharmaceutical bioaccumulation in juvenile rainbow trout via trophic level 
transfer was investigated in Chapter 3.0. A 28-day in vivo bioaccumulation 
experiment was carried out in a flow-through system in which the exposed fish 
were fed effluent exposed marine mussels. The PLE, SPE and LC-MS/MS methods 
previously developed were applied to the water and biotic samples. The 
pharmaceutical extraction method applied to marine mussels was further optimised 
for fish liver samples. Trimethoprim was the only pharmaceutical from the five 
selected to be quantified in the Mytilus spp. at concentrations of 6.68 ng.g
-1
 DW. 
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After 28 days of feeding and despite the presence of trimethoprim residues in the 
tissues of the Mytilus spp., no pharmaceutical residues were detected in the fish 
liver tissues or the carbon filtered municipal water supplied to the fish tanks. The 
presence of pharmaceuticals in other fish tissues were not assessed as the fillet 
could not be processed and other organs were used for biological analysis. The 
potential for pharmaceuticals, in particular trimethoprim, to biomagnify in the liver 
via trophic level transfer is not likely considering the LOD and LOQ for 
trimethoprim in mussel tissue and fish liver tissues were of equal value. However, 
bioaccumulation of pharmaceutical residues via dietary exposure may have 
occurred and gone undetected if pharmaceutical concentrations present in the 
mussel tissue and fish liver were less than the LOD value. Considering the 
possibility of pharmaceutical bioaccumulation in fish via trophic level transfer, the 
next step was to investigate the potential risk of pharmaceutical exposure to 
humans. 
The effect of cooking on the concentrations of five pharmaceutical residues 
in exposed mussel tissue was investigated in an attempt to assess the potential risk 
of exposure to humans via ingestion of contaminated seafood (Chapter 4.0). A 
preliminary in vivo experiment was carried out exposing marine mussels to high 
pharmaceutical concentrations via direct injection or water uptake over 96 h. After 
cooking (via steaming) a selection of the water-exposed mussels, an overall 
increase in pharmaceutical residues in the contaminated mussel tissue and cooking 
water was observed. In contrast, mussels exposed to effluent impacted marine 
surface waters were found to contain low-level residues of the antibiotic 
trimethoprim but, these residues were eliminated after steaming. It is for this reason 
why mussels were also exposed to pharmaceutical concentrations approximately a 
thousand times higher than those in the environment as the effects of cooking on 
pharmaceutical residues could be observed at a higher scale and changes in 
concentrations, which may have gone unnoticed at environmentally relevant 
concentrations close to the method LOD values, could be reported. The potential 
risk of pharmaceutical exposure to humans through the food chain is low but may 
exist if sourcing seafood from surface waters receiving highly contaminated 
effluent such as that reported in India by Larsson et al. (2007). 
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5.2 Final Conclusions 
5.2.1 Distribution of pharmaceuticals in the Irish aquatic environment  
It is clear from the results generated during this project that pharmaceutical residues 
are present in quite substantial quantities in the Irish aquatic environment. It has 
been shown that a number of commonly used pharmaceuticals persist beyond the 
wastewater treatment process and enter receiving surface waters. In general, 
research into the occurrence and fate of pharmaceuticals in the marine environment 
is limited in comparison to the number of studies carried out in various freshwater 
environments. This was previously addressed in Chapter 1.0 and a summary of the 
studies carried out to date in marine surface waters was provided in Section 1.7.1. 
Typical concentrations in marine surface waters were quantified in the very low to 
mid ng.L
-1
 concentration range with slightly higher pharmaceutical concentrations 
measured in estuarine water samples (Thomas and Hilton, 2004; Wille et al., 2010). 
In comparison to the results from other monitoring studies, pharmaceutical residues 
measured slightly higher in Irish marine surface waters, with the highest residues 
detected at 1.41 µg.L
-1
 for carbamazepine and all other selected compounds 
quantified in the mid to high ng.L
-1
 concentration range.  
When comparing marine surface waters from the east and west coasts of 
Ireland, pharmaceutical concentrations measured in both locations were directly 
related to the concentration of pharmaceuticals in the wastewater effluent released 
into each exposure site. Much higher concentrations of carbamazepine were 
detected in marine surface waters from the east coast (EXP1) whereas higher 
concentations of trimethoprim and gemfibrozil were detected in marine surface 
waters from the west coast (EXP2). Unlike WWTP1, effluent from WWTP2 was 
discharged through a diffuser pipe in the bay and impacted waters were predicted to 
contain much lower pharmaceutical residues than EXP1 due to the greater extent of 
dilution. However, high residues of the antibiotic, trimethoprim, in particular, at 
EXP2 may be due to the treatment of effluent from four major hospitals in a 
volume of wastewater almost ten times smaller than that treated by WWTP1. It has 
been previously highlighted that in some respects effluent from major hospitals 
differs in composition to general urban effluent and the need for specific 
monitoring and control may need to be considered particularly for antimicrobial 
residues (Cormican et al., 2012). 
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An in situ study carried out the previous year in the same estuary but at 700 
m from the effluent outfall pipe, revealed pharmaceutical residues of 
carbamazepine and trimethoprim in marine suface waters at concentrations up to 30 
ng.L
-1
. Taking these results into account, a decrease in the concentrations of 
pharmaceutical residues in marine surface waters could be observed with increasing 
distance from the coast. The reason for the decrease in pharmaceutical residues is 
believed to be as a result of both dilution and degradation processes hindering their 
transport further out of the estuary. 
 
 
5.2.2 Uptake of pharmaceuticals in non-target aquatic biota 
This research has highlighted the ability of marine mussels to bioaccumulate low-
level pharmaceutical concentrations present in their surrounding aquatic 
environment. The uptake of the antibiotic, trimethoprim, was reported in wild and 
caged Mytilus spp. at concentrations of 6.68 ng.g
-1
 and 9.22 ng.g
-1
, respectively, 
after exposure to one of the most contaminated marine surface water sites on the 
Irish coast, EXP1. Carbamazepine and mefenamic acid were also detected in caged 
marine mussel tissues from this site and from another heavily impacted marine site 
(EXP2) but residues were too low to be quantified. Previous pharmaceutical fate 
studies carried out in soils and sludges support some of the findings from this study, 
in particular, the higher concentration ability of antimicrobial agents, such as 
triclosan and triclocarban, in soils and sludges in comparison to pharmaceuticals 
from other classes (Barron et al., 2008). 
Selected pharmaceuticals were continuously detected in surrounding marine 
surface waters at average concentrations in the mid to high ng.g
-1
 range, except for 
gemfibrozil which was detected sporadically. Previous chronic exposure studies 
(see Table 1.3) have tested environmentally relevant concentrations of 
pharmaceuticals on the Mytilus spp. and other aquatic organisms with potentially 
lethal effects observed, such as increased oxidative stress, lesions on vital organs 
and reduced enzyme function in cells (Contardo-Jara et al., 2011; Cuklev et al., 
2011; Lajeunesse et al., 2011; Mehinto et al., 2010; Quinn et al., 2004; Quinn et 
al., 2011; Schmidt et al., 2011; Schmidt et al., 2013; Schwaiger et al., 2004). Due 
to the ability of these compounds to readily metabolise, there is a need to combine 
both chemical and biological analysis particularly for the assessment of 
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pharmaceutical uptake in naturally exposed aquatic organisms, as seen in this case 
where low uptake does not necessarily indicate low exposure or risk. 
 In Chapter 4.0, marine mussels were exposed to artificial seawater spiked 
daily with elevated pharmaceutical concentrations of 1 mg.L
-1
 over a 96-h period. 
Acidic compounds in the mussel tissue decreased drastically in concentration over 
the 96 hrs in contrast to carbamazepine and trimethoprim, respectively neutral and 
basic compounds, which gradually increased in concentration over time. The 
possibility of metabolic activity within the mussel was suggested following the 
overall reduction in concentrations of acidic compounds which have been 
previously shown to undergo efficient glucuronisation in fish bile (Lahti et al., 
2011). This possibility was further supported when higher pharmaceutical residues, 
of acidic compounds in particular, were detected in the mussels after thermal 
treatment, most likely due to the cleaving of glucuronised metabolites back to the 
parent compound. No correlations between the logDow values and the extent of 
uptake of pharmaceuticals in biota could be observed. Bioaccumulation does not 
seem to be exclusively driven by the hydrophobicity of the compound at a certain 
pH which makes it difficult to predict the partitioning of pharmaceuticals into 
different aqueous, solid and biotic phases of the aquatic environment. For this 
reason and their ability to extensively undergo biotransformation within biological 
tissues, information regarding their presence in both the aquatic phase and biotic 
tissue is required, which is provided within this thesis. 
 
 
5.2.3 The use of sample extraction and mass spectrometry in the analysis of 
pharmaceuticals in environmental matrices 
Chemical analysis in this area still proves to be very challenging, primarily due to 
the complexity of the environmental sample matrices involved. In particular, the 
co-extraction of the sample matrix with selected analytes, adversely affecting 
method sensitivity and detection. Ion suppression further affects the reliable 
quantification of pharmaceuticals. Deuterated standards can be used to address this 
problem, but this can add considerable cost to the analysis, coupled with their 
extremely limited availability. Standard addition and matrix-matched calibration 
are other commonly used quantification methods that prove more cost effective 
however, may be difficult to perform if there are very few samples available to 
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analyse or if it is difficult to obtain blank matrix-matched samples. The use of new 
separation technologies such as UHPLC can somewhat tackle this problem by 
providing better resolution from interfering compounds although this may not be 
the most cost effective option. 
The distinct diversity across the range of sample matrices investigated 
proved more problematic for some than others. A solution is to develop several 
separate matrix specific extraction methods coupled to LC-MS/MS analysis. For 
optimal performance, each extraction method must be tailored for compounds with 
similar physicochemical properties. However, such an approach is timely and costly 
and is therefore, not a feasible solution. Chemical analysis, in particular, LC-
MS/MS, remains the technique of choice for trace analysis of pharmaceuticals in 
environmental matrices, however, matrix effects and laborious sample preparation 
processes continue to limit its applicability to all samples. 
 
 
5.2.4 Risk assessment 
The requirement for a detailed risk assessment of pharmaceuticals is a priority to 
ensure there are no major risks to the environment and human health. The risks for 
the aquatic environment, associated with the measured water concentrations of the 
targeted pharmaceuticals within this thesis, cannot be fully assessed as there are 
currently no regulatory guidelines established for widely used and widespread 
occurring pharmaceuticals. Only recently, diclofenac has been added to a new 
‘watch list’ included in the EU Water Framework Directive and may be added to 
the priority list at a later date following further monitoring and toxicity studies (EU 
Directive 2013/39/EU). As demonstrated in this thesis, there are numerous other 
pharmaceutical residues present at substantial concentrations in marine surface 
waters which are also known to cause chronic effects in aquatic organisms at low 
doses (Quinn et al., 2004; Quinn et al., 2011; Schmidt et al., 2011; Schmidt et al., 
2013). 
As mentioned previously, the EMEA is the regulatory body responsible for 
carrying out environmental risk assessments on pharmaceuticals prior to their 
licensing. If PECs are >0.01 µg.L
-1
, risk is then determined by the ratio of 
PEC/PNEC, where PNEC values are based on results from acute toxicity studies. In 
order to perform a more comprehensive risk assessment, available information on 
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the chronic toxic effects of the selected pharmaceuticals i.e. lowest observed effect 
concentration (LOEC), were used instead of PNEC values and any uncertainty 
regarding single-species analysis was accounted for using the necessary assessment 
factor (European Chemicals Bureau, 2003). Based on previous chronic toxicity 
studies, the pharmaceutical monitoring data produced for carbamazepine and 
diclofenac within this thesis highlights a potential risk for chronic effects in aquatic 
species residing in the selected Irish coastal zones (Triebskorn et al., 2007).  
The measurement of pharmaceuticals in aquatic species that are important in 
terms of human consumption, such as mussels, is very useful in estimating the 
human exposure and dietary intake of these pharmaceuticals. It was observed that 
the European maximum residue limit (MRL) for trimethoprim in all food producing 
species (50 ng.g
-1
) was not exceeded in marine mussels collected from one of the 
most highly contaminated sites in Ireland, deeming it safe for human consumption 
(EU Regulation 37/2010). After cooking the wild contaminated mussels, 
trimethoprim was not detected and appeared to be eliminated in the mussel tissue. 
The effectiveness of thermal treatment was then assessed at higher pharmaceutical 
concentrations and interestingly, an overall increase in pharmaceutical residues in 
contaminated mussel tissue and cooking water was reported after thermal treatment. 
In the case of trimethoprim, this was the only pharmaceutical to be reduced after 
cooking, hence, marine mussels with MRL values acceptable before cooking should 
still be acceptable for human consumption after cooking. However, all of the other 
selected pharmaceuticals showed an increase in concentration in the marine mussels 
after cooking, with exceptionally high increases measured for acidic 
pharmaceuticals in particular. Although diclofenac and several other acidic 
pharmaceuticals are not monitored for in seafood, they are controlled in other 
foodstuffs in the EU. The research carried out in Chapter 4.0 highlighted the 
possibility for pharmaceutical residues in approved foodstuffs to exceed the 
assigned MRL values following thermal treatment of the food, potentially posing a 
risk to human health via dietary ingestion.  
In Ireland, the lowest oral dosages of the selected pharmaceuticals for 
humans on the market are approximately 80 mg and higher, except for diclofenac 
which is available in 25 mg tablets (IPHA, 2013). Considering medicines are 
usually taken every several hours and at various doses, the concentration of 
pharmaceutical residues in the environment may be considered negligible in 
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comparison. On the other hand, the lowest oral doses available for these 
pharmaceuticals are still very potent and should not be confused with LOEC values 
of pharmaceuticals in the human body, for which data is not publicly available. 
The scope of the work presented in this thesis has provided knowledge of 
the occurrence and distribution of pharmaceuticals in natural marine ecosystems in 
Ireland and the potential risk of pharmaceutical exposure to human health. It is 
suggested there is a very low risk of pharmaceutical exposure to humans via dietary 
ingestion of marine mussels, however, there may be potential for pharmaceutical 
exposure to humans via dietary intake of other exposed aquatic species. The 
information gathered using the developed analytical techniques has enhanced 
Ireland’s capacity towards the integrated monitoring of contaminants in the marine 
environment and these findings will contribute to future pharmaceutical fate studies 
and evaluations of the human risks posed by these emerging environmental 
pollutants. 
 
 
5.3 Future Work 
The following areas have been identified as possibly requiring further research and 
may be of relevance to those undertaking similar studies: 
 
 Following method performance testing, the measured ion suppression 
values for pharmaceuticals in complex matrices, such as wastewater 
effluent, marine surface water and biological tissues, were very high even 
after undergoing at least one extraction step. There is a need for more 
selective extraction techniques using efficient SPE sorbents to remove 
unwanted matrix components and allow for the accurate quantification of 
compounds present in the environment at sub ng.g
-1
 concentration levels. 
Although MIP is a very selective extraction technique, this is only suitable 
for target analyte screening of samples as only one compound or a class of 
structurally related compounds can be extracted at any one time, hindering 
the development of multi-class methods of analysis (Mahony et al., 2005). 
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 ‘Prevention is better than cure’ is the message from the Irish Environmental 
Protection Agency when it comes to water quality. Besides encouraging 
doctors against the unnecessary prescribing of pharmaceuticals and 
providing a greater awareness of correct ways of disposing unused or out of 
date pharmaceuticals, there is no alternative to reduce the presence of 
pharmaceuticals in sewerage systems. Removal technologies for 
pharmaceuticals should be employed in the wastewater treatment plant to 
prevent the release of potentially harmful pharmaceuticals into the 
environment however, emission limits first need to be set before the most 
cost effective treatments can be implemented. Previous studies have 
reported that a combination of advanced treatment technologies, such as 
UV/H2O2 and O3/H2O2, have proven successful in the efficient removal of 
pharmaceuticals from wastewater (Ternes, 2004). Although these 
technologies are costly to implement, they eliminate the need for water 
remediation and greatly reduce the human impact and potential biological 
effects on the natural aquatic environment. 
 
 The toxicity of a mixture of pharmaceuticals with similar modes of action 
has been previously found to be substantially higher than the toxicity of 
individual pharmaceuticals at the same concentrations (Cleuvers, 2003). As 
pharmaceuticals do not occur isolated in the natural environment, further 
study is required to assess the ecological relevance and ecotoxicological 
potential of prevalent pharmaceutical mixtures in the aquatic environment.  
 
 The inclusion of metabolites in analytical methods should be addressed, 
especially for the likes of prodrugs, which release the active compound after 
undergoing metabolism (Rautio et al., 2008). This will require availability 
of pharmacokinetic data and reference standards from pharmaceutical 
manufacturers. A current limitation in the area is the lack of reference 
standards, especially of pharmaceutical metabolites, and even if available, 
they are very expensive. Other products formed via environmental 
processes, such as photo transformation, should also be examined, thereby 
pharmaceuticals and their relevant product compounds can be included in 
analytical methods for a more complete environmental risk assessment. 
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 Based on the conclusions of this thesis, the possibility for antibiotics, such 
as trimethoprim, to bioaccumulate in aquatic species and potentially through 
the food chain was highlighted. The input of resistant bacteria into the 
environment has been previously shown to affect the health of aquatic 
organisms and may potentially pose a threat to human health (Kummerer, 
2009). A more in depth study of the fate of persistent antibiotics in the 
aquatic environment should be carried out and their abilities to 
bioaccumulate in other aquatic species further assessed.  
 
 The risk of biological effects occurring in aquatic organisms was assessed 
using previous chronic toxicity data, however, LOEC values were used due 
to the lack of PNEC data available. Chronic toxicity studies need to be 
carried out on a wider range of aquatic species and should include exposure 
to pharmaceutical concentrations lower than 1 ug.L
-1
 in order to produce 
PNEC data and allow for the accurate environmental risk assessment of 
pharmaceuticals. More of a focus should be certainly placed on the 
combination of chemical and biological analysis of aquatic biota to fully 
assess the exposure and uptake of pharmaceuticals and the effects exerted 
on the aquatic organism. As mentioned before, low measurements of 
pharmaceutical residues in the exposed organism does not necessarily 
indicate low exposure, especially in the case of highly metabolised 
compounds such as acidic pharmaceuticals. 
 
 Following the results of this thesis, it may be necessary to further 
investigate animal food products, containing pharmaceutical residues at 
concentrations close to the defined MRL values, after thermal treatment. 
This investigation should particularly target carboxyl containing compounds 
which are highly susceptible to glucuronidation.  
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II 
Table A.1: Pharmaceutical residues detected in wastewater effluent (µg.L
-1
), marine surface water (MSW) (µg.L
-1
) and mussels (ng.g
-1
 DW) 
sampled from WWTP1 and EXP1 from May to August 2011. Salinity and water temperature of MSW taken on site at 1 m below surface. Data for 
BOD, COD, suspended solids and flow rate of effluent provided with weather data from WWTP1 and Met Eireann  
EXP1 May 2011 Jun 2011 Jul 2011 Aug 2011 
 Effluent MSW Mussels Effluent MSW Mussels Effluent MSW Mussels Effluent MSW Mussels 
Trimethoprim 0.07±0.11 0.20±0.06 <4* 1.19±0.16 0.56±0.06 <4* 0.49±0.13 0.24±0.08 <4* 0.65±0.07 0.57±0.02 <4* 
Diclofenac 0.75±0.06 0.11±0.11 n.d. 1.22±0.30 0.46±0.05 n.d. 0.84±0.20 n.d. n.d. 1.52±0.15 0.06±0.05
a
 n.d. 
Carbamazepine 0.94±0.13 0.18±0.18 n.d. 0.86±0.07 0.31±0.06 n.d. 1.91±0.08 0.51±0.03 <6* 2.37±0.14 0.64±0.09 <6* 
Mefenamic acid 1.25±0.11 n.d. n.d. 0.54±0.10 0.08±0.08 n.d. 0.73±0.12 n.d. n.d. 0.42±0.18 0.14±0.01
a
 <23* 
Gemfibrozil 0.57±0.15 n.d. n.d. 0.45±0.14 0.29±0.04 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
Salinity (g.kg
-1
)  36   29        
Water temp. (°C)  6   9        
BOD (mg.L
-1
) 10   13   5   15   
COD (mg.L
-1
) 59   76   50   63   
SS (mg.L
-1
) 16   15   11   9   
pH 7.6 8.0  7.7 7.8  7.4 8.0  7.2 8.0  
Flow rate (m
3
.day
-1
) 343908   310622   339884   318524   
Rainfall (mm)    0.0   0.0    0.3    2.0 
Temp. range (°C)   10-16    10-19    13-20    13-21 
n.d. not detected 
a 
Quantification carried out using a three point standard addition calibration 
*Pharmaceutical residues detected at concentrations <LOQ 
III 
Table A.2: Pharmaceutical residues detected in wastewater effluent (µg.L
-1
), marine surface water (MSW) (µg.L
-1
) and mussels (ng.g
-1
 DW) 
sampled from WWTP1 and EXP1 from September to December 2011. Salinity and water temperature taken on site at 1 m below surface. Data for 
BOD, COD, suspended solids and flow rate of effluent provided with weather data from WWTP1 and Met Eireann 
n.d. not detected 
a 
Quantification carried out using a three point standard addition calibration 
*Pharmaceutical residues detected at concentrations <LOQ  
EXP1 Sep 2011 Oct 2011 Nov 2011 Dec 2011 
 Effluent MSW Mussels Effluent MSW Mussels Effluent MSW Mussels Effluent MSW Mussels 
Trimethoprim 0.59±0.19 0.35±0.08 <4* 0.85±0.05 0.16±0.07 9.22±1.54 0.34±0.05 0.29±0.10 7.28±1.70 1.08±0.21 0.35±0.04 <4* 
Diclofenac 0.51±0.04 0.30±0.01 n.d. 0.88±0.13 0.39±0.03 n.d. 1.22±0.16 0.46±0.12 n.d. 0.31±0.07 0.26±0.02 n.d. 
Carbamazepine 2.33±0.19 1.30±0.20 <6* 2.49±0.13 1.41±0.15 n.d. 3.16±0.32 0.97±0.19 n.d. 1.86±0.16 0.88±0.13 <6* 
Mefenamic acid 0.49±0.04 0.13±0.11
a
 <23* 0.46±0.04 0.31±0.11 <23* 1.07±0.22 0.11±0.11 n.d. 0.42±0.11 0.27±0.05 n.d. 
Gemfibrozil 0.10±0.09 n.d. n.d. 0.16±0.07 n.d. n.d. 0.31±0.05 n.d. n.d. 0.09±0.13 0.11±0.09 n.d. 
Salinity (g.kg
-1
)  
 
 
 
          38  
Water temp. (°C)           13  
BOD (mg.L
-1
) 9   14   22   10   
COD (mg.L
-1
) 55   44   61   54   
SS (mg.L
-1
) 10   14   28   12   
pH 7.6 7.7  7.5 8.1  7.4 8.1  7.6 8.1  
Flow rate (m
3
.day
-1
) 325659   362697   395197   467155   
Rainfall (mm)    0.0 
- 
 0.0 
- 
0.3 
- 
  1.0 
- 
Temp. range (°C)    5-18 
- 
8-13 
- 
4-11 
- 
  1-10 
- 
IV 
Table A.3: Pharmaceutical residues detected in wastewater effluent (µg.L
-1
), marine surface water (MSW) (µg.L
-1
) and mussels (ng.g
-1
 DW) 
sampled from WWTP1 and EXP1 from January to April 2012. Salinity and water temperature taken on site at 1 m below surface. Data for BOD, 
COD, suspended solids and flow rate of effluent provided with weather data from WWTP1 and Met Eireann  
n.d. not detected 
a 
Quantification carried out using a three point standard addition calibration 
*Pharmaceutical residues detected at concentrations <LOQ  
EXP1 Jan 2012 Feb 2012 Mar 2012 Apr 2012 
 Effluent MSW Mussels Effluent MSW Mussels Effluent MSW Mussels Effluent MSW Mussels 
Trimethoprim 1.20±0.10 0.21±0.02 <4* 0.65±0.07 0.07±0.03 <4* 0.60±0.16 0.52±0.06 <4* 0.06±0.11 0.21±0.05 <4* 
Diclofenac 0.60±0.17 0.25±0.08 n.d. 0.99±0.15 0.37±0.12 n.d. 1.40±0.17 0.38±0.03 n.d. 1.69±0.20 0.42±0.13 n.d. 
Carbamazepine 0.62±0.09 0.52±0.11 <6* 0.51±0.10 0.58±0.12 <6* 0.76±0.16 0.47±0.05 <6* 0.99±0.05 0.36±0.09 <6* 
Mefenamic acid 1.50±0.19 0.37±0.05 <23* 0.80±0.05 0.32±0.09 <23* 1.52±0.26 0.48±0.09 n.d. 1.55±0.31 0.41±0.07 <23* 
Gemfibrozil 0.36±0.04 0.24±0.10 n.d. 0.65±0.15 0.37±0.10 n.d. 0.43±0.11 0.14±0.15 n.d. 0.53±0.07 0.40±0.07 n.d. 
Salinity (g.kg
-1
) 
 
 
 
 42   16   24   23  
Water temp. (°C)  10   12   13   15  
BOD (mg.L
-1
) 11   16   11   13   
COD (mg.L
-1
) 54   45   54   63   
SS (mg.L
-1
) 15   22   16   13   
pH 7.3 7.5  7.5 8.1  7.5 7.8  7.6 7.7  
Flow rate (m
3
.day
-1
) 409324   474047   339308   344219   
Rainfall (mm) 1.0 
- 
0.0 
- 
0.0 
- 
0.0 
- 
Temp. range (°C) 2-10 
- 
-6-3 
- 
5-13 
- 
2-17 
- 
V 
Table A.4: Pharmaceutical residues detected in wastewater effluent (µg.L
-1
), marine surface water (MSW) (µg.L
-1
) and mussels (ng.g
-1
 DW) 
sampled from WWTP2 and EXP2 from May to August 2011. Salinity and water temperature of MSW taken on site at 1 m below surface. Data for 
BOD, COD, suspended solids and flow rate of effluent provided with weather data from WWTP2 and Met Eireann  
EXP1 May 2011 Jun 2011 Jul 2011 Aug 2011 
 Effluent MSW Mussels Effluent MSW Mussels Effluent MSW Mussels Effluent MSW 
Trimethoprim 0.95±0.25 0.76±0.10 <4* 1.17±0.26 0.80±0.14 <4* 0.50±0.08 0.74±0.11 <4* 1.03±0.14 0.87±0.14 
Diclofenac 2.63±0.19 0.22±0.19 n.d. 1.61±0.04 0.55±0.05 n.d. 0.45±0.16 n.d. n.d. 1.01±0.14 0.24±0.01
a
 
Carbamazepine 0.57±0.16 0.08±0.04 n.d. 0.40±0.19 0.05±0.12 n.d. 0.27±0.06 0.16±0.10 n.d. 1.71±0.21 0.40±0.10 
Mefenamic acid 2.42±0.11 n.d. <23* 2.80±0.15 0.61±0.14 <23* 0.52±0.07 0.27±0.09
a
 <23* 0.53±0.11 0.21±0.15
a 
Gemfibrozil 0.84±0.20 n.d. n.d. 1.48±0.25 0.49±0.16 n.d. 1.57±0.24 0.64±0.14
a
 n.d. 0.57±0.21 n.d. 
Salinity (g.kg
-1
) 
 
 
 
 30   28       
Water temp. (°C)  10   12       
CBOD (mg.L
-1
) 2   3   2   <4  
COD (mg.L
-1
) 29   28   28   27  
SS (mg.L
-1
) <5   7   <5   <5  
pH 7.60 7.97  7.23 7.95  7.29 8.21  7.12 8.20 
Flow rate (m
3
.day
-1
) 40103   46306   47145   38223  
Rainfall (mm) 4.0 
- 
0.1 
- 
0.8 
- 
2.0 
Temp. range (°C) 9-14 
- 
6-12 
- 
9-15 
- 
11-17 
n.d. not detected 
a 
Quantification carried out using a three point standard addition calibration 
*Pharmaceutical residues detected at concentrations <LOQ 
